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Thesis Summary  
 
The brain requires a constant supply of glucose and oxygen to meet metabolic 
needs at rest and during increased activity. If blood flow is disrupted, or if tissue 
has difficulty extracting or metabolising nutrients, cell damage or death may 
occur. Vascular and metabolic impairments in Multiple Sclerosis (MS) are 
hypothesised to contribute to disease progression.  This thesis develops 
empirical measures of neurovascular coupling using the relationship between 
magnetoencephalography (MEG) and functional Magnetic Resonance Imaging 
(fMRI). Visual MEG and fMRI  responses were reduced in MS. The relationship 
between them was unchanged suggesting preserved neurovascular coupling. 
Addressing the same questions with a naturalistic movie stimulus in MS, no 
coupling differences were found. In a healthy population, results show 
neurovascular coupling is dependent on brain region and frequency of neural 
oscillations. Under the hypothesis of reduced cerebral metabolic rate of O2 
(CMRO2) contributing to damage in MS, we quantified baseline CMRO2  and 
cerebral blood flow (CBF), amongst other parameters. This is the first application 
of dual-calibrated fMRI in MS, involving biophysical modelling of fMRI signals in 
response to changing inspired CO2 and O2. Reduced baseline CBF and CMRO2 
were found in MS, correlating with lesion and grey matter volumes. Relative 
visual-induced CBF and CMRO2 signals were investigated in MS; a reduction in 
CBF was found in a small visual region but no visual CMRO2  changes were 
found, or differences in CBF-CMRO2 coupling. Baseline CBF and CMRO2 
signals predicted visual stimulus responses, in both groups. As an alternative to 
externally supplied gases, we used a breath-hold design to create a CMRO2 
movie time-series but report no significant relationships between CMRO2 and 
MEG. Quantitative functional imaging can detect impairments in resting and 
stimulus-induced neural oscillations, blood flow and oxygen metabolism in MS, 
which should be explored further to understand their exact role in disease 
progression. 
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Aims of Thesis  
 
This thesis uses non-invasive neuroimaging methods to measure the energy demands 
of neural activity, and the coupling between neural activity and blood flow. The main 
aims of this thesis are to: 
 
1. Investigate neurovascular coupling (NVC) mechanisms using the 
relationship between magnetoencephalography (MEG) and functional 
Magnetic Resonance Imaging (fMRI) signals. The relationship between MEG 
signals (neural activity) and fMRI signals (blood flow response to neural activity) 
in response to the same stimulus is used as an empirical measure of NVC. NVC 
is not fully understood but is crucial to how the brain replenishes energy in active 
areas, as well as underpinning how the fMRI signal is interpreted.  
 
2. Develop more quantifiable and interpretable measures of vascular and 
metabolic brain function. The calibrated fMRI methods used in this thesis aim 
to parcellate out the commonly used Blood Oxygen Level Dependent (BOLD) 
fMRI signal into more quantifiable and interpretable signals, for example blood 
flow and oxygen metabolism. Importantly, blood flow and oxygen metabolism 
signals are quantified at baseline in this thesis, as well as relative signal 
changes to a stimulus. Characterising the baseline state is important for the 
interpretation of stimulus-induced changes, particularly when studying patient 
populations where this baseline state may be altered.  
 
3. Apply these MEG and fMRI methods to the investigation of vascular and 
metabolic impairment in Multiple Sclerosis (MS). Vascular and metabolic 
impairments are present in MS, but it is not clear when and how they contribute 
to the disease. We need more non-invasive ways of investigating these 
mechanisms in MS and therefore the methods described in aims (1) and (2) are 
used. This thesis presents the first application of a dual-calibrated fMRI study in 
MS, allowing baseline oxygen metabolism to be quantified, alongside baseline 
blood flow and many other relevant physiological parameters. Blood flow and 
oxygen metabolism changes are also investigated in response to visual stimuli, 
and the MEG-fMRI relationship is used to assess impairments in NVC. It is 
important to establish the practicality and utility of these methods in MS. 
 
This thesis contributes to the development of these methods, as well as their 
application to disease populations.  
   2 
Structure of Thesis 
 
Introductory Chapters (1-3): Chapter 1 introduces the biological signals and 
mechanisms of interest and Chapter 2 introduces the methods used to investigate these 
signals and mechanisms (see figure below). Chapter 3 gives a background to MS and 
explains the relevance of investigating these mechanisms in this disease. 
 
Research Chapters (4-9) 
SIGNALS METHODS
MagnetoEncephaloGraphy
Magnetic fields, induced by 
electrical currents, which 
reflect networks of post 
synaptic potentials in large 
populations of neurons, 
oscillating at certain 
frequencies. Beamforming 
for source estimation. 
Arterial Spin Labelling MRI
• Cerebral Blood Flow
• Blood Oxygen Level 
Dependent signal
Dual-Calibrated-ASL
Modelling the BOLD and CBF 
responses to hyperoxic and 
hypercapnic stimuli (inspired gases) to 
give quantitative estimates of baseline 
CBF, Oxygen Extraction Fraction, 
CerebroVascular Reactivity, CMRO2 
and Oxygen Diffusivity.
Neural 
Activity
Oxygen and glucose 
consumption
Metabolic changes
Hemodynamic 
Response
Blood Flow
Blood Volume
n
NVC
Calibrated-ASL
Hypercapnia induced with a gas 
challenge or breath-hold design, 
allowing estimation of relative changes 
in Cerebral Metabolic Rate O2
Flow-Metabolism 
Coupling (‘n’)
Neurovascular 
Coupling 
(‘NVC’)
Relationship 
between MEG 
and CBF/BOLD 
signals
DCBF/DCMRO2
Chapter 4. The coupling between visual gamma 
oscillations and BOLD and CBF signals: 
investigating NVC in MS.
Recruited: 
14 MS patients, 
10 controls
Chapter 5. Quantifying blood flow and oxygen 
utilisation at rest, in MS, using dual-calibrated fMRI 
Recruited:
26 MS patients, 
25 controls
Chapter 6. Blood flow and oxygen metabolism 
changes in MS, during visual stimulation, using 
calibrated-fMRI
Chapter 9. Coupling between brain oscillations, 
CBF, and BOLD signals during naturalistic movie 
viewing in MS  
22 MS, 22 Controls
15 MS, 12 Controls
(+3 controls from Ch 7)
Recruited:
19 healthy 
participants
Chapter 7. Coupling between brain oscillations, 
CBF, and BOLD signals during naturalistic movie 
viewing
Chapter 8. Using a breath-hold design to estimate 
the calibration factor M: can we model CMRO2 to a 
movie-stimulus? 14 participants
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1 Introduction to Biological Signals 
 
1.1 Neural Oscillations 
 
1.1.1 What are neural oscillations? 
 
In this thesis, neural activity is studied at the population level, via the oscillating 
electrical activity of large populations of neurons. These oscillations represent 
synchronous rhythmic neural activity. This synchronisation, in time, causes a 
summation of amplitude in space, measured over a certain area of the brain. Neural 
oscillations are typically described by their amplitude, frequency and phase, displayed 
in Figure 1-1. The first observations of neural oscillations in humans were reported by 
Hans Berger in the 1920s (Millett, 2001). He made the  electroencephalography (EEG) 
recording in a human, showing that fluctuations in voltage amplitude, at a frequency of 
~10Hz measured over the occipital cortex, varied with the participant’s attention to their 
visual environment. For example, when participants closed their eyes this produced 
large increases in the amplitude of these oscillations.  To measure these neural 
oscillations non-invasively we can use EEG or MEG. Whereas EEG measures electrical 
currents at scalp level, MEG measures magnetic field fluctuations, produced by 
electrical currents, outside the head. These electrical currents are caused by the flow 
of transmembrane ionic currents in large populations of neurons.  In this thesis, neural 
oscillations are measured non-invasively with MEG (see Chapter 2.1).  
 
 
Figure 1-1. A diagram displaying the amplitude, frequency and phase information of an 
oscillating wave. 
 
1.1.2 Biological origin of neural oscillations  
 
Neural oscillations are thought to represent rhythmic fluctuations of the local field 
potential (LFP). The LFP is a measured signal reflecting the summed electrical current 
over a volume of tissue, generated by transmembrane ionic current flow (Einevoll, 
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Kayser, Logothetis, & Panzeri, 2013). Ionic currents are thought to arise from two main 
types of activity: axonal and post-synaptic. Axonal activity involves the rapid 
depolarisation of the membrane, resulting in an action potential that propagates along 
the axon. Post-synaptic activity is the electrical input at the level of dendrites, 
contributing to an action potential but distinct in space and time. When an action 
potential reaches the presynaptic membrane, this leads to an excitatory (E) or inhibitory 
(I) postsynaptic potential (PSP), dependent on the type of neurotransmitters released 
and the type of receptors present. The summed effect of these EPSPs and IPSPs will 
contribute to whether an action potential is triggered.  
 
It is thought that LFPs, and therefore neural oscillations measured with EEG or MEG,  
predominantly originate from the post-synaptic current flow (Cohen, 2017; Hall, 
Robson, Morris, & Brookes, 2014). This is mainly due to the magnitude of the signal we 
detect. A single axonal or dendritic current flow is not sufficient to detect a signal outside 
the head; for a detectable field, tens of thousands of currents would need to flow in 
synchrony. The temporal duration of dendritic current is greater than an action potential 
and dendrites are also greater in number. As to the type of neuron, it is argued that 
stellate neurons, which have dendritic processes radiating from all around the cell body, 
are unlikely to contribute significantly to the magnetic field measured with MEG as their 
ESPS will not sum cumulatively. Therefore, apical dendrites of pyramidal cells, in 
parallel columns, are the most likely origin of MEG signals. Furthermore, these apical 
dendrites need to be oriented in parallel (tangential orientation) to the cortical surface 
for them to project detectable magnetic field components outside the head; neurons in 
gyri that are perpendicular (radial orientation) to the cortical surface do not project 
outside the head and cannot be measured with MEG (Ahlfors, Han, Belliveau, & 
Hämäläinen, 2010).  
 
Simultaneous measurements of invasive electrophysiology and MEG (Zhu et al., 2009), 
show that LFPs (mostly post-synaptic in origin) better match the MEG signal changes 
than multi-unit activity (largely axonal origin). However, although PSPs make the 
biggest contribution to the LFP, other neural processes also contribute. Importantly, a 
transmembrane current in any excitable membrane (dendrite, soma, axon, axon 
terminal) can contribute to the LFP (Buzsáki, Anastassiou, & Koch, 2012; Einevoll et 
al., 2013) as it is the temporal and spatial accumulation of all ionic processes that is 
being measured. 
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1.1.3 How are neural oscillations typically studied? 
 
When resting activity is examined, the brain exhibits a 1/frequency power spectrum; the 
lower the frequency the higher the amplitude, see part A of Figure 1-2. This remains 
the case when brain networks are activated (Jia & Kohn, 2011) but to a smaller degree, 
as the power of higher frequency oscillations often increases and low frequency 
oscillations decrease. This is why studies of neural oscillations typically look at changes 
relative to baseline, to characterise frequency components that are task-driven (part B 
of Figure 1-2). A wide range of frequencies of neural oscillations have been studied and 
linked to behaviour, typically catergorised into these approximate frequency bands: 
‘delta’ (<4Hz), ‘theta’ (4-8Hz), ‘alpha’ (8-13Hz), ‘beta’ (13-30Hz), and ‘gamma’ (> 30Hz), 
(Buzsáki & Draguhn, 2004; Ward, 2003). The functional significance of each band is 
still an active area of research, but they all have been linked to perception, cognition or 
memory in some way. For example, there is much animal literature, and some human, 
linking theta oscillations to episodic memory processes in the hippocampus, e.g. (Lega, 
Jacobs, & Kahana, 2012). Alpha is typically linked to attentional and inhibitory control 
(Mathewson et al., 2011), beta to sensorimotor control (Kilavik, Zaepffel, Brovelli, 
MacKay, & Riehle, 2013), and gamma to attention, perception, and mediation of 
information transfer across cortical areas (Fries, 2009; Jia & Kohn, 2011).  
 
 
Figure 1-2. Time-frequency spectrogram showing power at rest (A) and during a visual 
stimulus (B). (A) displays the typical 1/f power spectrum at rest, and (B) shows the 
relative change in power, in different frequency bands, elicited by a visual stimulus. 
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Changes in oscillatory frequency rarely happen in one frequency band alone; the 
amplitude of the signal in different frequencies change together in dynamic ways. This 
can be seen in Figure 1-2. In response to a reversing checkerboard (stimulus onset 0) 
a clear power increase in the gamma band is seen (a synchronisation) and a decrease 
in alpha and beta (a desynchronisation).  The slower visual evoked response can also 
be seen as a synchronisation in the delta/theta band. This plot displays both evoked 
and induced oscillatory components; it is therefore useful to explain their distinction. 
For evoked oscillations, the phase of the wave is locked to the stimulus, which is not 
the case for induced oscillations (David, Kilner, & Friston, 2006; Tallon-Baudry & 
Bertrand, 1999). To estimate evoked power only, an E/MEG signal is averaged over 
trials in the experiment, then the time-frequency components are examined. If a power 
increase related to the stimulus is not phase locked, this signal will therefore not remain 
in the average. For induced oscillations, time-frequency decomposition is performed at 
each trial first, then the power is averaged, as is summarised in Figure 1-3. To visualise 
induced activity only, the power of evoked signals can be subtracted (not the case in 
Figure 1-2). 
 
 
Figure 1-3. (A) Distinction between evoked and induced responses. (B) Time-frequency 
power of the evoked response after averaging over each trial. (C) Time-frequency 
power of each trial. (D) Average of each in C to give the induced gamma response. 
Figure from Tallon-Baudry & Bertrand (1999). 
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1.1.4 Functional relevance of neural oscillations  
 
Despite a large variability in brain volume across mammalian species, the intermittent 
and oscillatory patterns of LFPs, and even their behavioural correlates, are very closely 
preserved across species (Buzsáki, Logothetis, & Singer, 2013). Therefore, it seems 
neural oscillations constitute a fundamental biological mechanism in the mammalian 
brain. The features of neural oscillations are determined by the physical architecture of 
neural networks; the frequency of oscillation is constrained by the size of the neural 
population involved, with faster oscillations typically confined to more local networks, 
and slower oscillations reflecting larger spatial networks (Buzsáki & Draguhn, 2004). 
With the evoked response, we assume there is the same brain response at each trial, 
with surrounding fluctuating noise. They are often studied clinically, for example the 
visual evoked field (VEF) is thought to reveal integrity of the afferent visual pathway 
(Kothari, Bokariya, Singh, & Singh, 2016). Induced oscillations are thought to be 
generated by higher-order processes, with synchronisation of ionic current flows 
reflecting functional coherence. There is building evidence for neural oscillations being 
impaired in neurodegenerative diseases (Nimmrich, Draguhn, & Axmacher, 2015), and 
particularly in schizophrenia (Uhlhaas & Singer, 2010).  
 
1.2 Energy demands of neural activity: the response of the cerebrovasculature  
 
1.2.1 Energy demands of neural activity 
 
Neural oscillations, and neural activity in general, are very energy demanding 
processes. Energy is needed to restore ionic gradients to their baseline, after they 
change due to action potentials and PSPs, and also for the uptake and recycling of 
neurotransmitters at the synapse, particularly glutamate (Attwell & Laughlin, 2001; 
Shulman, Rothman, Behar, & Hyder, 2004). In order to do this, neurons, like other cells, 
need a source of free energy in the form Adenosine Triphosphate (ATP), a molecule 
that can store and transport chemical energy. When ATP is consumed due to metabolic 
processes, it converts to either Adenosine Diphosphate (ADP) or adenosine 
monophosphate. In the brain, the most efficient way to convert ADP back to ATP is 
through the oxidative metabolism of glucose (Buxton, 2009). Glucose and oxygen are 
converted to water, carbon dioxide (CO2) and energy; energy that can be used to 
convert ADP molecules to ATP.  First, the process of glycolysis in the cytosol involves 
the breakdown of glucose into pyruvate molecules. These can be further broken down 
in the mitochondria (through the Krebs cycle) to form CO2 and energy, and eventually 
water and energy to convert ADP to ATP. A small amount of ATP is formed during 
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glycolysis in the cytoplasm, without the use of oxygen. However, a much larger amount 
of ATP is produced in the mitochondria with the aid of oxygen (Du et al., 2008). For 
example, breaking down glucose into 2 molecules of pyruvate is coupled to the 
conversion of 2 molecules of ADP to ATP, whereas metabolism of 1 pyruvate and 3 
oxygen molecules is coupled to the conversion of 18 ADP to ATP (Buxton, 2009). 
Therefore, the energy demands of neural activity are greatly dependent on the direct 
supply of oxygen and glucose.  
 
In this thesis, the fMRI methods used do not measure changes in glucose directly but 
changes reflective of oxygen metabolism. Although it is the metabolism of glucose that 
provides the brain with the required ATP, this is strongly aided by the supply of oxygen. 
Therefore, oxygen and glucose metabolism are intrinsically coupled, both reflecting the 
energy demands of neural activity. 
 
1.2.2 Delivery of nutrients by blood flow  
 
Blood flow delivers the required oxygen and glucose to the brain. In proportion to its 
size, the resting metabolic demands of the brain are large; it represents approximately 
2% of body weight but requires 20% of cardiac output to deliver oxygen and glucose 
(Raichle & Gusnard, 2002). The brain does not store glucose and oxygen so requires 
a continuous supply to allow it to produce enough ATP. This makes the brain very 
vulnerable to tissue death if blood flow is disrupted. Both glucose and oxygen are 
carried in the blood first by arteries (large blood vessels) entering the brain, which 
branch into smaller arteries called arterioles, and end up at capillaries, very small blood 
vessels where the oxygen and glucose is exchanged with tissue. Waste products from 
neural activity (such as CO2) also exchange at the capillary level, and are carried away 
by venules, small blood vessels that carry blood to veins, which return the blood and 
waste products to the lungs. This is displayed in Figure 1-4. 
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Glucose, carried in blood plasma, does not easily cross the blood-brain barrier, but 
diffuses down its concentration gradient from the higher blood concentration to the 
lower tissue concentration, through transporters in the capillary wall (Buxton, 2009). 
The oxygen carried in the blood is mostly bound to the protein haemoglobin, although 
a small amount (~2%) is carried as dissolved gas in the plasma. This plasma 
concentration is important, as oxygen diffuses down its concentration gradient from 
dissolved gas in capillary plasma to dissolved gas in the active tissue (Dunn, Mythen, 
& Grocott, 2016), which is then quickly replaced by the release of haemoglobin-bound 
oxygen. We will return to glucose and oxygen metabolism below, but first will focus on 
how blood is delivered to an area of the brain. 
 
Perfusion is a general term for the arrival of arterial blood to the capillary bed. With fMRI 
measures, we refer to cerebral blood flow (CBF), which is expressed as the amount of 
blood volume flowing into a certain mass of tissue, over a given time. Typically, the 
units are expressed as ml per 100g of tissue per minute (ml/100g/min). Despite 
changes in arterial pressure (the pressure of blood on the walls of blood vessels) the 
brain is extremely good at maintaining a constant resting CBF, by a process known as 
autoregulation (Duffin et al., 2018). Autoregulation happens via the control of vascular 
smooth muscle (multiple layers of smooth muscle cells in the large pial arteries and a 
single layer in the arterioles). This smooth muscle can contract to constrict the vessel 
or relax to dilate it, therefore changing the vascular resistance. In general, 
Figure 1-4. Blood vessels within a volume of tissue. Arterial blood delivered 
through the arteries and then the arterioles, ends up at the capillary beds (F1 + 
F2). Once oxygen and glucose are extracted into the tissue, by-products are 
drained away in the venules. Figure from Buxton (2009). 
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autoregulation maintains a constant resting blood flow despite variations in pressure, 
but blood flow also needs to change in response to metabolic demand (Duffin et al., 
2018).  
 
1.2.3 Neurovascular coupling and the neurovascular unit 
 
Neural activity and CBF have a close spatial and temporal relationship; increases in 
oxygen and glucose consumption, due to an increase in neural activity, is followed by 
a local increase in CBF. The processes relating local neural activity and subsequent 
changes in vessel tone, and therefore local CBF, is termed neurovascular coupling 
(NVC). This spatial and temporal coupling is the basis of fMRI, relying on blood flow 
changes to map neural activity.  
 
It was initially thought that NVC was controlled directly by a negative-feedback system, 
with changes in ATP producing a metabolic signal that increased blood flow (Attwell et 
al., 2010; Girouard & Iadecola, 2006). As well as blood replenishing oxygen and 
glucose, a flow increase clears the brain of potentially toxic by-products of neural 
activity, for example lactate and CO2, as well as regulating the brain’s temperature 
(Iadecola, 2017). In fact, both lactate and CO2, as well as other by-products, are potent 
vasodilators (Ainslie & Duffin, 2009; Dienel, 2012). However, this negative-feedback 
mechanism is thought to be an oversimplified account. One reason is that CBF 
response is not altered by experimentally reducing glucose and oxygen (Mintun et al., 
2001; Powers, Hirsch, & Cryer, 1996). Another reason is that the small transient 
reduction in oxygen consumption at the active site cannot account for the sustained 
increases in CBF. This is covered in more detail in Section 2.3.1 but, in brief, the 
increase in CBF is much greater than the increase in oxygen metabolism, in response 
to neural activity. These findings suggest that depletion of these metabolic substrates 
is not the only mechanism causing this increase in CBF after neural activity.  
 
NVC is also mediated by a feed-forward system, supported by what is termed the 
neurovascular unit, see Figure 1-5. The neurovascular unit involves the interaction of 
neuronal, glial, and vascular cells. Neurons can signal directly to blood vessels (Attwell 
& Iadecola, 2002), or signal to astrocytes to release vasoactive agents which then act 
on blood vessels (Petzold & Murthy, 2011). Neurotransmitter signalling is involved in 
both of these routes, particularly glutamate which activates calcium dependent 
signalling pathways and results in the realise of vasoactive components (Iadecola, 
2017). Many by-products of synaptic activity, such as potassium, nitric oxide (NO), and 
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prostanoids (Attwell et al., 2010) are vasoactive, therefore able to trigger vasodilation 
or vasoconstriction of the local blood vessels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-5. Synapses between neurons (blue), interneurons (purple) and astrocytes 
(green). Astrocytes signal to blood vessels at the astrocytic end-feet, in direct contact 
with endothelial cells (red), pericytes (yellow) and myocytes/Smc (orange). Figure from 
Muoio et al (2014). 
 
These feed-forward and feed-backward mechanisms are not mutually exclusive; it is 
likely that both may be involved in NVC. Summarised by Iadecola (2017), the relative 
involvement of each mechanism may depend on “the timing, intensity, and duration of 
the activation as well as the brain region and the brain’s developmental stage.” 
Regardless of the direction of signalling, the traditional view of where the regulation of 
blood happens is at the level of the arterioles, but there is an emerging idea that 
regulation can also happen at the level of the capillaries, due to the contractile 
properties of cells called the pericytes, which line the capillary wall (Hamilton, Attwell, 
& Hall, 2010). There is much to still understand about NVC: the contribution of 
feedforward and feedback mechanisms, the cellular basis of the signalling pathways, 
the regional variations across the brain, the upstream propagation of vasoactive signals 
and the exact role of the capillaries (Iadecola, 2017). There is also a lot to learn about 
how sensitive our neuroimaging techniques are to measuring these processes, hence 
why a focus of some of the research questions in this thesis is to investigate NVC 
mechanisms.  
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1.2.4 Functional relevance of neurovascular coupling  
 
The health of the neurovascular unit is extremely important, considering its role in 
replenishing nutrients that have been used up by neural activity, as well as removing 
potentially toxic by-products.  An impaired blood flow response to an area can lead to 
tissue hypoxia, and eventually tissue death. Although this can occur rapidly in cases 
such as stroke or other traumatic brain injury, damage to blood vessels or disruption of 
NVC pathways can also build up over time in many neurodegenerative conditions 
(Girouard & Iadecola, 2006; Phillips, Chan, Zheng, Krassioukov, & Ainslie, 2015; 
Stanimirovic & Friedman, 2012). There also may be cases  where the blood flow 
response to an area is adequate, but mitochondrial impairment leads to the brain being 
unable to metabolise oxygen appropriately (Aboul-Enein & Lassmann, 2005; Lindroos 
et al., 2009). The neuroimaging field is developing metrics to help non-invasively assess 
some of these impairments and help understand their role in the progression of many 
diseases. For example, by quantifying regional blood flow, oxygen metabolism and the 
reactivity of blood vessels. These are all explained in the next section.
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2  Introduction to Methods 
 
2.1 Magnetoencephalography (MEG) 
 
Neural oscillations are measured in this thesis using MEG. Despite being around since 
the late 1960s (Cohen, 1968) it is only in the last two to three decades that MEG has 
started to be fully utilised as a technique to investigate neural activity. This is partly due 
to development of larger arrays of sensors (200+), measuring from the whole cortex. 
An electrical current generated by one neuron is too weak to be measured with MEG; 
tens of thousands of neurons need to synchronously fire to generate a signal large 
enough to be detected (Hansen, Kringelbach, & Salmelin, 2010). Hansen et al (2010) 
describe how 50,000 synchronous firing neurons would correspond to a patch of cortex 
approximately 0.63 mm2, with a diameter of 0.9mm assuming the cortical patch has a 
circular form. These values are based on estimating the diameter of cortical mini-
columns, and the density of neurons contained within. Despite the spatial scale at which 
a signal can be generated estimated at <1mm3, MEG signals are estimated at a much 
coarser spatial resolution due to limitations in source localisation (explained  below and 
in section 2.1).  
 
MEG is sensitive to neural activity due to the laws of electromagnetism: all electrical 
currents generate a magnetic field perpendicular to their direction (Figure 2-1). 
 
The electrical current induced by the activity of a group of neurons is called the ‘primary 
current’, and this is what the MEG signal is most sensitive to (Senior, Russell, & 
Gazzaniga, 2006, Chapter 12). EEG, in contrast, is sensitive to the secondary currents 
(or ‘volume currents’) generated from this primary current; they flow outside the cell in 
the opposite direction, forming irregular patterns because they take the path of least 
electrical resistance to get to the head surface, where they can be recorded as voltage 
differences (Cheyne & Papanicolaou, 2015). Magnetic fields are not distorted as they 
Figure 2-1. The ‘Right hand rule’ 
shows the direction of the 
magnetic field B (following the 
curvature of the fingers and shown 
by the lines in blue) caused by the 
electrical current I (the direction of 
the thumb and shown by the red 
arrows). Public domain image 
from Wikipedia.  
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pass through different tissue layers. However, volume currents still contribute to the 
externally measured magnetic field (Cheyne & Papanicolaou, 2015) and have to be 
taken into account during forward modelling (estimating the electrical/magnetic fields 
recorded at the sensors given a particular pattern of current sources in the brain).  
 
Magnetic field strength rapidly decreases as distance increases from the source, 
making it challenging to accurately measure activity from sources deep in the brain 
(Hillebrand & Barnes, 2002). However progress is being made to study oscillations in 
areas such as the hippocampus (Pu, Cheyne, Cornwell, & Johnson, 2018). As the 
magnetic field fluctuations measured with MEG are so weak (in the femtotesla range, 
10-15 tesla), modern MEG systems are housed in magnetically shielded rooms, to block 
out magnetic signals from the environment, including the earth’s magnetic field. Super 
Conducting Quantum Interference Devices (SQUIDs) allow such magnetic fields to be 
measured. They are small rings of material that are superconducting when immersed 
in liquid helium (at ~4.2 Kelvin), with the capability of  sensitively measuring tiny 
magnetic fields (Senior, Russell, & Gazzaniga, 2006, Chapter 12). These SQUIDS are 
attached to larger pickup coils (arranged in an array over the participant’s head) which 
funnel the magnetic flux into the smaller SQUID. There are lots of different types of 
pick-up coils, with the broad categories being ‘magnetometers’ and ‘gradiometers’. 
Magnetometers simply measure any orthogonal field, whereas gradiometers (pairs of 
coils that are close together and wound in opposite directions) can measure gradients 
in the magnetic field over space, therefore being able to better separate noise from the 
environment (same effect on each coil from distant sources) and signals from the brain 
(different effect on each coil from the nearby source), (Proudfoot, Woolrich, Nobre, 
Turner, & Turner, 2014). 
 
The biggest strength of MEG is that it measures signals that directly relate to electrical 
brain activity. The temporal resolution of MEG is only limited by the sampling rate, 
allowing magnetic fields to be characterised on the millisecond level, the timescale of 
neural activity. The biggest weakness of MEG is the precision with which it can locate 
the source in space. The goal is to relate the magnetic field fluctuations measured at 
the level of the sensors to the location of the currents in the brain. This is referred to as 
the ‘inverse problem’ and there is no unique solution i.e. there are an infinite number of 
possible current distributions in the brain that could generate one pattern of magnetic 
fields at the sensors. To solve this inverse problem, we introduce prior constraints on 
the solutions, and find the solution that best describes the data. In this thesis, 
beamforming techniques are used to solve the inverse problem, explained below. 
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2.1.1 Beamforming source localisation 
 
The magnetic fields measured with MEG are often modelled as current dipoles which 
have a position, orientation and strength. Estimates of the current dipole at each brain 
location come from some weighted contribution from each sensor. Beamformer 
techniques measure the contribution of a single brain location to the measured field at 
each sensor, by constructing a spatial filter to ‘tune in’ to each location independently. 
First, a volumetric grid of target locations is defined, and for each location an optimum 
set of beamformer weights is determined (Hillebrand, Singh, Holliday, Furlong, & 
Barnes, 2005). This volumetric grid (typically around 5mm in resolution) is based on 
each participant’s anatomical MRI, which is co-registered to the MEG data by recording 
the location of three fiducial coils during MEG scanning, placed at three anatomical 
landmarks. Therefore, if we match these coil positions to the MEG data and the 
anatomical MRI, it follows that we can superimpose the MEG data onto this anatomical 
space. For each location in the brain, the signal is taken from each of the sensors 
multiplied by the beamformer weight, and all of these products summed to give a single 
time-series that represents the estimate of the current dipole at that location (see Figure 
2-2). For each grid location we need to find the weights that maximise the contribution 
of that location to the sensor array and suppress the others. In order to do this, 
beamforming algorithms make the assumption that any two distant cortical areas are 
not perfectly correlated (Hillebrand & Barnes, 2005). i.e. they do not generate coherent 
LFPs over long time scales. Empirical data has shown this to be a reasonable 
assumption (Hillebrand & Barnes, 2005).  
Figure 2-2. MEG beamforming technique for source localisation. Figure taken from 
(Hillebrand & Barnes, 2005). 
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2.2 The physics of MRI: A brief recap 
 
Before a more detailed description of the functional MRI methods, the main focus of 
this thesis, a brief description of MRI physics is given.  
 
Magnetic moments of hydrogen nuclei. MRI relies on the magnetic properties of 
hydrogen nuclei, which are positively charged protons spinning on their axes. These 
properties induce a magnetic moment (Figure 2-3). When placed in a large static 
magnetic field (B0) the magnetic moments of hydrogen go from being randomly 
orientated (part A Figure 2-3) to aligning parallel or antiparallel with B0 (part B Figure 
2-3). A small excess of low-energy nuclei aligning parallel causes a net magnetic 
moment, the net magnetisation vector (NMV) of hydrogen (part C Figure 2-3), 
(Westbrook, Roth, & Talbot, 2011). 
 
 
 
 
 
 
 
 
Figure 2-3. Hydrogen nuclei = coloured circles; magnetic moments = black arrows; B0 
= static field; NMV = net magnetic vector. Blue nuclei aligning parallel to B0 are low 
energy ‘spin-up’. Red nuclei aligning anti-parallel to B0 are high energy ‘spin-down’. 
Figure is my own but based on figures from Westbrook, Roth, & Talbot (2011). 
 
 
Precession. Being placed in B0 causes this magnetic moment 
to precess in a circular path around B0 (direction of small orange 
arrows in Figure 2-4). The Larmor equation explains the 
frequency at which a specific nucleus precesses: ω0 = γ B0. 
Where the precessional frequency of the nucleus (ω0) is related 
to B0 by the constant γ, termed the gyromagnetic ratio. At typical 
MRI field strengths, hydrogen precesses in the radio frequency 
(RF) band.  
 
 
Figure 2-4. B0 = large white arrow. Hydrogen proton = grey circle. 
Magnetic moment = large orange arrow. Figure is my own but 
based on figures from Westbrook, Roth, & Talbot (2011). 
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Resonance. A RF pulse of energy at the larmor frequency must be applied in order for 
energy to be absorbed, a process termed resonance. Resonance has two effects on 
the NMV. Firstly, the energy absorption causes the NMV to no longer align perfectly 
with B0, as more nuclei join the high energy population. The angle of misalignment 
depends on the amplitude and duration of the RF pulse, termed the flip angle. The 
second effect of resonance is related to the phase of the magnetic moments of 
hydrogen (their position along the processional path around B0 at a specific time, for 
example the four small orange arrows on Figure 2-4). Resonance causes all the 
magnetic moments to eventually move to the same position along this processional 
path, referred to as being ‘in phase.’  
 
The MR signal. Magnetic field fluctuations inside an MR receiver coil induce an 
electrical voltage, and this is the MR signal. These magnetic field fluctuations will 
depend on the amount of magnetisation in the transverse plane (i.e. the amount of in-
phase magnetisation) at the larmor frequency. Once perturbed from the longitudinal 
direction, the NMV starts to realign back with B0, as hydrogen nuclei lose energy. This 
is known as relaxation. Magnetization in the longitudinal plane increases (‘recovery’), 
and the amount of magnetisation in the transverse plane decreases (‘decay’). This 
evolution of the signal in the MR receiver coil is referred to as free induction decay 
(FID).  The recovery of the longitudinal magnetization is due to nuclei giving up energy 
to their surrounding environment (lattice) and is termed ‘spin-lattice relaxation’. The 
magnetization recovers exponentially over time, with the T1 relaxation time being the 
time it takes for 63% of the longitudinal magnetization to recover. Decay of coherent 
transverse magnetisation is due to magnetic fields of near-by nuclei interacting, termed 
‘spin-spin relaxation’. This rate of decay is also an exponential process, with the T2 
relaxation time being the time it takes for 63% of transverse magnetization to decay.  
 
The amount of T1 and T2 relaxation allowed is manipulated with the choice of RF pulse 
timing parameters. The repetition time (TR) is the time between one excitation RF pulse 
to the next excitation RF pulse, determining how much T1 relaxation has occurred when 
reading the signal. The echo time (TE) is the time between the RF pulse and the peak 
of the signal in the receiver-coil, determining how much T2 relaxation has occurred 
when reading the signal.  As different tissue types have differing amounts and 
arrangements of hydrogen, this means the magnetic moments of hydrogen nuclei in 
these different tissues take a different amount of time to lose their transverse 
magnetisation, after the RF pulse has been turned off, and therefore induce different 
levels of magnetic field fluctuation. This is the basis of contrast in an MR image.  
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The spin-spin relaxation, characterised by T2 relaxation time, causes dephasing of the 
transverse magnetisation that is irreversible. Dephasing is also caused by macro- and 
mesoscopic magnetic field inhomogeneities and this is termed T2* relaxation. These 
field inhomogeneities mainly occur due to magnetic susceptibility of different tissues, 
(Chavhan, Babyn, Thomas, Shroff, & Haacke, 2009). fMRI, explained below, depends 
on this T2* relaxation as the basis of the signal contrast. When reading out the image 
using gradient-echo (GRE) sequences, transverse magnetisation is based on both spin-
spin relaxation as well as these magnetic field inhomogeneities which cause dephasing 
and increase the transverse relaxation. Therefore, as these sequences are sensitive to 
T2 relaxation and these extra dephasing effects, they are said to have T2*-weighting, 
with T2* always being shorter than T2. Using a different method of image read-out, 
spin-echo sequences, can eliminate these dephasing effects, making the contrast 
dependent on T2 relaxation only, by using a refocusing RF pulse with a flip angle of 
180° (Chavhan et al., 2009).  
 
2.3 Functional MRI (fMRI) 
 
2.3.1 The BOLD signal 
 
The Blood Oxygen Level Dependent (BOLD) signal was discovered in the early 1990s, 
first demonstrated in rat brains then shortly after in humans (Ogawa, Lee, Kay, & Tank, 
1990; Ogawa & Lee, 1990). Since then, a very large number (hundreds of thousands) 
of studies in cognitive neuroscience, clinical psychology, and presurgical planning have 
utilised this technique as a way to localise changes in brain activity (Glover, 2011). The 
principles of the BOLD signal rely on the fact that de-oxyhaemoglobin and 
oxyhaemoglobin have different magnetic susceptibilities. At rest, the arterial blood is 
almost fully saturated with oxygen i.e. the arterial oxygen content (CaO2) is close to 1. 
In the healthy brain, the amount of oxygen extracted from the blood is consistently 
reported to be around 40% at rest, making the Oxygen Extraction Fraction (OEF) 0.4 
(Leithner & Royl, 2014). We can model the Cerebral Metabolic Rate of Oxygen 
(CMRO2) if we know the delivery of oxygen (by oxygenated blood) and the amount 
extracted by the tissue: 
 
CMRO2 = CaO2 x OEF x CBF (Equation 2-1) 
 
During activation, CBF increases from its baseline state in much larger proportions than 
CMRO2 increases from baseline. This is characterised by the coupling ratio ‘n’ normally 
reported to be around 2-4, meaning the relative CBF response is typically 2-4 times 
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larger than the relative CMRO2 response (Buxton, 2009; Leithner & Royl, 2014). 
Assuming CaO2 is the same as it is at rest, it follows that OEF decreases with activation. 
This seems unintuitive, that the fraction of oxygen extracted from the blood goes down 
during activation. This is due to the increased rate of delivery of oxygenated blood, so 
the tissue extracts a lower proportion of oxygen from the blood at a given time.  
 
How does this lead to the BOLD signal? As the capillary and venous blood are more 
oxygenated, less deoxyhaemoglobin is present in the voxel that is being imaged. 
Oxyhaemoglobin is diamagnetic, meaning it is has similar magnetic properties to the 
surrounding tissue. Deoxyhaemoglobin is paramagnetic, meaning it distorts the 
surrounding magnetic field, causing shorter T2 and T2* relaxation times, and making 
the MR signal decay faster. Put another way, when the amount of deoxyhaemoglobin 
decreases in the imaged voxel, as is the case with increases in neural activity, the T2 
and T2* relaxation times become longer and the signal measured with a T2 or T2*-
weighted sequence slightly increases. Due to the most commonly acquired BOLD 
signal contrast being dependent on the T2* relaxation time (from GRE acquisition), it is 
particularly susceptible to signal drop-out in regions that are near air cavities (e.g. 
sinuses) as macroscopic susceptibility-induced magnetic field gradients cause de-
phasing and therefore signal loss. 
 
The BOLD response indexes only relative changes in neural activity, as it does not 
provide information about the concentration of deoxyhaemoglobin in the resting state, 
only the difference between rest and stimulus. The BOLD response not only reflects the 
relative increases in CBF and CMRO2, but also a local increase in cerebral blood 
volume (CBV), see Figure 2-5. The increases in CBV and CMRO2 cause a decrease in 
the BOLD signal, whereas an increase in CBF causes an increase in the BOLD signal; 
this CBF effect is typically dominant causing a net increase. As well as this, the 
maximum BOLD response is dependent on the resting physiological state of the tissue, 
determined by blood haematocrit (ratio of volume of red blood cells to total volume of 
blood), the resting OEF and the resting CBV. The maximum possible BOLD response 
increases when these resting parameters increase. 
 
Due to the BOLD response reflecting all these changes, its utility as a sole marker of 
brain activity in studies investigating diseases and pharmacology has been questioned 
(Iannetti & Wise, 2007). In any circumstance where two populations being compared 
have a different baseline state, the comparison of BOLD signal changes may not be a 
valid reflection of differences in neural activity. Furthermore, if the couplings between 
the CBF, CMRO2 and CBV responses are altered in disease, this could result in a 
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different BOLD response when the neural activity is the same, or no BOLD change 
when the neural activity is different. The focus of this thesis is to partial out these signals 
that contribute to the BOLD response, allowing us to more meaningfully interpret how 
the brain is responding to neural activity. This is the focus of the next sections: using 
Arterial Spin Labelling (ASL) to measure CBF and using calibrated-fMRI to model the 
CMRO2 response, as well as to estimate the baseline tissue physiology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.2 Arterial Spin Labelling for CBF measurements 
 
There have been many techniques developed, used in research and clinical practice, 
to measure CBF: perfusion CT-scan, dynamic susceptibility contrast-MRI (DSC-MRI), 
single-photo emission computed tomography and positron emission tomography (PET), 
(Ferré et al., 2013). However, these techniques require the injection of exogenous 
contrast media or ionizing radiation, making them invasive and challenging to use 
repeatedly on the same subject. This thesis focuses on non-invasive ways to study the 
brain, and therefore uses a non-invasive fMRI technique to measure CBF, called 
Arterial Spin Labelling (ASL).  Compared to BOLD-fMRI, ASL directly measures the 
delivery of arterial blood, therefore the signal is more localised to the capillary beds, 
whereas the BOLD signal is more influenced by venous oxygenation changes (Buxton, 
2009). 
 
Imaging techniques such as PET monitor the kinetics of an injected agent as it passes 
through the tissue, therefore reflecting the rate of blood flow. ASL works on similar 
Figure 2-5. Overview of the BOLD response, showing its dependence on changes in 
CBV, CBF and CMRO2, in response to a stimulus. The baseline state (levels of 
haematocrit, resting OEF and resting CBV) affect the maximum possible BOLD 
response. Figure taken from (Blockley et al., 2013).  
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principles but uses an endogenous tracer. With ASL, the blood water is magnetically 
labelled to flip the magnetization of hydrogen protons within  water molecules carried 
by arterial blood. After waiting a certain time to allow the labelled blood to travel to the 
slice of interest, a ‘labelled’ image is acquired. A ‘control’ image is acquired using the 
exact same imaging parameters, but without labelling the blood. The differences 
between the label and control images (repeated many times to get enough signal 
through averaging) is proportional to the blood flow into the slice of interest, under the 
assumption that static signal from the tissue subtracts out, leaving just the signal that 
represents the flow of the magnetically labelled blood into the tissue. The signal decays 
with the T1 relaxation rate; as the relaxation time for water in blood or tissue is 1-2 
seconds only a small amount of labelled water contributes to this ‘difference’ image, 
with the inflowing labelled blood only accounting for  0.5 – 1.5% of the full tissue signal 
(Petcharunpaisan, Ramalho, Castillo, & Carmichael, 2010). Therefore, ASL as a 
technique has a low signal to noise ratio (SNR), and lower temporal resolution than 
standard BOLD-fMRI considering both a label and a control image have to be acquired, 
as well as labelling of the blood. However, this label-control subtraction makes the CBF 
signal robust against slow drifts of the MR signal, making it more suitable for long task-
designs (Wang et al., 2003) than BOLD-fMRI.  
 
There are different options for labelling the blood. Two of the most common, pulsed 
ASL (PASL) and pseudo-continuous (pCASL), are displayed in Figure 2-6. 
 
 
 
Figure 2-6. Figure taken from (Haller et 
al., 2016) showing two different ASL 
labelling schemes. (A) shows pulsed 
ASL and (B) shows pseudo-continuous 
ASL. 
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In this thesis, both PASL and pCASL are used. With PASL, arterial blood water is 
labelled in an inversion slab below the imaging volume, labelling the blood in the arteries 
supplying the brain. All the blood in this slab is inverted simultaneously, in about 10 
milliseconds, and the time from labelling to acquiring the image is termed the inversion 
time (TI), (Haller et al., 2016). With pCASL the magnetisation of the blood water is 
continuously inverted as it flows through a much narrower labelling plane, typically for 
1-2 seconds (Haller et al., 2016), with a train of very short (~1ms) pulses. The post label 
delay (PLD) is the amount of time after the end of the labelling that passes before 
acquiring the image. PASL has lower SNR than pCASL because the arterial blood 
inverted with PASL undergoes T1 relaxation as it travels through the inversion slab and 
to the slice of interest. With pCASL, the blood is continuously inverted, meaning all 
blood that arrives at the tissue has the same amount of T1 decay regardless of when it 
was labelled (Haller et al., 2016), if a constant arrival time is assumed. In terms of the 
labelling inversion efficiency, in pCASL this is affected by the velocity of blood (Wu, 
Fernández-Seara, Detre, Wehrli, & Wang, 2007), whereas this is not a problem with the 
very short labelling duration used in PASL.  
 
Comparing the difference between labelled and control acquisitions during stimulus and 
baseline periods can give relative CBF changes. However, the great advantage of ASL 
techniques is that the signal can be quantified in units of ml/100g/min (Alsop et al., 
2015). Using PCASL as an example, this can be calculated in each voxel by: 
CBF (ml/100g/min) =	 #$$$	.		&	.		'()*+,-.+/0()1234	.5 67819,;/++<=	.		>	.		?9,;/++<	.		()68	.		(A05B C19,;/++<  (Equation 2-2) 
 
where 	𝜆 is the brain/blood partition coefficient (typically assumed to be 0.9 ml/g), 𝑆𝐼GHIJKHL and 𝑆𝐼?MN are the signal intensities of the control and labelled images, 𝑇A,PLHHQ 
is the longitudinal relaxation time of blood in seconds (typically assumed to be 1650ms 
at 3Tesla), 	𝛼 is the labelling efficiency (typically 0.85 for PCASL), 𝑆𝐼ST is the signal 
intensity of water in a proton density image acquired with the same characteristics as 
the CBF images (typically referred to as the M0 image in this thesis), and 𝜏 is the label 
duration. The 6000 simply converts the units from ml/g/s to ml/100g/min, which is how 
CBF is typically reported in the literature.  
 
For both PASL and PCASL CBF quantification, some assumptions are made in order 
to do this CBF quantification step. These assumptions (summarised by (Alsop et al., 
2015)) are: (1) The entire amount of labelled blood is delivered to the target tissue 
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(determined by the important choice of PLD in PCASL and TI in PASL), (2) There is no 
outflow of labelled blood water, and (3) T1 of blood only determines the relaxation of 
labelled spins, which is not likely to be completely true due to the difference between 
the T1 of blood and tissue. This is thought to only introduce small errors.  
 
The ASL scans used in this thesis allow the estimation of both CBF and BOLD weighted 
images. The specifics of each sequence are explained in each chapter but the general 
approach is described here. Using one RF excitation pulse, two read-outs can follow: 
one with a short TE (~3ms) for CBF time series with little BOLD weighing, and a later 
TE (~30ms) for the BOLD-weighted time series. A slightly different approach involves 
using an interleaved acquisition, with two RF excitation pulses. This results in a 
repeating sequence of 4 image volumes: ASL labelled image with short TE, BOLD 
image with long TE, ASL control image with short TE, BOLD image with long TE. Use 
of background suppression and a short TE reduces the BOLD weighted signal in the 
ASL time series (Warnock et al., 2018) and reduces noise contributions from static 
tissue. The dual excitation approach gives less ASL contamination to the BOLD time-
series, compared with the single excitation method. However, in both cases a ‘surround 
average’ processing approach is taken to isolate the BOLD time series, analogous to 
the ‘surround subtraction’ approach used to generate CBF time series (Liu & Wong, 
2005; Warnock et al., 2018). ASL provides a set of n control (C) and label (L) images: 
[C1, L1, C2, L2, C3, L3, Cn, Ln]. With surround subtraction, the perfusion (P) time-series 
can be calculated by taking the difference between the control image and its two 
surrounding label images (except for the first volume where only pair-wise subtraction 
occurs): 
 
[P1, P2, P3, Pn/2] = [C1 - L1, C2 – ((L1 + L2) /2), C3 – ((L2 + L3) /2) …] 
 
A similar approach can be taken for the BOLD-time series using surround averaging, 
where the average between the control image and its two surrounding label images is 
taken, to remove ASL contamination.  
 
2.3.3 Calibrated-fMRI  
 
Acquiring both BOLD and CBF time-series in the same sequence is useful for modelling 
the CMRO2 response, when some physiological manipulations are administered, and 
some assumptions made. Calibrated fMRI refers to measuring BOLD and CBF signals 
during hypercapnia to ‘calibrate’ the BOLD signal, then allowing a change in the relative 
CMRO2 response to a stimulus to be calculated. This approach was introduced by 
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Davis, Kwong, Weisskoff, & Rosen (1998) and later adapted by (Hoge et al., 1999). As 
described in Figure 2-5 the BOLD response can be expressed in terms of changes in 
CBF, CBV and CMRO2 changes: ∆WXYTWXYTZ	 = 𝑀\1 −	_GW`GW Z`a	_ GWbGWbZa0c 	d GefXgGefXgZhci	  (Equation 2-3) 
Here, the ∆ symbol means change from baseline and the 0 subscript refers to the 
baseline state. There is a power-law relationship between BOLD and 
deoxyhaemoglobin concentration, represented by the b parameter. This parameter 
varies with field strength and is dependent on vessel size distribution. It is typically 
assumed to be 1.3 when scanning with 3 Tesla MRI (Kennan, Zhong, & Gore, 1994). 
CBV is not commonly measured directly, as is the case in this thesis. Therefore, CBV 
changes are inferred from changes in CBF assuming the power law relationship  _GW`GW Z`a = k._GWbGWbZa>			(Equation 2-4) 
where k is a constant and α has typically been assumed to be 0.38, based on early 
animal work (Grubb, Raichle, Eichling, 1974). However, recent studies have started to 
use lower values, based on evidence showing this coupling to be closer to ~0.2 in 
human fMRI calibration studies (Chen & Pike, 2009, 2010; Mark & Pike, 2012).The 
modelled BOLD signal now becomes:  ∆WXYTWXYTZ	 = 𝑀\1 −	_ GWbGWbZa>0c 	d GefXgGefXgZhci			 (Equation 2-5) 
In order to model CMRO2 the only remaining unknown in this equation is therefore the 
M value. M is a scaling parameter often described as the maximum BOLD signal 
change that would occur if all deoxyhaemoglobin were washed out of the venous blood 
vessels, and therefore reflects the baseline physiological state of the tissue. We do not 
measure M directly like BOLD and CBF signals, but we can estimate it using a gas 
calibration manipulation.  
 
CO2 is a vasoactive stimulus that increases blood flow by dilating the blood vessels, 
normally as a by-product to neural activity. The principles of calibrated-fMRI involves 
administering a hypercapnic (increased CO2) gas mixture to the subject to increase 
CBF (and therefore also increase BOLD), with the assumption that there is no change 
in CMRO2 (Davis et al., 1998), This has been carried out in many research studies with 
healthy volunteers (Liu, De Vis, & Lu, 2018), and shown to be safe, well tolerated and 
feasible in patient populations (Spano et al., 2013).  Typically, a gas mixture of 5% CO2, 
21% oxygen and 74% nitrogen is used. Assuming there is no change in CMRO2, the 
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relative CMRO2 term in Equation 2-5 equates to 1 so the modelled BOLD signal 
becomes: ∆WXYTWXYTZ	 = 𝑀d1 −	_GWbGWbZaj0c	h  (Equation 2-6) 
As we measure the BOLD and CBF change to the hypercapnic stimulus, and we 
assume values for α and β, we can simply re-arrange Equation 2-6 to get the M value 
in that region. In the same scanning session, in the same subject, if we collect BOLD 
and CBF response to a task or stimulus, we can then re-arrange Equation 2-5 to give 
relative changes in CMRO2 to the stimulus: 
GefX=GefX=Z = 	 _GWbGWbZaA0	mn	 . \1 −	 ∆op78op78Ze i9n	(Equation 2-7) 
Another way CO2  inhalation is commonly used in the fMRI literature is to characterise 
the reactivity of the blood vessels. As CO2  is a vasodilator it will increase blood flow all 
across the brain. A response to CO2  therefore gives an indication of the ability of the 
blood vessels to dilate or constrict, informing about vascular health and reserve (Liu et 
al., 2018). This metric is referred to as Cerebrovascular Reactivity (CVR) in the 
literature. Concentrations of the inhaled and exhaled CO2  are recorded through-out the 
experiment via a face-mask or nasal cannula.  As arterial blood gas measurements are 
invasive, end-tidal partial pressure of CO2 (PETCO2), the partial pressure of CO2 at the 
end of the exhalation, is used as a surrogate measure of arterial CO2  (McSwain et al., 
2010). Gas measurements are typically quantified in units of millimetres of mercury 
(mmHg), a unit of pressure. The measured BOLD or CBF response can then be 
expressed in percentage or absolute change in BOLD/CBF per mmHg change in 
PETCO2.  
 
Instead of a gas-paradigm, a breath-hold (BH) task where participants hold their breath 
typically for 10-20 seconds can also act as a hypercapnic stimulus, in order to 
characterise CVR (Urback, MacIntosh, & Goldstein, 2017). An estimate of M can also 
be gained from a BH task, to model CMRO2 the same way as explained above. 
Developing such methodology is the focus of Chapter 8 of this thesis. 
 
2.3.4 Dual Calibrated-fMRI  
 
Calibrated-fMRI gives relative CMRO2 changes to a stimulus, which we expect to offer 
a closer reflection of the metabolic demands of brain activity compared to BOLD-fMRI 
alone. An extension of this technique has been recently developed (Bulte et al., 2012; 
Gauthier, Desjardins-Crépeau, Madjar, Bherer, & Hoge, 2012; Wise, Harris, Stone, & 
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Murphy, 2013) showing that information about baseline CMRO2  can also be estimated, 
by adding a second calibration step. In the original calibrated-fMRI design, the baseline 
physiological state is summarised by the M parameter, and its effect on the BOLD signal 
is considered. With dual-calibrated designs, the models attempt to separate out the 
different physiological contributions to M and estimate the baseline physiological state. 
Characterising baseline CMRO2 measurements, alongside other parameters such as 
baseline CBF, has potential valuable information to help understand the cause of a 
disease, including what mechanisms might relate to disease progression. As with BOLD 
and CBF signals, interpreting relative CMRO2 signal changes still may be confounded 
if baseline CMRO2  is altered in disease (Iannetti & Wise, 2007), therefore it is also 
useful to consider the baseline in the interpretation of any stimulus-induced changes.  
 
The BOLD response modelled by (Davis et al., 1998) and (Hoge et al., 1999) can be 
expressed in terms of CBV (CBV substituted with CBF by Equation 2-4) and venous 
deoxyhaemoglobin concentration [dHb] in response to changes in partial pressure of 
O2 and CO2: 
 ∆WXYTWXYTZ	 = 𝑀 d1 −	_GWbGWbZaj 	_ QqPQqPZach	(Equation 2-8) 
 
where the subscript 0 represents the baseline (normoxic and normocapnic) conditions 
(Wise et al., 2013). As explained in the Calibrated-fMRI section, M can be calculated 
with a hypercapnic stimulus. The aim with dual-calibrated fMRI is to estimate the [dHb0] 
which is not possible with hypercapnia alone. The change in [dHb] concentration, with 
respect to baseline, when arterial oxygen content is increased and/or CBF altered is 
given by:  
 QqPQqPZ = 	 GWbZGWb −	 AQqPZ rA∅ _𝐶𝑎𝑂= − _GWbZGWb a 𝐶𝑎𝑂=|$a + [𝐻𝑏] _GWbZGWb − 1a}	(Equation 2-9) 
 
where [Hb] is haemoglobin in g/dL (grams per decilitre of blood), ϕ is the O2 carrying 
capacity of [Hb] in mlO2/gHb, and CaO= is the oxygen content of arterial blood. Subsisting 
Equation 2-9 into 2-8 leaves the only unknown term as [dHb0], therefore this can be 
obtained from measurement and estimation of all the other physiological parameters.  
Full derivation of equations can be found in Wise et al (2013). 
 
This dual-calibrated design includes a hypercapnic stimulus to increase CBF as before, 
and a hyperoxic stimulus to increase the BOLD signal, to first approximation, without a 
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CBF change. As with hypercapnia, the hyperoxia is assumed to be isometabolic (no 
change in CMRO2), just leading to an increase in the BOLD response due to more 
oxygen being bound to haemoglobin in the blood and dissolved in blood plasma on the 
arterial side of the supply. With CBF and CMRO2 constant, this hyperoxia produces an 
increase BOLD signal.  The fraction of inspired O2 is typically increased to 50%, a trade-
off between maximising the BOLD response during hyperoxia and avoiding artefacts  
(Germuska & Wise, 2018). Under the assumption that CMRO2  is the same 
under hypercapnia and hyperoxia, estimates of the baseline venous deoxyhaemoglobin 
concentration can obtained. Once we have an estimate of [dHb0] baseline OEF can be 
estimated as OEF is simply the difference between the 𝐶𝑎𝑂= and the 𝐶𝑣𝑂=	(venous 
blood content), and [dHb0] determines the venous blood oxygen saturation. 𝐶𝑎𝑂= is the 
total amount of oxygen transported in the blood, either bound to haemoglobin or 
dissolved in plasma. The amount of haemoglobin bound to oxygen can be estimated 
with an assumed or measured value of haemoglobin and the amount dissolved in 
plasma is based on the partial pressure of O2 estimated from the end-tidal physiological 
traces. Once we have a value for resting OEF, resting CMRO2 can be calculated using 
Equation 2-1, alongside ASL measurements of CBF and estimates of CaO2.  
 
In the original implementations of this dual-calibrated model (Bulte et al., 2012; Gauthier 
et al., 2012; Wise et al., 2013) the CBF and BOLD data were analysed independently, 
to separately estimate the M and the baseline [dHb]. In later adaptations, and what is 
implemented in this thesis, all physiological parameters are estimated together ( 
Germuska et al., 2016). This helps create more stable solutions due to less error 
propagation along different steps of the analysis pipeline and allows the CBF to inform 
the modelling of the BOLD signal changes and vice versa. This is done by finding the 
set of parameters that minimises the error between a forward model (describing how 
the BOLD and CBF are expected to respond to the CO2 and O2 manipulations) and the 
acquired data (Germuska et al., 2016). This is the implementation used in Chapter 5, 
with a new addition to the modelling which uses the CBF and OEF observations to 
model the exchange of oxygen between the capillaries and the tissue (the effective 
oxygen diffusivity), (Germuska et al., 2019).  
 
2.4 The relationship between MEG and fMRI: an empirical measure of 
neurovascular coupling 
 
In this thesis, the relationship between MEG and fMRI signals is used as an empirical 
measure of NVC. The rationale of why NVC is an important physiological mechanism 
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has already been covered; this section will briefly cover the practicalities of 
characterising it with MEG and fMRI. 
 
NVC is characterised by quantifying how much the fMRI signal changes relative to the 
MEG signal change. The obvious limitation to this approach is the need to carry out two 
scans separated in time. Therefore, an assumption made in order to characterise this 
MEG-fMRI relationship is that the brain is responding in a similar way in both scanning 
modalities. Both MEG and fMRI signals are thought to largely reflect post-synaptic 
(dendritic) rather than axonal activity (Hall et al., 2014; Logothetis, 2002; Logothetis, 
Pauls, Augath, Trinath, & Oeltermann, 2001; Zhu et al., 2009), and literature shows 
good spatial coherence between MEG and fMRI signals (Muthukumaraswamy & Singh, 
2008; Singh, Barnes, Hillebrand, Forde, & Williams, 2002). Most findings show negative 
correlation between BOLD and low frequency neural oscillations (e.g. alpha and beta), 
and a positive correlation with higher frequency bands (e.g. gamma), (Logothetis, 2002; 
Mukamel et al., 2005; Zumer, Brookes, Stevenson, Francis, & Morris, 2010). From 
manipulating stimulus parameters, commonly visual, some have suggested BOLD 
signals are most reflective of gamma oscillations. However, the picture is complex. 
BOLD signals and visual gamma oscillations seem to be tuned similarly by some 
stimulus features (i.e. visual contrast, (Muthukumaraswamy & Singh, 2009; Scheeringa 
et al., 2011)) but some seem to greatly influence the visual gamma response but not 
the BOLD response (i.e. spatial frequency (Muthukumaraswamy & Singh, 2008, 2009) 
and colour (Swettenham, Muthukumaraswamy, & Singh, 2013). It is therefore not clear 
how stable these coupling behaviours are under different stimulus conditions, and 
across different brain areas.  
 
Compared to MEG, and other neuroimaging methods, fMRI has superior spatial 
resolution, providing information about the location of neural activity at millimetre 
resolution.  However, the temporal resolution of BOLD and CBF is limited by the 
restrictions in acquiring the signals but predominantly by low frequency nature of the 
signals themselves: the CBF response to neural activity is typically delayed by 1-2 
seconds, peaks at around 5 seconds, and takes a similar amount of time to return to 
baseline.  This is opposite to MEG, which has superior temporal resolution, at the level 
of milliseconds. However, MEG suffers from the mathematically ill-posed ‘inverse 
problem’, when trying to locate the neural origins of signals measured at scalp, which 
limits spatial resolution. Any choice of stimulus design to investigate common MEG and 
fMRI signals will therefore be a trade-off between these very different temporal and 
spatial resolutions.  
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Previous non-invasive studies have predominantly looked at the relationship between 
BOLD-fMRI signals and neural activity. There are a few studies collecting both MEG 
and CBF data in the same participants, for example resting state dynamics in stroke 
and aging (Kielar et al., 2016; Sakamoto et al., 2016) and in response to LSD (Carhart-
Harris et al., 2016). There is also some work comparing EEG and CBF responses to a 
visual stimulus (Mayhew, Macintosh, Dirckx, Iannetti, & Wise, 2010). There are some 
invasive recordings carried out in somatosensory cortex of rodents showing 
relationships between neural activity and CBF, for example: correlations between the 
LFPs and CBF which depended on frequency of electrical forepaw stimulation (Ureshi, 
Matsuura, & Kanno, 2004), a power law function describing the relationship between 
LFPs and CBF during whisker stimulation (Hewson-Stoate, Jones, Martindale, Berwick, 
& Mayhew, 2005), and findings that show CBF and CMRO2 signals more directly 
correlate with neural activity than BOLD signals during forepaw stimulation (Masamoto, 
Vazquez, Wang, & Kim, 2008). To the best of our knowledge, the coupling between 
MEG and CBF signals have not been compared in the context of NVC, as they are in 
this thesis.  As explained in the earlier sections, CBF directly reflects blood flow to an 
area. The BOLD signal gives better SNR but can be difficult to interpret under any 
conditions where the baseline state may be altered.  Therefore, in this thesis both BOLD 
and CBF signals are compared with MEG signals, with the aim of increasing the 
understanding of NVC mechanisms, in both the healthy brain and in MS (explained in 
Chapter 3). 
 
2.5 Software and statistics 
 
Pre-processing of structural and functional MR images was performed with FSL 
(Jenkinson, Beckmann, Behrens, Woolrich, & Smith, 2012) or MATLAB (The 
MathWorks Inc), unless otherwise stated.  
 
In FSL: 
• fslmaths function was uses to combine, binarise and threshold images  
• fslstats function used to get descriptive statistics 
• Registration of images were carried out with FLIRT (Jenkinson & Smith, 2001) 
• Non-brain removal with BET (Smith, 2002) 
• Segmentation of tissue performed with FAST (Zhang, Brady, & Smith, 2001) 
• Task-responses were modelled with FEAT Version 6 (Jenkinson et al., 2012). 
 
Statistical analysis was performed with MATLAB (The MathWorks Inc), IBM SPSS 
Statistics (Versions 20-25), or R software (R Core Team, 2017). For Man-Whitney U-
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tests, the non-parametric version of the independent t-test, an exact sampling 
distribution was used for U. For each comparison, if the shape of the distribution 
between the two groups was similar (by visual inspection) medians between groups 
were compared.  
 
Assumptions of statistical tests were met, unless otherwise stated. Outliers were 
classed as 3 standard deviations (SD) above or below the mean. Data was also 
visualised as boxplots and checked for extreme outliers. The use of boxplots to 
visualise the distribution of data (Tukey, 1977) is implemented in SPSS.  The 
interquartile range (IQR) is the upper quartile (Q3, 75th percentile) minus the lower 
quartile (Q1, 25th percentile). Possible outliers are classed as 1.5xIQR below Q1 and 
1.5xIQR above Q3 (outside the ‘inner fence’). Extreme outliers are classed as 3xIQR 
below Q1 and 3xIQR above Q3 (outside the ‘outer fence’). With a normal probability 
distribution, it is estimated that approximately 99.2% of values fall within the inner fence 
(equivalent to ± 2.67 SD from the mean) and 99.99% of values within the outer fence 
(equivalent to ± 4.67 SD from the mean), (Dawson, 2011). In reality, with smaller sample 
sizes, it is reasonable to assume a smaller percentage of values fall within these inner 
and outer fences, as is assumed with the Student’s  t distribution.  
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3 Introduction to Multiple Sclerosis 
 
3.1 Overview  
 
3.1.1 Etiology 
 
MS is the leading cause of non-traumatic neurological disability in young adults, 
estimated to affect 2.3 million people worldwide (Aarli et al., 2014). Symptom onset 
peaks between 20-40 years. For common forms of adult MS, higher prevalence rates 
are reported in women compared to men (~2:1 ratio), as well as in people living in higher 
latitudes, although this has decreased over recent decades (Kamm, Uitdehaag, 
Polman, & Kamm, 2014). Smoking, Vitamin D exposure and viral infections  are all risk 
factors, yet the etiology of MS is unknown (Kamm et al., 2014). Although many genetic 
variants have been found, MS is not considered hereditary and there is extensive 
overlap between genetic risk variants for MS and other autoimmune diseases 
(Baranzini & Oksenberg, 2017). 
 
 
 
 
 
 
 
 
 
 
3.1.2 MS pathology 
 
MS is classed as a chronic inflammatory autoimmune disease of the central nervous 
system (CNS), with the hallmark pathological feature being focal demyelination of white 
matter (WM) in the CNS (Noseworthy, Lucchinetti, Rodriguez, & Weinshenker, 2000), 
see Figure 3-1. These areas of demyelination are referred to as WM lesions or 
‘plaques’. It is thought that this damage is caused by autoreactive immune cells from 
the periphery crossing the blood-brain barrier (BBB) into the brain and spinal cord 
(Dendrou, Fugger, & Friese, 2015).  
Figure 3-1. An axial slice from a T2-FLAIR image 
showing widespread white matter hyperintensities. 
This data is an example MS patient from Chapter 5. 
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The BBB separates the blood from neural cells in the CNS; it is a made up of endothelial 
cells that line the micro-vessels to form a physical barrier impermeable to large 
molecules and immune cells, maintaining a regulated environment for neuronal 
signalling (Abbott, Rönnbäck, & Hansson, 2006). There is evidence that immune cells 
(T cells/lymphocytes) react against components within the myelin sheaths (e.g. myelin 
basic protein, proteolipid protein and myelin oligodendrocyte glycoprotein). Once the 
T-cells are activated they rapidly divide and secrete proinflammatory cytokines (small 
signalling proteins) which promote microglia and macrophage activity (Dendrou et al., 
2015). This leads to damage to the myelin sheaths and therefore a slowing of the 
signal propagation along the axon, leading to functional impairments. The exact process 
of how and why the immune cells infiltrate the BBB is still not known although many 
environmental factors have been proposed (O’gorman, Lucas, & Taylor, 2012).   
 
MS has been traditionally viewed as a disease of WM, with myelin loss proposed as the 
key cause of functional impairments, however there is clear evidence that grey matter 
(GM) inflammation, demyelination and degeneration occur. This dysfunction of GM, 
both cortical and subcortical, is present from the early stages of MS and changes with 
disease progression (Crespy et al., 2011; Klaver, De Vries, Schenk, & Geurts, 2013b; 
Lucchinetti et al., 2011). Post-mortem studies show significant GM demyelination and 
microglial activation. However, there is some evidence for less extensive influx of 
immune cells and BBB leakage in GM compared to WM (Bø, Vedeler, Nyland, Trapp, 
& Mørk, 2003; Bø, Vedeler, Nyland, Trapp, & Mørk, 2003; Klaver, De Vries, Schenk, & 
Geurts, 2013). Another challenge to the traditional view of MS pathology is the evidence 
that axonal injury, thought to be responsible for progressive neurological deficits 
(Neumann, 2003), is present at sites of active inflammation and demyelination early in 
the disease (Bitsch, Schuchardt, Bunkowski, Kuhlmann, & Brück, 2000; Ferguson, 
Matyszak, Esiri, & Perry, 1997). Axonal injury and GM atrophy have been typically 
regarded as secondary to myelin damage, however this may not be the case. There is 
much debate over whether one mechanism is solely responsible for initiating MS 
pathology, or whether there are parallel multiple mechanisms, and whether 
autoimmunity leads to cytodegeneration or vice versa (Dendrou et al., 2015; Stys, 
Zamponi, van Minnen, & Geurts, 2012), see Figure 3-2.  
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3.1.3 Symptoms and disease course 
 
Symptoms depend on stage of disease, and the location of damage across the brain or 
spinal cord and are therefore very varied. However, initial symptoms typically include: 
limb weakness, sensory disturbances, monocular visual loss (optic neuritis), double 
vision, gait instability and ataxia (Kamm et al., 2014). Later in the disease, bladder 
dysfunction, fatigue, heat sensitivity, vertigo, weakness or pain and spasms are often 
reported. Cognitive deficits (Guimarães, Sá, & Massano, 2012) and depression 
(Siegert, 2005) are also commonly reported. MS is classified into different disease 
subtypes or courses (Lublin et al., 2014). About 85% of cases are Relapsing Remitting  
MS (RRMS), characterised by periods of increased disability due to an immune attack 
(a relapse), interspersed with periods of functional recovery (a remission), see part A of 
Figure 3-3. 
 
 
 
 
 
 
 
 
Figure 3-2. Traditional theories say 
that dysregulation of the immune 
system is the initial event, eventually 
leading to tissue injury (Outside-In). 
Alternatively, cytodegeneration may 
happen first, promoting an 
autoimmune and inflammatory 
response (Inside-Out). 
Figure 3-3. Disability 
progression for different MS 
subtypes. The height of the 
light blue bars and dark blue 
triangles indicate functional 
disability, and the solid and 
dotted lines mark the course 
of this disability over time. 
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During relapses, peripheral immune cells infiltrate the CNS due to BBB breakdown and 
target myelin proteins, as explained earlier. During a remission, remyelination occurs 
(Franklin & Goldman, 2015). Earlier on in the disease course, this can often lead to full 
functional recovery. For remyelination to occur, oligodendrocyte progenitor cells have 
to migrate to the damaged area then differentiae into mature oligodendrocytes to 
form new myelin sheaths (Brück, Kuhlmann, & Stadelmann, 2003). This 
remyelination process becomes less efficient as the disease progresses (Franklin, 
2002), and functional recovery during remissions lessens. Approximately 75% of 
people with RRMS transition onto Secondary Progressive MS, a steady worsening of 
disability, relapses remaining in 40% of cases, see part B of Figure 3-3. Less common 
types of MS present with progressive disability from onset (15% with Primary 
Progressive MS, of which 40% have relapses), see part C of Figure 3-3. 
 
3.1.4 Diagnosis 
 
The most recently revised McDonald criteria for diagnosis of MS was last updated in 
2017 and is discussed by (Thompson et al., 2018). The key diagnostic criteria for MS 
are the dissemination in space and dissemination in time,  which can apply to lesions 
(i.e. across different areas of the CNS) or to symptoms tracked by clinical assessments. 
A diagnosis of MS will be given based on clinical history being suggestive of MS and 
when there is no better clinical explanation i.e. alternative diagnoses must be ruled out. 
When a patient without an existing diagnosis of MS presents with symptoms alongside 
evidence of inflammatory demyelinating activity (duration of at least 24 hours), the 
diagnosis of Clinically Isolated Syndrome is given. This diagnosis of Clinically Isolated 
Syndrome, without the full criteria being met, is classed as possible MS.   
 
A neurologist will perform physical examinations to check for changes in weakness, 
coordination, balance, and sensation.  Sometimes latency and amplitude of evoked 
potentials are examined, an impairment of which can indicate slowing of signal 
propagation along axons. This can be done for visual, auditory, sensory and motor 
systems. Visual is most common, considering optic neuritis is a common initial symptom 
in MS, as well as broader visual problems (Graham & Klistorner, 2017). The Expanded 
Disability Status Scale (EDSS) (Kurtzke, 1983) is a commonly used clinical metric to 
represent the degree of disability, and monitor changes over time. Scores range from 0 
to 10 (in 0.5 increments) and are based on clinical assessment of 8 systems: pyramidal 
(limb movement), cerebellar (co-ordination or tremor), brainstem, (speed and 
swallowing), sensory (loss or numbness), bowel or bladder function, visual function and 
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cerebral (cognitive) function. EDSS of less than 5 means the patient can walk without 
a walking aid. 
 
Conventional structural MRI can non-invasively detect lesions and therefore plays a big 
role in demonstrating disseminating symptoms in space and time. Typical sequences 
include T2-weighted and pre and post contrast T1-weighted images. Gadolinium-
enhancing lesions indicate BBB breakdown, i.e. areas of active inflammation. 
Importantly for a diagnosis of MS, there needs to be no alternative diagnosis that can 
better explain the clinical presentation, and blood and CSF samples help rule out other 
diagnoses. Analysis of a CSF sample (via a lumbar puncture) can contribute to MS 
diagnosis by looking for the presence of oligoclonal bands (bands of antibodies called 
immunoglobins) in the CSF compared to blood, and higher levels of other proteins 
evident of myelin breakdown (e.g. neurofilaments).   
 
3.1.5 Treatment 
 
There is no cure for MS. Drugs typically prescribed for MS can be divided into relapse, 
disease-modifying and symptomatic treatment (Kamm et al., 2014). Corticosteroids 
(typically methylprednisolone) are used to treat relapses, suppressing the immune 
system and decreasing inflammation. Disease Modifying Treatments (DMTs) are used 
to alter the disease course (mainly CIS, RRMS) by reducing the likelihood of relapses. 
Available first-line therapies include Interferon beta, Glatiramer acetate, Teriflunomide 
and Dimethyl fumarate. Some patients transition onto second-line therapies (or start on 
this, if the MS is very active), if disease activity remains, which 
include Fingolimod, Natalizumab, Ocrelizumab and Alemtuzumab  (Torkildsen, Myhr, & 
Bø, 2016). In general, these drugs work to inhibit the proliferation and migration of 
inflammatory cells into the CNS, and to shift the cytokine response from an 
inflammatory response to an anti-inflammatory profile, although many of the drug 
mechanisms are not completely known (Torkildsen et al., 2016). There are also many 
drug treatments prescribed based on specific symptoms experienced, for example for 
depression or spasticity. Symptomatic treatments are particularly important for people 
with progressive forms of MS, to limit the impact of disability on daily activities.  
 
3.2 Neurovascular and metabolic dysfunction in MS 
 
GM damage undeniably plays a role in MS pathology. In fact, as GM damage is not 
typically a part of the diagnostic process, this may go some way to explain the clinic-
radiological paradox  (Barkhof, 2002; Chard & Trip, 2017), i.e., the observation that the 
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number and volume of WM lesions only explain a small amount of variability in clinical 
outcomes. However, despite recent advances in characterising GM damage with MRI, 
challenges with the sensitivity of these techniques remain (reviewed by Amiri et al., 
2018). Further, the mechanism that leads to GM damage, and the cause of MS 
pathology in general, is not fully known. Therefore, it is important that neuroimaging 
research also studies functional signals, as well as structural tissue characteristics, to 
try to further the understanding of causal mechanisms. Below, the evidence for 
neurovascular and metabolic dysfunction in MS is summarised, followed by a 
discussion of the mechanisms.  
 
3.2.1 Neuroimaging Evidence 
 
Vascular and metabolic impairments are acknowledged to be a pathological feature of 
MS (D’haeseleer et al., 2015; Lapointe, Li, Traboulsee, & Rauscher, 2018; Paling, 
Golay, Wheeler-Kingshott, Kapoor, & Miller, 2011; Spencer, Bell, & DeLuca, 2018). 
Perfusion alterations within lesions, normal appearing WM (NAWM) and GM have been 
widely reported and some key findings are summarised below. In the studies below, 
perfusion and oxygen metabolism have mostly been measured with ASL-MRI imaging 
or with DSC-MRI (where an intravenous paramagnetic contrast agent is administered, 
and the brain is scanned with a rapid T2-weighted imaging technique). There are a few 
studies using PET imaging and Dynamic Contrast-Enhanced MRI, which uses T1-
shortening due to a contrast agent to detect area of BBB disruption (Lapointe et al., 
2018). 
 
MS Perfusion changes in Normal Appearing Brain Tissue 
 
Grey matter. In GM, a reduction in CBF and CBV is seen in both cortical and deep GM 
structures, mostly reported for RRMS subtypes but also for Secondary Progressive MS 
and PPMS (Aviv et al., 2012; Brooks et al., 1984; D’haeseleer et al., 2013; Debernard 
et al., 2014; Hojjat et al., 2016; Inglese et al., 2007, 2008; Lycke, Wikkelsö, Bergh, 
Jacobsson, & Andersen, 1993; Ota et al., 2013; Papadaki et al., 2012; Rashid et al., 
2004; Steen et al., 2013; Sun, Tanaka, Kondo, Okamoto, & Hirai, 1998; Vitorino et al., 
2016). There is some evidence, in RRMS, that reduced CBF in many GM regions is 
seen in the absence of atrophy (Debernard et al., 2014). In support of this, another 
study reported decreases in CBF and CBV in frontal regions for cognitively impaired 
patients compared to unimpaired patients, after adjusting for volumetric differences 
(Vitorino et al., 2016).  
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White matter. In NAWM, DSC and PET studies have mostly reported decreases in 
CBF and CBV, and increases in mean transit time (MTT), in MS patients (Adhya et al., 
2006; Debernard et al., 2014; Ge et al., 2005; Guo, Jewells, & Provenzale, 2001; 
Inglese et al., 2008; Narayana et al., 2014; Papadaki et al., 2012; Steen et al., 2013; 
Sun et al., 1998). However, these CBF and CBV reductions in NAWM appear less 
consistent in the literature compared to the GM findings. A study by  Rashid et al (2004) 
reported an increased CBF in 60 patients with mixed subtypes, and Paling et al (2013) 
reported increased CBF in NAWM of RRMS patients. This inconsistency could be due 
to varying levels of inflammation in these patients populations; Bester et al (2015) 
characterised RRMS into a high or low inflammatory group depending on the number 
of new contrast enhancing lesions and found that the high inflammatory group had 
higher CBV and CBF values in NAWM. There is also evidence that patients with CIS 
have higher CBV, CBF and MTT values in deep GM and NAWM, compared to RRMS 
patients (Papadaki et al., 2012). 
 
These reductions of CBF and CBV have been shown to correlate with neurological 
disability (Lycke et al., 1993), fatigue (Inglese et al., 2007), cognition (Inglese et al., 
2008) and memory (Debernard et al., 2014). However, in the review by Lapointe et al 
(2018), they argue that “Despite compelling and reproducible perfusion abnormalities 
in MS, their relation to clinical measures of disability and disease severity has not been 
strongly established”, giving an overview of the studies that have addressed this. 
 
Perfusion changes in MS Lesions 
 
In active WM lesions, evidence points towards increased perfusion, mostly likely due to 
increased metabolic activity at the site of active inflammation. This increase was 
demonstrated in a longitudinal study by Wuerfel et al (2004). In 20 RRMS patients, they 
tracked the formation and progression of gadolinium-enhancing lesions. They showed 
regional increases in CBF and CBV 3 weeks before gadolinium enhancement. They 
saw a further increase at the time of gadolinium enhancement, and a decline to baseline 
during the 20 weeks after. Their study provides evidence for the role of the vasculature 
preceding BBB breakdown (or at least before this is measured with gadolinium 
enhancement). Other DSC or DCE studies also found CBV and CBF increased in 
contrast-enhancing lesions compared with NAWM (Ge et al., 2005; Haselhorst et al., 
2000; Ingrisch et al., 2012). For chronic WM lesions, looking at T1-hypointense, there 
is evidence for a reduction in CBF (Haselhorst et al., 2000; Li et al., 2014) presumably 
due to axonal loss therefore having less metabolic activity. There are very few studies 
looking at perfusion in cortical lesions, due to the technical challenges, however one 
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DSC study reports lower CBF and CBV in cortical lesions, in RRMS patients, compared 
to normal appearing GM (Peruzzo et al., 2013). A small subset of cortical lesions did 
show increased CBF and CBV, as with WM, suggestive of acute inflammation. A very 
recent ASL study (Dury et al., 2018) was the first to quantify CBF in cortical lesions 
using 7 Tesla MRI, showing the majority of cortical lesions to be hypoperfused 
compared to normal appearing GM.   
 
Cerebrovascular Reactivity in MS 
 
There is some evidence for impaired reactivity of blood vessels to a CO2 stimulus in 
MS, termed CVR, introduced in Chapter 2.3.3. PASL was used to measure the CBF 
response to hypercapnia, compared to normocapnia, finding decreased global GM CVR 
in patients in multiple brain regions, and a negative correlation between GM CVR and 
lesion load (Marshall et al., 2014). No baseline CBF differences between groups were 
reported in this study. The same research group reported, in a different MS cohort, 
decreases in CVR in different functional networks (default mode, frontoparietal, 
somatomotor, and ventral attentional), and again correlations with lesion load and GM 
atrophy (Marshall, Chawla, Lu, Pape, & Ge, 2016). A study by a different research group 
reported no significant difference in CVR in patients with RRMS across three different 
time points (first two days after a relapses but pre-treatment, just after steroid treatment, 
and one month later), as well no differences with healthy controls at one time point 
(Uzuner, Ozkan, & Cinar, 2007). This study used transcranial Doppler imaging to asses 
vasomotion in response to a BH task, so there are many methodological factors that 
could explain their different findings to Marshall et al (2014; 2016).  
 
Oxygen Utilisation in MS 
 
Many studies have used the BOLD-fMRI contrast to demonstrate functional connectivity 
deficits in MS (e.g. Sbardella, Petsas, Tona, & Pantano, 2015), altered task responses 
which relate to disability or structural damage (Hubbard et al., 2016; Rocca & Filippi, 
2007) and as a way to assess functional reorganisation of the cortex (Tomassini et al., 
2012). This research contributes to the evidence that there is a strong hemodynamic 
impairment in MS. However, as explained in Chapter 2.3.1, the BOLD response alone 
can be hard to interpret in a patient group; despite it reflecting changes in oxygen usage, 
it is a relative composite signal that depends on CBF, CBV, oxygen metabolism 
changes, and the baseline tissue activity. Therefore, research is needed to measure 
and quantify more specific and interpretable signals, such as the fraction of oxygen 
extracted from the blood (OEF) or rate of oxygen metabolism in the tissue (CMRO2). 
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Very few studies have characterised such signals in an MS group. Some early papers 
using PET and MRI did show reductions in CMRO2 and CBF in both WM and GM, with 
correlations with atrophy, cognition, vision, EDSS and number of relapses (Brooks et 
al., 1984; Lycke et al., 1993; Sun et al., 1998). One MRI studying characterised CMRO2 
at rest in an MS population using a T2-relaxation-under-spin-tagging (TRUST) 
technique, which gives a global estimate of oxygen consumption (Ge et al., 2012).  They 
found increased global venous oxygen saturation, decreased OEF and decreased 
CMRO2, which significantly correlated with EDSS and lesion load. 
 
3.2.2 Discussion of the mechanisms 
 
Finding both increases and decreases in perfusion within lesioned tissue can be partly 
explained by the levels of inflammation and metabolic activity at that stage of the 
lesion’s development. What is less clear is why there are alterations in BOLD, CBF, 
CBV and CMRO2 in normal appearing WM and GM. It is thought that this reduced 
perfusion and oxygen metabolism may contribute to the progressive neurodegeneration 
seen in MS, due to tissue hypoxia (Trapp & Stys, 2009), yet the mechanisms are 
unclear. 
 
It is possible that perfusion to the active tissue is restricted in some way, as there is 
increased cardiovascular risk reported in MS, but this increased risk appears to be small 
(Christiansen et al., 2010; D’haeseleer, Cambron, Vanopdenbosch, & De Keyser, 
2011). A simple explanation for reduced perfusion is reduced metabolic demand: if 
there is neuronal loss, less blood will need to flow to the area as less energy is being 
used. However, as discussed in section 2.7.1, there is evidence for perfusion changes 
before neuronal loss. Furthermore, reduced blood flow and oxygen metabolic changes 
are often reported as widespread changes across the brain, and not just localised near 
lesioned areas. Some studies report increases in CBF and CBV in NAWM and 
decreases in GM in the same patients (e.g. Rashid et al., 2004), as well as correlations 
between T2 lesion load and global cortical CBF (e.g. Amann et al., 2012) and CVR (e.g. 
Marshall et al., 2014). It is of course possible that there is more extensive damage 
across the GM and WM that is not being measured, however it still appears that focal 
BBB disruption occurs alongside widespread functional perfusion changes. 
 
Another proposed mechanism is the increase of different vasoactive agents circulating 
in the blood, released from reactive astrocytes near lesions, or upregulated due to the 
presence of many proinflammatory cytokines. NO has been shown to be elevated in 
MS lesions (Smith & Lassmann, 2002a), and has been proposed as a potential mediator 
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leading to hypoperfusion.  It is a strong vasodilator, and therefore its overproduction 
could desensitise smooth muscle function over time, resulting in decreased vascular 
capacity (Marshall et al., 2014). Furthermore, NO is synthesized by endothelial cells 
(which make up the BBB), and one study showed patients with endothelial dysfunction 
to have decreased cerebrovascular reactivity (Lavi, Gaitini, Milloul, & Jacob, 2006). A 
different vasoactive agent, Endothelin-1 (ET-1), has also been proposed as a potential 
mediator (D’haeseleer et al., 2013). ET-1 is a vasoconstrictor secreted by endothelial 
cells.  D’haeseleer et al (2013) reported higher plasma ET-1 levels in patients, from 
both the internal jugular vein and a peripheral vein, and only in patients was the internal 
jugular ET-1 plasma levels higher than the ET-1 levels in the peripheral vein. They 
interpreted this as evidence that ET-1 is released from the brain into circulation. They 
also reported, with data from an ASL acquisition, that CBF was lower in MS patients, 
but increased to control levels after an ET-1 antagonist administration. They included 
post-mortem immunohistochemistry analysis of  WM tissue, from different patients, 
suggesting reactive astrocytes to be the likely source of ET-1 increase. Increased NO 
and ET-1 are just two examples of ways in which the inflamed environment can have a 
direct effect on blood vessels, potentially changing how they respond to metabolic 
demands of neural activity. 
 
There is evidence for mitochondrial dysfunction in MS (Paling et al., 2011) and this has 
been proposed as a potential mechanism leading to the neurodegeneration seen, with 
the mitochondria not able to make sufficient ATP in response to energy demands. Ge 
et al (2012) explain how NO may also play a role in this, as NO inhibits oxygen binding 
to mitochondria, affecting ATP synthesis. They explain how this is termed ‘metabolic 
hypoxia’ – even if there is enough blood flow to an area, the cells and tissue may be 
unable to use it properly.  
 
3.2.3 MS and MEG literature 
 
Compared to fMRI, there is a small amount of literature using MEG imaging to 
investigate neural oscillations in MS, as done in this thesis. Studies have mostly focused 
on MEG connectivity, from resting state paradigms. For theta band, there are reports of 
increased connectivity in MS (Schoonheim et al., 2013; Tewarie et al., 2014). For the 
alpha band, there are reports of decreased connectivity in MS (Cover et al., 2006; 
Tewarie et al., 2013, 2014), but some studies split their analysis into smaller frequency 
bands and show increased connectivity in lower (8-10Hz) alpha bands and decreased 
connectivity in upper (10-13Hz) alpha bands, (Schoonheim et al., 2013; Van der Meer 
et al., 2013).  For beta bands, increased network strength has been reported 
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(Schoonheim et al., 2013; Tewarie et al., 2013) and decreased functional connectivity 
(Tewarie et al., 2014). Thalamic volumes have been linked to network disruption in MS 
(Tewarie et al., 2013, 2015). Although it is difficult to pull out consistent directional 
trends, there is clear evidence showing abnormal functional network connectivity in MS, 
and many of these alterations in connectivity where shown to correlate with impaired 
cognition or disease severity. There are a few recent studies showing impaired visual 
and motor task-based MEG responses (Arpin et al., 2017; Barratt et al., 2017a) and 
these are discussed in Chapter 4.  
 
As explained earlier, one explanation for reduced CBF or CMRO2 in MS is simply 
reduced demand from the tissue. However, in these studies that looked at flow or 
oxygen metabolic changes in MS, neural activity was not directly measured.  In order 
to address this mechanism more directly, we need to establish if there is a decrease in 
flow or oxygen metabolism above and beyond any decrease in neuronal activity. This 
is the rationale for measuring MEG signals in MS, in order to correlate with fMRI signals 
as a measure of NVC. Studying the amplitude and frequency of brain oscillations with 
MEG can also be informative for understanding disease mechanisms in MS.   
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4 The coupling between visual gamma oscillations and BOLD 
and CBF signals: investigating neurovascular coupling in 
Multiple Sclerosis 
 
The work presented in this chapter has been published as a part of a peer-reviewed 
journal article:  
 
Stickland, R., Allen, M., Magazzini, L., Singh, K. D., Wise, R.G., Tomassini, V. (2018). 
Neurovascular Coupling During Visual Stimulation in Multiple Sclerosis: A MEG-fMRI 
Study. Neuroscience (in press). Available online from 23rd March 2010.  
DOI: doi.org/10.1016/j.neuroscience.2018.03.018 
 
4.1 INTRODUCTION 
 
There is abundant evidence showing vascular and metabolic impairments in MS and 
this was covered in detail in Chapter 3.2. In summary, there is evidence for reduced 
blood flow, less reactive blood vessels, altered levels of vasoactive compounds, and 
reductions in oxygen metabolism in MS. NVC, the mechanism responsible for ensuring 
local blood flow increases to an area with increased neural activity, is affected by many 
of these processes. Therefore, NVC may be altered in MS, which would likely contribute 
to tissue dysfunction and damage. 
 
In this chapter, we investigated NVC in MS using two complementary non-invasive 
imaging modalities: MEG and fMRI. Commonly, when cortical networks are activated 
there is an increase in the signal power of faster oscillations, i.e. in the gamma band 
(Demanuele, James, & Sonuga-Barke, 2007; Jia & Kohn, 2011). Most findings show a 
positive correlation between changes in gamma band activity (typically >30Hz) and 
haemodynamic responses (Mukamel et al., 2005; Niessing et al., 2005; Zumer et al., 
2010), as well as good spatial coherence between these signals (Muthukumaraswamy 
& Singh, 2008; Singh et al., 2002). By displaying the same reversing checkerboard 
stimulus at five levels of contrast, we probed neural oscillations, BOLD and CBF 
responses in the visual cortex, expecting them to increase monotonically with 
increasing contrast (Goodyear & Menon, 1998; Hall et al., 2005; Henrie & Shapley, 
2005; Muthukumaraswamy & Singh, 2009; Perry, Randle, Koelewijn, Routley, & Singh, 
2015). We used the positive relationship between gamma power (30 – 80Hz) and fMRI 
signals as an empirical measure of NVC. This design addresses the question of whether 
there are vascular and metabolic alterations in MS above and beyond alterations in 
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neural activity.  
 
At the time of this research, no studies had reported on gamma oscillatory changes in 
MS. Given possible GM dysfunction and damage, we predicted a reduction in gamma 
power in the MS group. Based on the vascular and metabolic impairments reported in 
MS, we predicted that the MS group would have a reduced haemodynamic response 
to stimulation, and that NVC in the visual cortex would be altered.  
 
4.2 METHODS 
 
Participants 
 
Patients with a diagnosis of MS (Polman et al., 2011) were recruited at the University 
Hospital Wales, Cardiff. Patients were treatment naïve, but eligible to start first line 
disease-modifying treatment and had not experienced a relapse in the last 3 months. 
Age and gender matched healthy controls were recruited. Written consent was obtained 
according to the protocol approved by Research Ethics Committee, Wales, UK.  
 
Data Collection 
 
All participants had a behavioural session, a MEG and a MRI scan performed on the 
same day, except for one control who returned on a different day for the MRI scan.  
 
Behavioural Testing. Patients’ disability was assessed using the EDSS score 
(Kurtzke, 1983). Tests from the MS Functional Composite (Cutter et al., 1999) were 
carried out on the patients and controls: 9 Hole Peg Test (9-HPT) for upper limb motor 
function, the Timed 25-Foot Walk (T25-FW) for mobility and walking, and the Paced 
Auditory Serial Addition Test (PASAT) 2 and 3 seconds as a measure of sustained 
attention. Visual acuity was assessed, in each eye separately, with a SLOAN letter chart 
(Precision Vison) at 100%, 25%, 10%, 2.5%, 1.25% and 0.6% contrast, expressed as 
a decimal that represented viewing distance divided by the letter size (in M-units). All 
participants except five required corrective lenses for daily use and wore them 
throughout the testing sessions.  
 
Visual paradigm during scanning. Identical stimulation parameters were used for 
fMRI and MEG. The visual stimulus consisted of a black and white checkerboard, 
polarity reversing every 250ms. Checks were squares, with a spatial frequency of 1 
cycle per degree. The checkerboard was displayed on a mean luminance background, 
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with a small red fixation circle in the centre. The rest conditions consisted only of this 
background and fixation. For both scanning modalities, the entire stimulus field was 
16x16° of visual angle and the stimulus was projected on screens with a 1024 x 768 
resolution and 60 Hz refresh rate. The checkerboard was displayed at 5 Michelson 
contrast levels: 6.25%, 12.5%, 25%, 50% and 100%. Stimuli were displayed in 30 s 
blocks and each contrast level was presented 4 times. The rest blocks were also 30 s 
long and were presented 8 times. The block order was pseudorandomised across 
participants, but for each participant the same block order was used for both MEG and 
fMRI. The task lasted for 14 minutes and was repeated twice, once for each eye, with 
the untested eye covered with a cotton pad. We tested separate eyes because a 
common initial presentation of MS is optic neuritis, an acute, often unilateral, visual 
impairment characterised by a reduction in visual acuity and connectivity in visual 
pathways (Polman et al., 2011; Toosy, Mason, & Miller, 2014) The experiments were 
programmed in MATLAB, using the Psychophysics Toolbox extensions.  
 
MEG data acquisition. A 275-channel CTF axial gradiometer system was used to 
obtain whole-head MEG recordings, sampled at 1200 Hz (0-300 Hz band-pass). An 
additional 29 reference channels were recorded for noise cancellation, and 3 of the 275 
channels were turned off due to excessive sensor noise. Fiduciary coils were placed at 
fixed distances from three anatomical landmarks (nasion, left, and right pre-auricular) 
and the positions of the coils were monitored continuously. For co-registration, these 
landmarks were later identified on the subject’s structural MRI and also verified with 
digital photographs. The MEG data were acquired continuously and epoched offline. 
 
MRI data acquisition. MRI data were acquired on a 3T GE HDx MRI system using an 
eight-channel receiver head coil. A 3D T1-weighted structural scan was obtained for 
each participant: fast-spoiled gradient recalled echo (FSPGR): acquisition matrix = 256 
x 256 x172, 1x1x1 mm voxels, TE = 2.9ms, TR = 7.8ms.  
 
During the visual task, a PASL scan sequence was acquired with a dual GRE spiral k-
space readout (TR/TE1/TE2 = 2200/3/29ms, 64 x 64 x 12 slices, voxels 3.4 x 3.4 x 7 
mm, 1mm inter-slice gap, ascending order, 22cm field of view in-plane, flip angle 90°), 
the first echo being used to estimate CBF changes and the second echo being used for 
BOLD time series analysis. The proximal inversion and control for off-resonance effects 
(PICORE) labelling scheme was used, with a label thickness of 20cm (TI1 = 700ms, 
TI2 = 1600ms for most proximal slice) and 10mm gap between labelling slab and bottom 
slice. An adiabatic hyperbolic secant inversion pulse was used with quantitative imaging 
of perfusion using a single subtraction (QUIPSS II), with a 10cm saturation band 
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thickness (Wong, Buxton, & Frank, 1998). 191 tag-control pairs resulted in 382 volumes 
being acquired over the 14-minute task. Whilst the participant was at rest, two single 
echo multi TI PASL scans (Chappell et al., 2010) were acquired in order to estimate 
baseline perfusion (scan 1, TIs: 400, 500, 600, 700ms, scan 2, TIs: 1000, 1100, 1400, 
1700 and 2000ms). The same PICORE labelling sequence was used as explained 
above, with a QUIPSS II cut of at 700ms for TIs > 700ms. A variable TR was used in 
order to minimise scan time. 16 tag-control pairs for each TI were acquired.  
 
Before both PASL scans, a calibration scan was acquired in order to obtain the 
equilibrium magnetisation (M0) of cerebrospinal fluid for the purposes of perfusion 
quantification: a single volume with the same acquisition parameters but without the 
ASL preparation and with an effectively infinite TR (so magnetization fully relaxed). 
Additionally, a minimum contrast scan was acquired to correct for received image 
intensity variation with the same previous parameters, except TE = 11ms, TR = 2s, and 
8 interleaves.  
 
Data analysis  
 
Behavioural data analysis. The 9-HPT, T25-FW, PASAT-2, and PASAT-3 were all 
scored with the ‘Brief Repeatable Battery of Neuropsychological Tests in Multiple 
Sclerosis’ manual. Responses from 9-HPT and the T25-FW were measured in seconds 
to complete, and the PASAT in number of correct trials. For visual acuity, the MAR value 
(MAgnification Requirement – the inverse of the visual acuity score) was calculated. 
Values were then expressed in log(MAR) units, which indicate “visual acuity loss”. A 
value of 0 indicates no loss so is equivalent to visual acuity at the reference standard 
(20/20), and an increment increase of 0.1 log(MAR) indicates one line of loss.  
 
MEG data analysis. The analysis of MEG data was performed in MATLAB using the 
Fieldtrip toolbox (Oostenveld, Fries, Maris, & Schoffelen, 2011). First, data segments 
including large muscle artefacts were identified semi-automatically (by applying 
individual z-value thresholds to the z-transformed sensor time-series, band-pass filtered 
between 110-140 Hz) and excluded. Second, eye-movement artefacts and cardiac 
signals were projected out of the data using independent component analysis. The 30 
s stimulus blocks were then epoched into 1 s long trials (4 reversals within one trial) 
and the 30 s rest blocks were also epoched into 1 s trials.  
 
For source localisation, each participant’s anatomical MRI was divided into an irregular 
grid by warping the individual MRI to the MNI template brain and then applying the 
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inverse transformation matrix to the regular MNI template grid (5mm isotropic voxel 
resolution), allowing source estimates at brain locations directly comparable across 
participants. For each grid location inside the brain, the forward model (i.e. the lead 
field) was calculated for a single dipole orientation by singular value decomposition, 
using a single-shell volume conduction model (Nolte, 2003). Source power at each 
location was estimated using an LCMV (linearly constrained minimum variance) 
beamformer (Van Veen, Van Drongelen, Yuchtman, & Suzuki, 1997). The weights were 
computed using a covariance matrix calculated after band-pass filtering the data 
between 30 and 80 Hz, combining trials from all conditions. For each participant, the 
voxel of greatest increase in gamma power (30-80 Hz) was located within either the 
Calcarine sulcus (primary visual cortex) or two adjacent regions (cuneus and lingual 
gyrus), found by contrasting the 1 s stimulus epochs with the 1 s baseline epochs (as a 
percentage change from baseline). Anatomical masks were created using the AAL atlas 
(Tzourio-Mazoyer et al., 2002). At this peak location, the source-level time-series were 
reconstructed by multiplying the sensor-level data by the beamformer weights. Trials 
were represented in the time-frequency domain by calculating the amplitude envelope 
of analytic signal obtained with the Hilbert transform. Stimulus-induced peak gamma 
power was extracted, separately for each visual contrast condition. This analysis was 
performed separately for the left and right eye acquisitions. The analysis steps are 
summarised in Figure 4-1. 
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To assess potential alterations in transmission to the visual cortex, latencies of VEFs 
were characterised, for the left and right eyes separately, and across all five contrast 
conditions together. The trials were first re-epoched around the time of reversal (0 s), 
with the baseline period defined as -0.04 to 0 s, and the stimulus period as 0 to 0.21 s. 
The data were then low-pass filtered at 15 Hz and baseline corrected. The VEFs were 
first investigated at the sensor level (mirroring methods used clinically for VEPs) by 
Figure 4-1. Summary of the analysis steps used in order to characterise the peak 
gamma power response, for each participant. 
   46 
averaging over trials for five posterior occipital sensors. The VEFs were subsequently 
also characterized in source space (more comparable with the analysis of the gamma 
power changes) by multiplying the pre-processed sensor level data with the 
beamformer weights for the location found to be the peak gamma response to the 
checkerboard stimuli. For both types of analysis, the latency of the peak amplitude 
between 0 and 0.21 s was then extracted for each participant. 
 
MRI data analysis 
 
Lesion filling. Lesion filling was carried out with the FSL function lesion_filling, 
following the protocol by Battaglini, Jenkinson, & De Stefano (2012), to improve 
registration, segmentation and volumetric measures of brain tissue. In brief, a lesion 
mask was manually created by drawing around any visible lesions on the patient's T1-
weighted image. At least one lesion was visible for 11 out of the 14 patients. For these 
11 patients, the lesion mask, their T1-weighted image, and a WM mask (FAST 
segmentation) was used in order to “fill” the lesion area in the T1-weighted image with 
intensities that are similar to those in the non-lesioned neighbourhood (WM only). 
 
Tissue volumes. Brain tissue volume, normalised for subject head size, was estimated 
with SIENAX in FSL (Smith, De Stefano, Jenkinson, & Matthews, 2001; Smith et al., 
2002). For patients with visible lesions, their T1-weighted images with filled lesions 
where inputted. Brain and skull images were extracted from the single whole-head input 
data. The brain image was then affine-registered to MNI152 space, using the skull 
image to determine the registration scaling, and to obtain the volumetric scaling factor. 
Next, tissue-type segmentation with PVE was carried out in order to calculate total 
volume of brain tissue (and volume of GM and WM separately), normalised for head 
size using the volumetric scaling factor.  
 
Regional GM tissue volumes from the visual cortex were calculated for each subject. 
These visual ROIs were defined functionally, based on significant group activation to 
the visual checkerboard stimulus (explained below). The group visual ROI for the left 
and right eye stimulation were transformed from standard space to T1 subject space 
and multiplied with the GM partial volume estimate (PVE) image to give visual GM ROIs 
for each subject. Estimates of volume within these ROI were then normalised with the 
volumetric scaling factor outputted from the SIENAX analysis.  
 
BOLD and CBF response to the visual checkerboard stimulus. The BOLD signal 
was isolated by surround averaging the second echo to remove the tag-control signal. 
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Registration of functional data to individual T1 structural data (linear, 6 degrees of 
freedom - DOF) and then to MNI standard space (linear, 12 DOF) was carried out using 
FSL FLIRT. Motion correction of time series data was performed using MCFLIRT, non-
brain removal using BET spatial smoothing using a Gaussian kernel of FWHM 5mm, 
and a high-pass temporal filter applied with a cut off of 90s. Using FEAT, perfusion time 
courses were modelled from the first echo data with the inclusion of regressors explicitly 
describing the tag-control signal differences. Five stimulus conditions, and an average 
across the conditions, were specified as six output contrasts relative to the rest 
conditions.  
 
A higher-level analysis was performed with FEAT using a mixed effects model (FLAME 
1+2) to model the effect of group membership. Z statistic images were thresholded 
using clusters determined by Z>2.3 and a (corrected) cluster significance threshold of 
p = 0.05. A group region of interest (ROI) was generated from the output of this group 
analyses. The group ROI was determined as common significant voxels in the BOLD 
and CBF thresholded z-statistic images (for the contrast averaged across conditions 
and groups). After binarising this group ROI and transforming to subject space for each 
participant, a percentage signal increase in BOLD and percentage increase in CBF was 
calculated for each participant within that region. This higher-level analysis and group 
ROI creation was done separately for the left and right eye acquisitions. The final BOLD 
and CBF values were then averaged across eyes for each participant.  
 
Baseline perfusion. As patients with MS are reported to be hypoperfused at rest a 
measure of resting CBF in ml/per/100g per min was quantified to establish if there were 
any differences in baseline perfusion. Baseline perfusion was estimated following a 
protocol described by (Warnert et al., 2014), using in-house scripts that used AFNI 
software (Analysis of Functional NeuroImages) and FSL-BASIL (Chappell, Groves, 
Whitcher, & Woolrich, 2009). In brief, ASL scans were first motion corrected using AFNI. 
All TIs (from both scans) were merged into one 4D dataset which included a single 
mean difference image per TI, averaged over the 16 volumes. The M0 image was 
registered to this perfusion series and a mask of the lateral ventricles was created, and 
this was used in the subsequent model to calculate the equilibrium magnetization of 
blood (M0). A two-compartment kinetic model was fitted to the multi-TI data to calculate 
baseline perfusion, in native space, in ml/100g/min along with mean arrival time 
(Chappell et al., 2010). Individual subject GM masks (from partial-volume tissue-
segmentation, see Tissue Volumes above) were transformed to native space in order 
to estimate the baseline blood flow over GM. The standard-space ROI used in the 
checkerboard analysis was also transformed to native space, and the baseline 
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perfusion in this region was used to convert fractional estimates of task-induced change 
in blood flow to changes in absolute blood flow units.  
 
Characterising Neurovascular Coupling 
 
We characterised NVC by fitting a linear model that reflected the relationship between 
the electrophysiological response and the haemodynamic response to the visual 
checkerboard stimulus. Three coupling models were fitted for each subject: the 
relationship between gamma oscillations and the relative BOLD signal, the relative CBF 
signal, and the quantified CBF signal. We used BOLD signal changes, dependent on 
both metabolism and flow, as this has been the focus of most previous studies relating 
MEG and fMRI signals. We also quantified this CBF signal change in ml/100g/min, due 
to evidence showing baseline CBF can affect BOLD and CBF responses to stimulus 
(e.g. Cohen, Ugurbil, & Kim, 2002), and that absolute changes in CBF may more closely 
represent the neuronal response to a stimulus (Whittaker, Driver, Bright, & Murphy, 
2016).  
 
For each subject, there were 10 data points: one point for each visual contrast and for 
each eye. We chose not to average across eyes in order to retain useful variance in the 
responses between eyes, therefore helping us to better model the relationship between 
MEG and fMRI signals. The gradient of the line, extracted for each participant, was 
taken to be our coupling measure, indicating the strength of the relationship between 
these signals.  
 
Statistical analysis of group differences and stimulus responses 
 
Statistical analysis was carried out using IBM SPSS Statistics (Version 20) and R 
software packages (R Core Team, 2017). Independent t-tests assessed differences 
between MS patients and controls on age, behavioural measures, tissue volumes and 
baseline signals. Mann-Whitney U-tests were used to assess differences between MS 
patients and controls on the visual acuity scores, for each contrast level tested. Mixed 
ANOVAs were used to assess the effect of group membership and eye on the latency 
of the peak (of the VEFs), and the effect of group membership and contrast level on 
peak gamma power, BOLD and CBF metrics. For the NVC measure, gradients and 
intercepts were extracted from the linear model that was fitted separately for each 
person, and Mann-Whitney U-tests were used to test the differences in medians 
between MS patients and controls.   
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For the Mann-Whitney U-tests, an exact sampling distribution was used for U. For each 
comparison, the shape of the distribution was similar between groups, as assessed by 
visual inspection, so medians were compared. GG in the results refers to the 
Greenhouse-Geisser correction used when the assumption of homogeneity of 
variances is violated. In these statistical analyses, all hypothesis testing was two-tailed. 
The family wise error rate was controlled for dependent tests with the Holm-Bonferroni 
correction, a popular variant of the Bonferroni correction that is less conservative (Holm, 
1979). 
 
4.3 RESULTS 
 
Demographics and Clinical Profile 
 
The demographic and clinical characteristics of the 14 patients and 10 healthy controls 
are reported in Table 4-1. One patient did not complete the T25-FW. Patients were 
significantly slower than controls when completing the 9-HPT task and showed a trend 
towards being significantly slower in the T25-FW task.  
 
 
Patients (14) Controls (10) P-value 
Age 43.46 ± 3.50 42.40 ± 3.73 0.69 
Sex (M/F) 5/9 1/9 0.34 
Disease Duration (Years) 7.31 ± 2.06 - - 
EDSS (Median, Range) 3.0, 0 - 4.5 - - 
History of Optic Neuritis 6/14 - - 
9-HPT (seconds) 25.65 ± 0.82 22.41 ± 0.95 0.02 
T25-FW (seconds) 13.08 ± 1.58 9.63 ± 0.19 0.05 
PASAT-3s (no. correct responses) 46.54 ± 2.57 48.10 ± 3.37 0.71 
PASAT-2s (no. correct responses) 31.92 ± 1.86 36.20 ± 2.95 0.21 
Normalised Brain Volume (mm3) 
(lesion-filled images for patients)  
1,492,761.57 
± 26644.57 
1,523,284.20 
± 25006.90 
0.43 
Table 4-1. Demographic and clinical characteristics. Values are Mean ± SEM. 9-HPT is 
a mean of two trails for each hand. T25-FW is a mean of two trials. P-values from two-
tailed unpaired t-tests (except for Fisher's Exact Test used to test sex differences). 
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Visual acuity and VEFs  
 
One patient was not included in the right eye group analysis due to blindness of the 
right eye. The log(MAR) values were extremely non-normal in their distribution across 
eyes and groups, and different cells of the design (group vs. eye vs. contrast level) had 
different variances. Therefore, as the group difference was the focus, separate Mann-
Whitney U tests were used to test the group difference in the visual acuity at each 
contrast level, and the p values were corrected for multiple comparisons with the Holm-
Bonferroni correction. Group differences were assessed at each contrast (100%, 25%, 
10%, 5%, 2.5%, 1.25%, 0.6%) and for each eye (left, right). There were no significant 
group differences between MS patients and controls in visual acuity scores (Table 4-2). 
We investigated the effect of group (controls, patient) and eye (left, right) on the latency 
of the peak amplitudes of the VEFs, for the sensor and source space analyses. The 
data were normally distributed, with no outliers. Results reported here are Mean ± 
Standard Error of the Mean(SEM), expressed in milliseconds. For latencies calculated 
in sensor space, MS patients (146 ± 9) and controls (147 ± 10) did not have significantly 
different latencies (F(1,21) = 0.001, p = 0.98), and the left eye (156 ± 9) and the right 
eye (137 ± 8) also did not differ (F(1,21) = 3.04, p = 0.10), for both groups. The results 
were similar for latencies calculated in source space: there was no main effect of group 
(MS patients: 137 ± 5, controls: 142 ± 6, F(1,21) = 0.38, p = 0.55) and no main effect of 
eye (left: 145 ± 6, right: 134 ± 6, F(1,21) = 1.83, p = 0.19). There was no significant 
interaction between group and eye for the latencies calculated in sensor space, (F(1,21) 
= 0.001, p = 0.98), or source space (F(1,21) = 0.16, p = 0.70).  
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Table 4-2. Median log(MAR) visual acuity scores, for each contrast level and eye. 
Higher scores indicate greater visual acuity loss. Mann-Whitney U-tests, with holm-
bonferroni correction (last row shows the threshold at which the p-value is significant.
Eye 
Visual 
Contrast 
(%) 
MEDIAN 
Mann-
Whitney U 
P 
value 
Significant 
if less than: 
Controls Patients 
Left 
100 0.10 0.00 52.5 0.63 0.016 
25 0.10 0.10 62 0.92 0.05 
10 0.20 0.20 69 0.58 0.01 
5 0.40 0.49 72.5 0.38 0.006 
2.50 0.85 1.00 80 0.20 0.004 
1.25 1.65 2.00 73 0.42 0.006 
0.60 2.00 2.00 69 0.58 0.01 
Right 
100 0.00 0.05 79.5 0.20 0.004 
25 0.10 0.10 79 0.23 0.005 
10 0.20 0.25 71 0.50 0.007 
5 0.40 0.49 75 0.35 0.005 
2.50 0.80 1.30 82.5 0.14 0.004 
1.25 2.00 2.00 71 0.47 0.007 
0.60 2.00 2.00 66 0.72 0.025 
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MEG and fMRI responses to reversing checkerboard stimuli 
 
There were no significant differences in GM volume, baseline CBF or baseline gamma 
power between MS patients and controls, across the whole brain and within the regions 
of interest used to characterise the visual response to the checkerboard stimulus (Table 
4-3).  
 
  Group N Mean Std. Dev P value 
GM Volume (Total) 
(mm3) 
Controls 10 788328.70 55506.80 
0.29 a 
Patients 14 755677.88 66346.84 
GM Volume (L) 
(mm3) 
Controls 10 5514.29 673.20 
1.00 c 
Patients 14 5515.19 768.02 
GM Volume (R) 
(mm3) 
Controls 10 4154.44 530.05 
0.90 b 
Patients 14 4184.46 585.56 
Baseline CBF GM  
ml/100g/min 
Controls 10 36.91 10.17 
0.90 c 
Patients 13 37.34 6.32 
Baseline CBF GM 
(L ROI) ml/100g/min 
Controls 9 57.73 21.18 
0.45 a 
Patients 13 51.96 15.16 
Baseline CBF GM 
(R ROI) ml/100g/min 
Controls 9 57.30 21.00 
0.48 b 
Patients 13 51.70 16.81 
Baseline Gamma  
(L ROI) *10 -14 Tesla 
Controls 10 6.10 0.83 
0.10 b 
Patients 13 7.07 1.63 
Baseline Gamma  
(R ROI) *10 -14 Tesla 
Controls 10 6.80 1.19 
0.94 c 
Patients 13 6.80 1.29 
 
L refers to left and R refers to right: the ROIs refer to the location used to extract 
the stimulus response to the checkerboard. Gamma power is a mean of the 
power at each frequency between 30-80 Hz, averaged over the 30-s rest block. 
 
Table 4-3. Tissue volumes, and baseline signals compared between groups. P-values 
for GM Volume (3), Baseline CBF (3) and Baseline Gamma Power (2) were corrected 
separately with Holm-Bonferroni: a is significant at p<0.017, b at p<0.05, c at p<0.025. 
 
Spatial comparison of MEG and fMRI results 
 
One control’s fMRI data was not useable due to a corrupted image file. Figure 4-2 
shows the location of the ROI used in the BOLD and CBF analyses, for all participants, 
overlaid onto the primary visual cortex. Included in Figure 4-2 are the locations of the 
peak gamma responses for each patient and control, where the time-frequency analysis 
was performed. Figure 4-3 explores the whole-brain MEG source localisation plots for 
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each group. Figure 4-4  shows the whole-brain CBF activity for each group, and Figure 
4-5 the whole-brain BOLD activity. Patients showed significantly higher CBF activity in 
a small cluster located in the intracalcarine and supracalcarine cortex, as well as the 
cuneus. Patients showed significantly higher BOLD activity in lingual gyrus, 
intracalcarine cortex, pre-cuneus and cuneus. These were localised using the Harvard-
Oxford Cortical Structural Atlas. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2. BOLD and CBF responses extracted over a group ROI (yellow), overlaid 
onto V1 (red). Top plot = left eye, bottom plot = right. Dots indicate location of the peak 
gamma response (% change) for each individual (blue = 10 controls, green = 13 
patients). 
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Figure 4-3. Beamformer contrast images (30-80 Hz), projected onto a template brain. 
Negative t-stats indicate lower amplitude for patients compared to controls. T-values 
are plotted here at the uncorrected level. Data averaged over both eyes. 
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Figure 4-4. Significant CBF voxels at the group level in response to the checkerboard. 
Data is averaged over both eyes. Significant activity shown is the average activity 
across all visual contrasts. Voxel clusters thresholded at Z>2.3 and p<0.05. Right side 
of the image corresponds to the left side of the brain. No voxels showing greater activity 
for the control group compared to the patients. 
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Figure 4-5. Significant BOLD voxels at the group level in response to the checkerboard. 
Data is averaged over both eyes. Significant activity shown is the average activity 
across all visual contrasts. Voxel clusters thresholded at Z>2.3 and p<0.05. Right side 
of the image corresponds to the left side of the brain. No voxels showing greater activity 
for the control group compared to the patients 
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Effect of group and stimuli contrast on BOLD, CBF and gamma power change 
 
Given the absence of significant differences in the visual acuity scores and latency of 
the peak amplitudes between groups, the effect of group and stimuli contrast was 
statistically tested on data averaged across the two eyes. Figure 4-6 displays the effect 
of group and stimuli contrast on BOLD, CBF and peak gamma power signal changes.  
 
BOLD, CBF quantified and CBF percent signals increased significantly as stimuli 
contrast increased: F (1.75,33.17) = 46.59, p < 0.001 GG; F (4,76) = 35.41, p<0.001; F 
(4,76) = 35.63, p<0.001, respectively. MS patients had significantly lower signal 
responses, compare with controls, for BOLD and CBF quantified signals, but this was 
not significant for CBF percent: F (1,19) = 7.97, p = 0.01; F (1,19) = 6.62, p = 0.02; F 
(1,19) = 2.76, p = 0.11, respectively. All pairwise comparisons between contrast levels 
were significant. There was no significant interaction between the effect of contrast and 
group on BOLD changes (F (1.75, 33.17) = 0.86, p = 0.42, GG) CBF quantified changes 
(F (4, 76) = 1.25, p = 0.30), or CBF percent changes (F (4, 76) = 0.70, p = 0.59).  
 
For the MEG results, there was a significant interaction between the effect of contrast 
and group on the peak gamma power changes (F (1.50,31.54) = 7.87, p = 0.01, GG). 
Therefore, simple main effects were investigated. There was no significant group 
difference at the 6.25% or 12.5% contrast levels (F (1,21) = 1.13, p = 0.30; F (1,21) = 
1.99, p = 0.17, respectively), but MS patients showed significantly lower peak gamma 
power changes at 25%, 50%, and 100% (F (1,21) = 6.28, p = 0.02; F (1,21) = 12.13, p 
< 0.01; F (1,21) = 10.71, p < 0.01, respectively). Peak gamma power signals increased 
significantly as stimuli contrast increased, for both the control group (F (1.59,14.29) = 
46.03, p<0.001, GG) and the patient group (F (1.12, 15.99) = 22.46, p < 0.001, GG). All 
pairwise comparisons between contrast levels were significant, except between 6.25% 
and 12.5%, and 12.5% and 25% in the patient group.  
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Figure 4-6. Effect of group and visual contrast on peak gamma power, BOLD, CBF 
(percentage change) and CBF quantified (ml/100g/min change).  Values are Mean ± 
SEM. *p<0.05, **p<0.001. Pairwise comparisons significant at p<0.05, with Holm-
Bonferroni correction. 
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Neurovascular coupling in MS patients and controls   
 
The relationship between peak gamma power and BOLD and CBF signals was 
compared between groups. Figure 4-7 visually displays these coupling relationships, 
and Table 4-4 shows the statistical testing between groups.  
 
Figure 4-7A displays the coupling relationships using the median values across each 
group. At this group averaged level, there is a good fit between the MEG and fMRI 
signals. The MS patients appear to have higher gradients on average (i.e. for the same 
peak gamma power change, higher BOLD and CBF change), as well as lower 
intercepts on average. Figure 4-7B shows what the coupling relationship looks like for 
every participant separately, showing that the patient group displays more variability in 
the coupling between peak gamma power and BOLD change compared to the controls. 
CBF coupling results for each participant (not shown) showed similar trends.  
 
To statistically test these coupling differences, the median gradients and intercepts 
were extracted for each person and compared between groups. In general, higher 
gradients and lower intercepts are seen in the patient group, but no significant 
differences are found between groups (Table 4-4). 
 
Table 4-4. Median gradients and intercepts compared between groups, using peak 
gamma power to predict BOLD and CBF. q refers to quantified. Mann-Whitney U-tests 
performed; p values corrected with Holm-Bonferroni, for two dependent tests (gradient 
and intercepts).  
Outcome measure 
MEDIAN Mann-
Whitney U 
P 
value 
Significant 
if less than: Controls Patients 
Gradient 
BOLD  0.03 0.04 66 0.42 0.050 
CBF  1.03 1.30 65 0.46 0.050 
CBF(q) 0.67 0.58 58 0.81 0.050 
Intercept 
BOLD  0.31 0.04 24 0.03 0.025 
CBF  5.08 1.97 38 0.28 0.025 
CBF(q) 3.91 1.16 35 0.19 0.025 
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Figure 4-7.  (A) relationship between gamma power and BOLD/CBF change in 
response to the checkerboard, using group median values. Each point represents a 
different contrast level for each eye. (B) BOLD relationship shown for each control (n=9) 
and patient (n=12). Colours represent each participant and the black line shows the 
linear fit.  
 
 
 
 
 
 
 
 
 
 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
0 10 20 30 40 50
B
O
LD
 s
ig
na
l c
ha
ng
e 
(%
)
0
10
20
30
40
50
60
0 10 20 30 40 50
C
B
F 
si
gn
al
 c
ha
ng
e 
(%
)
0
5
10
15
20
25
30
0 10 20 30 40 50
C
B
F 
si
gn
al
 c
ha
ng
e 
(m
l/1
00
g/
m
in
)
R2 = 0.85
R2 = 0.87
R2 = 0.89
R2 = 0.90
R2 = 0.88
R2 = 0.75
-0.5
0
0.5
1
1.5
2
2.5
-5 0 5 10 15 20 25 30 35 40 45 50 55 60
B
O
LD
 s
ig
na
l c
ha
ng
e 
(%
)
<     Peak Gamma Power change (%)    > 
Controls 
-0.5
0
0.5
1
1.5
2
2.5
-5 0 5 10 15 20 25 30 35 40 45 50 55 60
Patients 
A
B
<     Peak Gamma Power change (%)    > 
   61 
4.4 DISCUSSION   
 
We investigated the neuronal and haemodynamic responses to a reversing 
checkerboard visual stimulus in relapsing-remitting MS, observing smaller peak gamma 
power changes and BOLD and CBF responses. While the range of electrophysiological 
and haemodynamic responses were altered in MS, we found no significant group 
difference in the coupling relationship between these responses, indicating that NVC 
may remain intact in MS. Whilst the lack of significant differences between groups may 
be due to the limited statistical power of this study, due to relatively small samples sizes, 
it may also reflect the complexity and heterogeneity of MS as a disease, and NVC as a 
biological process.  
 
Source localisation of gamma oscillations, BOLD and CBF  
 
The group ROI used to extract the BOLD and CBF signals for all participants was 
located clearly in the primary visual cortex (Figure 4-4). For characterising the gamma 
response, we searched for the peak gamma power change within the calcarine sulcus 
and two adjacent regions: the cuneus and lingual gyrus. This was because previous 
studies suggest visual gamma, in response to this type of stimulus, to be located in the 
primary visual cortex. This method also ensured that the area was comparable to the 
fMRI source whilst allowing for some error in MEG signal localisation. Although we took 
a ROI approach to characterising the peak gamma, CBF and BOLD responses, we also 
visualised these responses across the whole brain. At the whole-brain group-averaged 
level, we saw a reduction in gamma power responses in visual areas for the MS patients 
(Figure 4-3). A reduction was also seen in sub-cortical and temporal regions; this 
possibly indicates activity differences more extensively along visual processing 
pathways, yet this was not further explored. For the CBF and BOLD group-average 
plots, a similar pattern of activity in the early visual cortex was seen for both groups 
(Figure 4-4 and Figure 4-5). There were voxels within the intra/supra-calcarine cortex 
and cuneus (for CBF) and the lingual gyrus, intracalcarine cortex, and cuneus (for 
BOLD) showing significantly greater activity in the MS group compared to the controls. 
A possible explanation of this result is compensatory functional reorganization of the 
cortex in MS patients (Tomassini et al., 2012; Werring et al., 2000).  
 
Reduction of peak visual gamma, BOLD and CBF responses in MS 
 
Here we used the oscillatory activity in the gamma band (30-80 Hz) to characterise the 
neuronal response. Broadly, the gamma rhythm is theorised to reflect the balance 
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between excitatory and inhibitory signalling; networks of fast-spiking, parvalbumin-
expressing, GABAergic interneurons act on pyramidal cells to bring about synchronous 
inhibitory post synaptic potentials (Bartos, Vida, & Jonas, 2007; Buzsáki & Wang, 2012; 
Cardin et al., 2009). A large body of research shows an increase in gamma power when 
functional networks are engaged, widely across the brain and for many different 
processes e.g. (Jensen, Kaiser, & Lachaux, 2007; Jia & Kohn, 2011; Nyhus & Curran, 
2010). Specifically, gamma oscillations are thought to have a functional role in attention, 
perception and mediation of information transfer across different cortical areas (Fries, 
2009).  
 
Disruptions in gamma oscillations have been reported in many brain disorders (Uhlhaas 
& Singer, 2006). In MS, task-induced changes have remained largely unexplored until 
recently (Arpin et al., 2017; Barratt et al., 2017b). Barret et al (2017) reported 
significantly reduced visual gamma amplitudes in a similar MS population, the only 
other study, to our knowledge, that has investigated task-induced gamma oscillatory 
changes in MS. There is evidence that parvalbumin-expressing GABAergic 
interneurons, thought to contribute to gamma oscillations, are reduced in normal 
appearing GM of the motor cortex in MS (Clements, McDonough, & Freeman, 2008), 
and that secondary progressive MS patients have significantly lower GABA levels in the 
hippocampus and sensorimotor cortex (Cawley et al., 2015).  
 
GABA concentration has also been related to visual gamma oscillations and BOLD 
signals in healthy participants in the visual cortex (Magazzini et al., 2016; 
Muthukumaraswamy & Singh, 2009). Therefore, a possible interpretation of our results 
is that these gamma power reductions in the visual cortex of MS patients could be an 
indicator of early GM dysfunction, mediated by GABAergic changes. However, more 
conclusive empirical evidence is needed to fully understand the role of gamma 
oscillations in neural communication, and their relationship with GABA, therefore 
making any interpretation of their alteration in MS a tentative one at this stage. 
Furthermore, we did not see a significant reduction in whole brain or visual GM volumes 
in the MS group when compared to the healthy control group. A lack of volumetric 
differences may simply result from the small sample size, but a contributing factor may 
also be ongoing inflammation as these patients were treatment naïve. The contribution 
of inflammation to an increase in brain volume (and thus to an apparent normalisation 
despite MS pathology) has been indirectly demonstrated by showing that the onset of 
DMT leads to the occurrence of brain volume reduction, a phenomenon called “pseudo-
atrophy” (Gasperini et al., 2002; Vidal-Jordana et al., 2016; Zivadinov et al., 2008).  
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Although they presented with preserved visual acuity and latency of VEFs, the MS 
patients showed significant haemodynamic alterations, in the form of reduced BOLD 
and CBF responses to the visual checkerboard, in the primary visual cortex. In the 
context of largely preserved NVC, the reduced haemodynamic response is consistent 
with the reduced electrophysiological response. Changes in the BOLD response to 
visuomotor tasks have been previously demonstrated, showing that inflammation and 
WM structural damage play a role in altering haemodynamic responses in MS (Hubbard 
et al., 2016; Tomassini et al., 2016). Our alterations in BOLD and CBF responses 
support these findings, as well as altered responses to visual stimuli at different 
contrasts (Faro et al., 2002).  Uzuner & Uzuner (2016), also using a 2Hz reversing 
checkerboard stimulus, found blood flow velocities in the posterior cerebral arteries to 
be higher in a large MS patient group in the state of relapse. Although a different 
measure, this is in contrast to the reduced blood flow responses we reported in this MS 
group, but highlights the potential impact of testing MS participants at different states 
of the disease.  
 
No significant alteration of neurovascular coupling in MS  
 
The relationship between the peak gamma power change and the BOLD/CBF response 
(using the variance given by the visual contrast manipulation) was our empirical 
measure of NVC. While this is intuitive, assuming that the blood flow response only 
reflects a coupling with gamma oscillatory activity is simplistic. The amplitude of gamma 
oscillations can be modulated by the phase of slower oscillations, termed cross-
frequency phase-amplitude coupling (Buzsáki & Wang, 2012), and an increase in 
gamma power is often accompanied by a decrease in power of lower frequencies. 
BOLD and gamma oscillations are also known to be decoupled in some circumstances. 
For example, in the visual cortex, gamma amplitudes are altered with changes in the 
spatial frequency and colour of the stimuli, but BOLD signals are not ( 
Muthukumaraswamy & Singh, 2008, 2009; Swettenham et al., 2013). Despite these 
limitations, and although the temporal relationship of MEG and fMRI signals is complex, 
they are generally thought to originate from the same electrophysiological source and 
have reasonable spatial overlap. Gamma oscillations have high test-retest reliability, 
with stable features within the same participants for at least 4 weeks 
(Muthukumaraswamy, Singh, Swettenham, & Jones, 2010; Tan, Gross, & Uhlhaas, 
2016), which is important considering the practical limitation of doing the MEG and fMRI 
scanning sessions separately.  
 
In this study, we could not demonstrate significant differences in NVC between the MS 
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patients and controls. While this may be related to the power of the study, it may also 
reflect the complexity of the biology underlying the relationship between neuronal 
activity and the haemodynamic response, which in MS is affected by the inflammatory 
milieu. Indeed, the response of blood vessels to neuronal activity is not only mediated 
by reactivity of the smooth muscle cells, but also by neuronal and glial signalling, 
involving many chemical mediators. Increased levels of both vasodilators (e.g., NO, 
(Smith & Lassmann, 2002) and vasoconstrictors (e.g., ET-1, D’haeseleer et al., 2013) 
have been reported in MS, due to the proliferation of glial cells to damaged areas, which 
could interfere with NVC pathways in contrasting ways. In line with the hypothesis that 
inflammation affects NVC, there is the evidence that the MS group appeared to display 
more variance in their coupling relationships, suggesting a greater inter-individual 
variability.  
 
While not significantly different from healthy volunteers, the analysis of the NVC showed 
a trend for the MS group to have lower intercepts and higher gradients, when predicting 
the BOLD and CBF changes from the peak gamma power changes. An increased blood 
flow response, for same gamma power change, may seem counterintuitive considering 
the reports of blood vessels being less reactive in MS (Marshall et al., 2014, 2016). 
However, an increased blood flow response could reflect the need to deliver more 
oxygen or nutrients to tissue, if there is inefficiency in their use to support a given level 
of electrophysiological activity. 
 
Conclusion 
 
We found evidence for reduced neuronal and haemodynamic responses in the early 
visual cortex in MS in response to visual stimulation, in the absence of substantial 
functional impairments to visual acuity or delayed VEFs, or baseline CBF. Despite 
altered neuronal and vascular responses, NVC appears to be preserved in MS, at least 
within the range of damage and disability studied here. 
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5 Quantifying blood flow and oxygen utilisation at rest, in 
Multiple Sclerosis, using dual-calibrated fMRI  
 
5.1 INTRODUCTION 
 
In MS, the directionality of damage is not clear; the classic theory is a dysregulation of 
the immune system leading to tissue injury, but some have proposed that 
cytodegeneration happens first, which promotes an autoimmune and inflammatory 
response (Stys et al., 2012). As covered in Chapter 3.2, there is evidence that 
individuals with MS present with clear vascular and metabolic impairments, within 
normal-appearing GM and WM, and within lesioned tissue. The extent of these vascular 
and metabolic impairments, and how and when they contribute to the disease 
progression, is still not fully known. The consistently reported finding of hypoperfusion 
in MS has many biological interpretations. It could simply be due to a reduced demand 
because of neurodegeneration, or due to the vasculature not responding adequately to 
demand because of a reduction in reactivity of blood vessels. Further to this, tissue 
hypoxia could occur due to restricted CBF or restricted diffusion of oxygen into the 
tissue, possibly mediated by the proposed mitochondrial dysfunction in MS. These 
disease mechanisms could happen in parallel, and also include compensatory 
mechanisms. It is therefore important to develop non-invasive methods of separating 
out these physiological signals, to inform about the state of the vasculature, and 
metabolic activity, in MS. This chapter extends the work of Chapter 4, studying a larger 
sample, and characterising multiple quantitative physiological measurements related to 
oxygen utilisation, as opposed to the relative BOLD signal in response to a visual 
stimulus which has restrictions to its interpretation.  
 
This chapter presents a dual-calibrated fMRI method, the background to which was 
explained in Chapter 2.3.4. This refers to a modulation of blood flow, blood volume, and 
venous blood oxygenation using both hypercapnic and hyperoxic gas challenges during 
MRI. In this chapter, measurement and physiological modelling allows quantitative 
estimates of CBF, OEF, CMRO2, CVR, and Effective Oxygen Diffusivity of the capillary 
network  (Dc) at rest. Dual-calibrated fMRI modelling has, until now, not been used to 
estimate Dc, which, alongside CBF, determines the direct transport of oxygen into the 
neural tissue (Hayashi et al., 2003; Hyder, Shulman, & Rothman, 1998; Vafaee & 
Gjedde, 2000a). In the model we apply here (Germuska et al., 2019) , the exchange of 
oxygen between the capillaries and the tissue (Dc )  is modelled from the observations 
of CBF and OEF. Despite Dc largely reflecting capillary density (Gjedde, Poulsen, & 
Ostergaard, 1999), it also been shown to change according to metabolic demand 
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(Hayashi et al., 2003; Fahmeed Hyder et al., 1998) therefore potentially playing an 
important role in NVC mechanisms.  
 
Dual-calibrated fMRI techniques are still being actively developed and there are only a 
few examples in the literature of applications of this method to patient populations, for 
example in Alzheimer’s Disease (Lajoie et al., 2017) and internal carotid artery 
occlusion (De Vis et al., 2015). Lajoie et al (2017) report decreases in CBF and CMRO2, 
particularly in parietal and temporal regions, in the Alzheimer’s group. A small number 
of PET studies have estimated regional quantitative oxygen metabolism in MS, showing 
reductions in CMRO2 and CBF in both WM and GM, with correlations with atrophy, 
cognition, vision, EDSS and number of relapses (Brooks et al., 1984; Lycke et al., 1993; 
Sun et al., 1998). One MRI study has characterised global venous oxygen saturation 
and CMRO2 at rest in an MS population (Ge et al., 2012) finding increased venous 
oxygen saturation and decreased CMRO2, which significantly correlated with EDSS and 
lesion load. Calibrated-fMRI has also been used in MS to show reduced task-induced 
regional changes in relative CMRO2 (Hubbard, Araujo, et al., 2017; Hubbard, Turner, 
et al., 2017). However, this chapter presents the first study using a dual-calibrated fMRI 
method in a MS population, to non-invasively quantify blood flow and oxygen utilisation 
at rest, across the whole GM. Based on the previous literature, we predicted a reduced 
CBF and CVR in the MS group. We also expected to see reduced CMRO2 in the MS 
group and a relationship between CMRO2 and disease burden. 
 
5.2 METHODS 
 
Participants 
 
26 patients and 25 age and gender matched controls were recruited. In total, complete 
calibrated-fMRI datasets were collected for 22 patients and 22 controls, due to 3 in each 
group either having gas screening contraindications or data acquisition errors. Figure 
5-1 gives an overview of the patient recruitment process. Extensive screening 
questionnaires were carried out for patients and controls to ensure no MRI 
contraindications, and to ensure that it was safe for them to experience the respiratory 
gas modulations. None of the participants were current, or previous, smokers. The list 
of inclusion and exclusion criteria can found in Supplementary Figure 5-1. Written 
consent was obtained according to the protocol approved by Research Ethics 
Committee, Wales, UK. All participants received £10 per hour for taking part.  
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Patients had a diagnosis of relapsing-remitting MS (Polman et al., 2011) and were 
recruited at the University Hospital Wales, Cardiff. Patients had been medication stable 
and relapse-free for at least 3 months. One participant used a unilateral walking aid. 
 
 
Figure 5-1. MS patient recruitment overview, showing numbers at each recruitment 
stage.  This took place over approximately 14 months, alongside recruiting and testing 
25 matched controls. Patients were approached in person within MS clinics or through 
neurologist referrals, but mostly contacted directly via phone, email or letter with contact 
details obtained from the MS research database. Out of the 27 patients recruited and 
booked in for a testing session, one was not able to be scanned due MRI 
contraindications that became apparent on the day of testing.  3 patients were scanned 
but without the gas-paradigm due to gas contraindications, discomfort, or technical 
problems.  *No follow-up refers to when the patient initially replied expressing interest 
but did not reply to further contact. **Patients were not eligible to take part due to not 
meeting eligibility criteria, normally MRI or gas-paradigm contraindications. 
 
Data Collection 
 
The same controls and patients were used in Chapter 5 (this chapter), Chapter 6 and 
Chapter 9; an overview of this data collection is displayed in  Supplementary Figure 5-
2. Patients and controls all completed questionnaires and behavioural testing, a 
haemoglobin (finger prick) blood sample, and an MRI session (explained in detail 
below). Before the MRI scanning, the participant’s tolerance of hypercapnic periods and 
breathing through a face-mask was tested outside the MRI scanner, and the 
researchers ensured the participant was comfortable and happy to continue before 
proceeding to the MRI scanning.  
 
Questionnaires and behavioural testing. All participants completed a socio-
demographic and lifestyle questionnaire. This included age, height, weight, alcohol 
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consumption (if yes: ‘how many units per week?’), caffeine intake (if yes: ‘Do you drink 
more than 3 cups of coffee, tea and cola 
 drinks combined per day?’), and years of education (from start of school onwards). 
Tests from the MS Functional Composite (Cutter et al., 1999) were carried out on all 
participants: 9-HPT for arm/hand function, the T25-FW for leg function/ambulation, and 
the PASAT 2 and 3 seconds as a measure of cognitive function. The Symbol Digit 
Modalities Test (SDMT) was also used to assess cognitive function (Benedict et al., 
2017). Visual acuity was assessed, in each eye separately, with a SLOAN letter chart 
(Precision Vision) at 100% contrast and scored in two ways: (1) the smallest letter size 
(in M-units) where 3 out of 5 letters were correctly read, and (2) a cumulative score of 
total letters read correctly, out of 60. Participants were tested with corrected-vision; 
matched to the correction that they had during the MRI scans.  
 
For patients only, disability and disease impact was assessed with the self-reported 
Multiple Sclerosis Impact Scale (MSIS-29) (Hobart, Lamping, Fitzpatrick, Riazi, & 
Thompson, 2001) and the Fatigue Scale for Motor and Cognitive Functions (FSMC) 
(Penner et al., 2009). Clinical records and a short interview on disease history and 
impact gave information on: disease onset, EDSS (Kurtzke, 1983), relapse history and 
impact of MS on occupation.  
 
Haemoglobin blood concentration. A blood sample was drawn via a finger pick with 
a 1.8mm lancet and analysed with the HemoCue® Hb 301+ system as per the 
manufacturer’s guidelines (Hemo Ängelholm, Sweden). This gave a reading of systemic 
haemoglobin concentration, in grams per litre. This was done within one hour of the 
start of the MRI scan. A measure of haemoglobin represents the oxygen carrying 
capacity of blood and is used in the modelling of the dual-calibrated fMRI data. 
 
MRI Scanning. Data were acquired on Siemens Prisma 3T MRI scanner 
(Siemens  Healthineers, Erlangen, Germany), using a 32-channel head coil. All of the 
scans described below were acquired during one scanning session. A magnetization-
prepared rapid acquisition with gradient echo (MPRAGE), T1-weighted scan was 
acquired for registration and brain segmentation purposes (1mm isotropic resolution, 
200 slices, TR/TE = 2100/3.24ms). A 3D T2-weighted Fluid Attenuated Inversion 
Recovery (FLAIR) image (1mm isotropic resolution, 256 slices, slice thickness = 1mm, 
TR/TE = 5000/388ms) and T2/Proton Density dual-echo image (41 slices, slice 
thickness = 3mm, 0.8 x 0.8 x 3.9 mm, TR/TE1/TE2= 4050/11/90ms) were acquired for 
lesion identification.  
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Whilst participants were at rest, a dual-calibrated fMRI scan including interleaved 
periods of hypercapnia, hyperoxia and medical air were delivered through a facemask 
worn by the participant, following the protocol previously described by (Germuska et 
al., 2016; Merola, Germuska, Murphy, & Wise, 2018). This gas delivery circuit is shown 
in Supplementary Figure 5-3. Three periods of hypercapnia were given, interleaved with 
two periods of hyperoxia (see Figure 5-3.A). During the hypercapnic blocks, 5% CO2 in 
air was given. During the hyperoxic blocks 50% O2 in air was given, with short period 
of 100% O2 and 10% O2 delivered to accelerate the transitions to the hyperoxic state 
and back to baseline. Participant’s heart rate and oxygen saturation were monitored 
with a pulse oximeter constantly throughout the scanning session. PETCO2  and PETO2 
(partial pressure of end-tidal carbon dioxide or oxygen) were sampled from the 
facemask, using a rapidly responding gas analyser (AEI Technologies, Pittsburgh, PA, 
USA). An example breathing trace is shown in Figure 5-3.B. 
 
During this gas protocol, a pCASL acquisition was run, using pre-saturation and 
background suppression (Okell, Chappell, Kelly, & Jezzard, 2013), with a dual-
excitation (DEXI) readout (Schmithorst et al., 2014). The labelling duration and PLD 
were both 1.5s, GRAPPA acceleration (factor of 3) was used with TE1=10ms and 
TE2=30ms. An effective TR (the total TR including labelling and both readouts) of 4.4 
seconds was used to acquire 16 slices, in-plane resolution 3.4 x 3.4 mm and slice 
thickness 7mm with a 20% slice gap. A diagram of this sequence is shown in Figure 
5-2. Before this scan, an M0 image was acquired for ASL quantification with TR of 6 
seconds, TE=10ms.  
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Figure 5-3. Inspired gas fractions used during the respiratory protocol, and (B) Example 
trace of one subject. The design is 18 minutes in total and consisted of three blocks of 
hypercapnia (fixed inspired fractions of 5% CO2 in air), interleaved with two periods of 
hyperoxia (fixed inspired fractions of 50% O2 in air). A short period (14 seconds) of 100% O2 is delivered before each hyperoxic block, to aid the fast transition from 
baseline to stable hyperoxia. A short period of hypoxic gas mixture (10% O2, 90% N2) 
was delivered to ensure fast transition back to baseline. These periods were not 
included in the modelling. Oxygen saturation levels were constantly monitored with a 
pulse oximeter, and the hypoxic gas delivery did not induce arterial hypoxia due its short 
duration and because it follows a longer hyperoxic block. 
 
Figure 5-2. Pulse sequence timing diagram for the DEXI-pCASL acquisition. 
Sequence timings are in milliseconds (ms) to the nearest 5ms. This figure is produced 
by Michael Germuska and used here with permission. 
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Data Analysis 
 
Normalised Whole Brain Volume. Whole brain tissue volume, normalized for subject 
head size, was estimated with SIENAX (Smith, De Stefano, Jenkinson, & Matthews, 
2001; Smith et al., 2002)  in FSL. Brain and skull images were extracted from the single 
whole-head input data (T1-weighted image, lesion-filled for the patients). The brain 
image was then affine-registered to MNI152 space using the skull image to determine 
the registration scaling, and to obtain the volumetric scaling factor. Three-class 
segmentation was carried out and whole brain volumes, normalized for head size, were 
calculated using the volumetric scaling factor. 
 
Lesion Volumes, Lesion Filling and GM mask. Figure 5-4 describes the protocol 
followed to calculate lesion volumes, and improve the accuracy of the segmentation 
(Battaglini et al., 2012; Gelineau-Morel et al., 2012). First, the T2, PD, and T2-FLAIR 
images were brain extracted. The T2-FLAIR image was transformed to the same space 
as T2-PD image (linear, 6 DOF). Using JIM (Version 6.0) lesions were drawn around 
manually using the contour ROI tool, without 3D propagation. All three image contrasts 
were used to locate the lesions, and if in doubt a lesion was not drawn around. This 
lesion map was exported as a NIFTI file, with a pixel area threshold of 50% threshold, 
and a lesion volume was calculated for each patient. 
 
For the lesion filling of the T1 image, the PD image was registered to the T1 image, and 
the lesion map was binarised and transformed to T1-space. The lesion map was 
thresholded at 0.4, to approximately preserve the size of the original lesion map but 
also allow a small amount of inflation so that that the lesion map better overlapped the 
lesions on the T1-image, in case of registration errors. The lesion map was then 
binarised. The function lesion_filling (Battaglini et al., 2012) was used; this fills the 
lesion area with intensities similar to those in the non-lesion neighbourhood (restricted 
to WM only – a WM PVE map was created with FAST previous to this). Using the lesion-
filled T1-image, FSL-FAST was run again to produce a new  PVE of GM.  
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Dual-calibrated fMRI pre-processing. Motion correction was performed with FSL-
MCFLIRT and spatial smoothing (FWHM=4.5mm) of the BOLD data (surround average 
of echo 2) was performed with SUSAN (Smith & Brady, 1997). ASL data (surround 
subtraction of echo 1) and the M0 acquisitions were spatially smoothed using a 3D 
Gaussian kernel (FWHM 4.5mm). Functional DEXI data was registered to the structural 
T1-weighted image using FSL’s epi-reg tool, which also creates and outputs GM, WM 
and CSF PVE through FAST segmentation of the T1-weighted image. Using the inverse 
of this matrix, the T1-image and the GM-PVE image were transformed to DEXI space. 
The GM-PVE image was thresholded at 0.5 and binarised and used as a GM mask for 
the parameter estimates. The GM-PVE was also used for regularisation of the Dc 
estimates (non-lesion filled for the patients), explained below. 
 
Dual-calibrated fMRI modelling. Code for the pre-processing of physiological traces 
was written by Michael Germuska (Germuska, 2018b), alongside the code for 
physiological modelling of the dual-calibrated fMRI data (Germuska, 2018a). The model 
development was not the focus of this chapter but the application of this model to the 
patient-control comparison. For details, see (Germuska et al., 2016) and (Germuska et 
al., 2019).  
Figure 5-4. Summary of the pipeline used to calculate lesion volumes, and perform 
lesion filling, on each patient’s T1-weighted image, to improve tissue segmentation. 
   73 
In brief, a compartmental model of oxygen exchange is used to model the relationship 
between CBF, Dc and OEF. Quantification of resting OEF and CBF (and therefore 
CMRO2) is calculated using a dual-calibrated fMRI method (Bulte et al., 2012; Gauthier 
et al., 2012; Wise et al., 2013), within a forward modelling framework (Germuska et al., 
2016). A simplified calibration model is used (Merola et al., 2016), assuming 
isometabolic alteration of flow during hypercapnia, and isometabolic alterations of 
venous oxygenation during hyperoxia. End-tidal traces were aligned with the DEXI data 
via a cross-correlation between PaCO2 (partial pressure of CO2) and the mean GM ASL 
signal. Measured haemoglobin concentration helped inform the relationship between 
baseline CBF and Dc to OEF in the fitting. A non-linear least squares minimisation 
routine was used to optimise voxel-wise estimates of baseline Dc, OEF, CBF and CVR. 
Regularisation was applied to Dc and OEF to reduce instability in fitting a non-linear 
model to the data and reduce sensitivity to noise variation across voxels and 
participants. The regularisation parameter for OEF was assumed to be uniform, with a 
nominal baseline OEF of 0.4. As Dc nominally scales with CBV, GM-PVE were used to 
impose spatial variation on the Dc regularisation, with a PVE of 1 corresponding to a 
nominal diffusivity of 0.12 ml/100g/mmHg/min. See Figure 5-5 for a brief overview of 
how the data collected is used in this modelling framework. 
 
Figure 5-5. Diagram explaining how the different data acquired during DEXI-pCASL 
scan (and the Hg measurement) is modelled to estimate the multiple physiological 
parameters that are compared between patients and controls. 
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GM voxel-wise comparison. A  GM voxel-wise comparison between groups was 
carried out by another researcher in the lab and therefore the results are included in 
this chapter, in order to aid the interpretation of the average GM parameter results. With 
FSL-FLIRT, two transformation matrices were created and combined into one: a 
registration from the individual’s functional DEXI space to their T1-anatomical space, 
and from T1-anatomical space to MNI (2mm) template space. All parameter maps, 
including the GM-mask, were then transformed to MNI-space. In MNI space, each 
parameter map was masked with their MNI GM-mask. After merging all participants into 
one 4D file, FSL’s randomise function was used to perform nonparametric t-tests to test 
the difference between patients and controls, for each parameter. Two t-statistic 
contrasts were produced (Patients > Controls, and Controls > Patients), thresholded at 
p<0.05, with Threshold-Free Cluster Enhancement correction. 
 
Statistics 
 
Group-comparisons. For each participant a map of CBF, CMRO2, OEF, CVR and Dc 
was outputted in native space, from the physiological modelling. An average value 
(median) across voxels in the GM mask was outputted for each parameter. In SPSS, 
independent sample t-tests were used to test differences between patients and controls 
for each parameter. When the assumption of normality was violated (tested with 
Kolmogorov-Smirnov test) Man-Whitney U tests were performed (with an exact 
sampling distribution for U). When distributions of scores were similar for patients and 
controls, determined by visual inspection, medians were compared.  For comparison of 
categorical variables, between groups, Pearson’s Chi-square tests were run. Outliers 
were defined as being 3xSD above or below the mean, or 3xIQR above or below the 
lower or upper quartile, respectively. All p-values reported are two-tailed. Group means 
and standard errors are presented in brackets as Mean ± SEM, and errors bars display 
± SEM unless stated otherwise. 
 
Patient regressions. In SPSS, Multiple linear regressions were performed to 
investigate what disease characteristics could predict the variability of CBF and CMRO2 
GM averages. Unless stated in the results, the assumptions of multiple linear regression 
were met: normality of residuals, predictor variables linearly related to the outcome 
variable, homoscedasticity (residuals are equal for all values of the outcome variable), 
multicollinearity (high correlations between predictor variables), and no significant 
outliers or highly influential points. For outliers, standardized and studentized deleted 
residuals were examined, and outliers were classed as ± 3. Cook’s distance was 
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calculated, with a typical cut-off of greater that 1 being used to indicate highly influential 
points.  
 
5.3 RESULTS 
 
For the group comparisons, 2 controls and 1 patient were left out of the analysis due to 
bad quality data. These three participants did not return to a stable PETCO2 baseline 
during the periods of medical air delivery; this was judged to be a deviation of greater 
than 5mmHg with reference to the first baseline block. This was alongside lower quality 
physiological and imaging data in general for these participants, due to noticeable 
motion artifacts. This left 20 controls and 22 patients. Patient disease characteristics 
are displayed in Table 5-1 and demographics and behavioural tests scores for both 
groups are displayed in Table 5-2. An example of all the parameter maps is shown for 
one control and one patient in Figure 5-6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5-1. Patient disease characteristics. a refers to Mean ± SD. Some data were not 
normally distributed and therefore b refers to Medians (IQR). FSMC (total scores for 
each domain); MSIS-29 (total scores for each domain), and Job change refers to 
whether their job had changed due to MS 
 
 
 
    
Patients 
Min – Max 
(Outliers) 
  
Lesion Vol (mm3)b 7253.64 
(7392.75) 
 2062 – 35963 
(P1 =35963; 
P2 = 33850).  
 
Disability: EDSS a 2.23 ± 1.38  0 - 6  
D
is
ea
se
 
H
is
to
ry
 Months since onset a 95.54 ± 59.37  20 - 253 
Months since relapse a 33.95 ± 20.25  5 - 78 
Se
lf-
re
po
rt 
D
is
ea
se
 Im
pa
ct
 FSMC-Motor 25.73 ± 11.31 10 - 45 
FSMC-Cognitive 24.59 ± 9.91 10 - 43 
MSIS-29-P b 31 (21.5)  20 - 76 
MSIS-29-C a 16.91 ±  6.57  9 - 32 
Job change? Y/N 4/18 / 
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Table 5-2. Demographics and behavioural data compared between groups. a refers to 
Mean ± SD, alongside Independent Sample T-tests, and b refers to Medians (IQR), 
alongside Mann-Whitney U Tests. For the categorical variables, Pearson’s Chi-square 
tests were run. [BMI = Body Mass Index; Caffeine >3 = drink more than 3 caffeinated 
drinks per day; Visual Acuity is based on the cumulative score across all letter sizes; 
dom = dominant  hand, ndom = non-dominant hand; Brain Vol  = whole brain volume 
normalised for skull size. 
 
 
 
 
 
 
 
 
 
  
 Patients Controls Test Statistic P 
D
em
s 
& 
Li
fe
st
yl
e  
Gender (M/F) 5 / 17 6 / 14 χ(1) = 0.29 0.592 
Age (Yrs) a 35.45 ± 7.15 34.15 ± 5.69 t(40) = -0.65 0.519 
Education (Yrs) b 18 (2) 18 (5) U = 148 0.182 
BMI a 26.81 ± 4.95 24.67 ± 4.02 t(40) = -1.53 0.133 
Caffeine >3 Y/N 11 / 11 5 / 15 χ(1) = 2.78 0.096 
Alcohol (Units/wk) b 2 (2.5) 2 (3.75) U = 148 0.362 
Vi
su
al
 Visual Acuity-L b 45 (9.5) 48 (7) U = 162 0.223 
Visual Acuity-R b 44 (8) 47 (8) U = 134 0.045 
M
ot
or
 T25-FW (sec) 
a 4.66 ± 0.63 3.98 ± 0.63 t(39) = -3.50 0.001 
9HPT-dom (sec) a 19.76 ± 2.53 20.18 ± 2.28 t(38) = 0.594 0.556 
9HPT-ndom(sec) a 22.86 ± 2.56 21.25 ± 2.97 t(40) = -1.891 0.066 
C
og
ni
tiv
e PASAT3 (/60) a 50 (21) 54 (16) U = 187 0.398 
PASAT-2 (/60) a 34.90 ± 12.16 35.9 ± 12.21 t(39) = 0.80 0.795 
SDMT a 59.90 ± 7.14 62.40 ± 9.75 t(40) = 0.95 0.348 
 
Brain Vol (mm3) a 
1508183 
± 76523 
15488667 
± 59496 
t(40) = 1.91 0.063 
Outliers (C = Control, P = Patient) 
Alcohol (C1 = 24 units, C1 = 18 units, P1 = 15), Visual Acuity-L (C1 = 8 score), 
Visual Acuity-R (P1 = 0), T25-FW (P1 =11.03), 9HPT-dom (P1 = 30.53, P2 = 
38.07).  
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Model fit 
 
 For each patient and each control, the average of the residuals and the SD of residuals 
across voxels was calculated, to broadly estimate how well the model fit for each 
participant.  Median residual estimates for patients (0.64) and controls (0.63) were not 
significantly different, U = 252, z = 0.81, p = 0.420.  Median residual SD estimates were 
higher in patients (0.30) compared to controls (0.26), suggesting more variance in the 
model fit across voxels for the patient group, however this was not a significant 
difference, U = 294, z = 1.86, p = 0.062. 
 
Model outcome parameters 
 
The following data refer to Means ± SEM and are displayed in Figure 5-7. For GM CBF 
averages, patients (46.64 ± 1.29 ml/100g/min) displayed significantly lower values than 
controls (51.53 ± 1.44 ml/100g/min), t(40) = 2.53, p = 0.015. For GM CMRO2 averages, 
patients (131.55 ± 4.81 µmol/100g/min) also showed significantly lower values 
compared to controls (145.51 ± 4.28 µmol/100g/min), t(40) = 2.15, p = 0.038. There 
were no significant differences between patients and controls for GM OEF (Patients: 
0.41 ± 0.14, Controls: 0.40 ± 0.14, t(40) = -0.493, p = 0.625), GM CVR (Patients: 2.27 
± 0.14 %CBF change/mmHg CO2, Controls: 2.51 ± 0.15 %CBF change/mmHg CO2, 
t(40) = 1.17, p = 0.249) or GM Dc (Patients: 0.081 ± 0.004 ml/100g/mmHg/min, Controls: 
0.087 ± 0.003 ml/100g/mmHg/min, t(40) = 1.211, p = 0.233). GM volume (the area used 
to extract these average values) was significantly lower in patients (489273.31 ± 
13881.48 mm3), compared to controls (528354 ± 13622.62 mm3), t(40) = 2.00, p = 0.05. 
The hemoglobin measurement, used in the modelling of capillary oxygen content, was 
not significantly different between patients (135.7 ± 3.29 g/L) and controls (136.5 ± 2.83 
g/L), t(39) = 0.19, p = 0.849.  
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Figure 5-6. Example  baseline parameter maps for one control (top) and one patient 
(bottom), showing  CBF (ml/100g/min), CMR02 (µmol/ml/min), OEF, Dc 
(ml/100g/mmHg/min), CVR (%CBF change/mmHg CO2), GM-PVE (probability 
estimate) in individual subject space, the GM mask (binarised) which is the GM-pve 
thresholded at 0.5, and the residuals of the model fit. 
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Are partial volume estimates different in the patient group, and how does this 
affect the GM averages? 
 
If patients have different partial volume characteristics than controls this has the 
potential to introduce bias in our parameter estimates from GM.  Studies have reported 
a relationship between lesion load and GM volume estimation, when segmentation 
involves modelling intensity distributions of different classes of tissue (Battaglini et al., 
2012; Popescu et al., 2016).  By performing the tissue segmentation of lesion-filled T1 
images we hoped to mitigate this effect, however some biases may still remain. To 
investigate this, a mean across voxels in the unbinarised GM PVE image, thresholded 
at 0.5, was calculated for each participant. This gives an estimate of the amount of GM 
in each voxel, on average, after thresholding. This GM PVE voxel-average for patients 
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Figure 5-7. Comparing patient (n=22) and control (n=20) group means for CBF 
(ml/100g/min), CMR02 (µmol/ml/min), OEF, Dc (ml/100g/mmHg/min), CVR (%CBF 
change/mmHg CO2) and volume of the GM mask (mm3) used to extract average 
(median) parameter values for each participant. Differences between means are 
tested with independent t-tests. *p≤0.05, ns = p>0.05. Errors bars display ± SEM. 
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(Group median = 0.61) and controls (Group median = 0.62) were not significantly 
different, U = 160.52, z = -1.157, p = 0.116. Furthermore, we compared all parameters 
after thresholding the GM PVE at 0.75, a more conservative value. The results were 
unchanged compared to the 0.5 thresholded results, except for no significant difference 
in volume of the GM mask (when thresholding at 0.75).  Only CBF and CMRO2 were 
significant different between groups, as before. The mean difference between patients 
and controls actually increased with the threshold of 0.75. For CBF,  the mean 
difference between groups for the 0.5 threshold was 4.89 (t(40) = 2.53, p = 0.015), and 
for the 0.75 threshold it was 6.411 (t(40) = 2.66, p = 0.011).  For CMRO2, the mean 
difference between groups for the 0.5 threshold was 13.96 (t(40) = 2.15, p = 0.038), 
and for the 0.75 threshold it was 16.55 (t(40) = 2.26, p = 0.029).  
 
What disease characteristic can explain the reduced CBF and CMRO2 in 
patients? 
 
As CBF and CMRO2 were significantly different between groups, we investigated what 
patient disease characteristics could predict variability in these scores. As the CBF and 
CMRO2  are averages across the whole GM, we did not include behavioural data 
specific to one functional system (e.g. SDMT for cognition, or 25FW for motor function).  
As an indication of recent and general disease impact, across functional systems, we 
used the MSIS-19 and FSMC questionnaire data, in physical and cognitive domains. 
Higher scores indicated higher impact of cognitive and physical symptoms on everyday 
life. As a general indictor of whole brain disease activity, we included lesion volume and 
GM volume (used to extract the CBF and CMRO2 averages).  
 
Scores from the four questionnaire subsections all strongly correlated with each other: 
MSIS-19 physical and cognitive (r = 0.73, p <0.001), FSMC cognitive and FSMC 
physical (r = 0.88, p <0.001), MSIS-19 physical and FSMC physical (r = 0.75, p <0.001), 
MSIS-19 cognitive and FSMC cognitive (r = 0.80, p <0.001), MSIS-19 cognitive and 
FSMC physical (r = 0.84, p <0.001),  MSIS-19 physical and FSMC cognitive (r = 0.57, 
p <0.01).  Therefore a 'total disease impact' scores was included in the model instead, 
which was simply the sum of each questionnaire domain. Therefore, the models to 
predict CBF and CMRO2 included these predictors: total disease impact, GM volume, 
and lesion volume. 
 
For predicting CBF, the overall model was significant, with an R2 of 35.7% and an 
adjusted R2 of 25.0% (F (3, 18) = 3.33, p = 0.043). Lesion volume significantly 
contributed to this model (β = -0.64, p = 0.008), but GM volume (β = -0.17, p = 0.483) 
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and composite disease impact score (β = 0.036, p = 0.827) did not. CBF decreased by 
0.000432 ml/100g/min for every 1mm3  increase in lesion volume.  For the CMRO2 
regression, one patient had studentized deleted residual of -3.25, and also a cook's 
distance of 1.1, suggesting it has a large effect on the regression. Therefore, this patient 
was removed from the regression. The overall model was significant, with an R2 of 
37.3% and an adjusted R2 of 26.3% (F (3, 17) = 3.37, p = 0.043. GM volume significantly 
contributed to the model (β = 0.62, p = 0.038), but lesion volume (β = -0.13, p = 0.596) 
and composite disease impact score (β = -0.447, p = 0.116) did not. CMRO2 increased 
by 0.0002 µmol/100g/min for every 1mm3 increase in GM volume. The relationship 
between CBF, CMRO2, GM volume and lesion volume are displayed in Figure 5-8. To 
establish whether the  relationship between GM volume and CMRO2 was specific to 
patients, this was also explored in the controls. No significant relationship between GM 
volume and CBF or GM volume and CMRO2 was seen for the controls (Supplementary 
Figure 5-4).  
 
 
Figure 5-8. The relationship between lesion volume and GM CBF (top left), lesion 
volume and GM CMRO2 (top right), GM volume and CBF (bottom left) and GM volume 
and CMRO2 (bottom right). These results are for the patient group only. Lesion volume 
was the only significant predictor of CBF, and GM volume the only significant predictor 
of CMRO2. The p-values refer to the significance of the beta coefficients in the multiple 
regression model. 
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Voxel-wise differences between groups 
 
Four small significant clusters, showing higher values for controls compared to patients, 
were found for both the CBF and for CMRO2 voxel-wise comparisons (Figure 5-9). No 
significant voxel-wise differences were found for CVR, OEF or Dc. The following p-
values refer to the maximum corrected p-value in that cluster, with the corresponding 
MNI coordinates [x,y,z]. The brain regions refer to the peak location, referencing the 
Harvard-Oxford Cortical Structural Atlas in FSL. The peak locations of common 
significant clusters for both CBF and CMRO2 were located in the Subcallosal Cortex 
(CBF: p-value = 0.024, 54 voxels; CMRO2: p-value = 0.025, 27 voxels, both located at 
[45 73 40]), and medial/orbital frontal regions (CBF: p-value = 0.047, [50 77 24], 14 
voxels; CMRO2: p-value = 0.037, [49 79 23], 39 voxels). For CBF, the peak location of 
the other two significant clusters were located in the occipital pole (p-value = 0.031, [44 
16 41], 41 voxels), and the para-hippocampal gyrus  (p-value = 0.046, [55 42 28], 6 
voxels). For CMRO2, it was the nucleus accumbens (p-value = 0.033, [40 70 34], 39 
voxels) and the paracingulate gyrus (p-value = 0.048, [51 85 42], 2 voxels).  
 
 
Figure 5-9. Clusters of  voxels showing significantly higher CBF and CMRO2 in the 
control group compared to the patient group. Red displays voxels with significantly 
higher CBF and CMRO2, green displays voxels with significantly higher CBF only and 
blue displays voxels with significantly higher CMRO2 only. 
   83 
5.4 DISCUSSION  
 
This chapter presents the first application of a dual-calibrated fMRI protocol in a MS 
population, allowing simultaneous baseline quantification of many important 
physiological parameters reflecting vascular and metabolic function. The patients and 
controls were age and gender matched and did not differ on years of education, BMI 
and self-reported caffeine and alcohol intake. Behaviourally, patients showed 
significant impairments in visual acuity (right eye only) and the 25-foot walk, suggesting 
impaired mobility and leg function in this group. For the GM parameter averages, CBF 
and CMRO2 were significantly lower in patients, but no significant differences were seen 
for CVR, OEF or Dc. In the patient group, self-reported disease impact did not 
significantly predict CBF or CMRO2, however lesion volume did significantly predict 
variability in CBF, and GM volume predicted variability in CMRO2. Consistent with the 
GM-average analysis, the voxel-wise analysis only showed significant group 
differences for CBF and CMRO2 signals, in a few small clusters. Firstly, the GM 
parameter comparisons will be discussed, followed by modelling limitations and lastly 
practical considerations. 
 
A reduction in CBF and CMRO2, over the GM, is consistent with previous literature in 
MS, as summarised in Chapter 3.2. In the introduction of this chapter, some potential 
mechanisms were proposed: a reduced CBF reflecting a reduced metabolic demand 
due to neurodegeneration; a reduced CBF due to an impaired CVR which could lead to 
hypoxic tissue; a restricted CBF or alterations in the diffusion of oxygen into the tissue 
also leading to hypoxia. As we only report reductions in CBF and CMRO2, but no 
differences in OEF, CVR or Dc, this suggests that the reduced CMRO2 and CBF most 
likely reflect a reduced demand from the tissue, with little evidence for a hypoxic state. 
The lack of difference in oxygen diffusivity supports this interpretation, considering there 
is evidence suggesting diffusivity can increase with increasing demand (Hayashi et al., 
2003; Hyder et al., 1998). 
 
Two previous studies reported widespread CVR decreases in MS (Marshall et al., 2014, 
2016), in contrast to our results. These studies used a pCASL sequence, as done here, 
so their units of measurement for CVR were the same (%CBF change/mmHg CO2). 
The cause of this discrepancy is not clear, and they report similar disease durations 
and EDSS scores for their patients. In the calculation of their CBF-CVR maps they 
implemented GM partial volume correction, and their GM tissue mask was defined at 
70%. We defined ours at 50%, however also showed no significant differences in CVR 
when exploring the results with a threshold of 75%. In contrast, a study by a different 
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lab used transcranial doppler imaging with a BH task, and report no CVR differences in 
MS across three time points (Uzuner et al., 2007). Therefore, more research is needed 
to understand how relevant CVR deficits are to MS pathology. Nevertheless, in this MS 
group, normal CVR suggests that the blood vessels were dilating appropriately when 
stimulated. There are very few studies applying dual-calibrated fMRI to study a patient 
population. One of them is by Lajoie et al (2017); they carried out a dual-calibrated 
study in Alzheimer’s Disease (AD) and had similar aims: to assess the extent of 
vascular and metabolic impairments in AD, as well as to assess the feasibility and 
practicality of these types of methods. They highlight some key methodological 
challenges to overcome (choice of post-labelling delay, presence of susceptibly 
artefacts, and challenges administering hypercapnia to elderly participants). 
Nevertheless, they report similar results to us: decreased CBF and CMRO2 in GM 
parietal, precuneus and temporal regions in AD patients, with no differences in OEF, 
CVR and M values in their ROI analysis. However, they do find some reductions in OEF 
and M in their voxel-wise analysis, in a small parietal-precuneus cluster. They state that 
these results tend to rule out chronic global cerebral ischemia at this stage of AD. 
 
The reasons for the lower CBF and CMRO2 GM signals in MS is not fully clear. The 
volumes of the GM mask, used to extract these parameter averages, were significantly 
lower in patients compared to controls, suggesting GM atrophy in this patient group. 
However, as the parameter estimates are averages over each voxel in the remaining 
GM, the CBF and CMRO2 reductions cannot simply be attributed to a lower GM volume. 
However, the density of GM in each voxel (the PVE) could still have been different in 
the patient group (Battaglini et al., 2012; Popescu et al., 2016), biasing the overall 
averages. We report no significant group differences in the average PVE across voxels, 
above 0.5, and no difference in the parameter comparisons when thresholding at 0.75. 
This suggests that partial volume effects of the GM mask did not contribute significantly 
to the group differences report. However, the regression analyses showed a positive 
association between GM volume and CMRO2 GM averages, in the patient group only. 
This suggests GM atrophy may reflect some disease activity that is also affecting the 
metabolism of oxygen specifically, as there was no significant relationship between 
CBF and GM volume. A significant relationship between lesion volume and GM CBF 
averages was reported, showing patients with higher lesion volume to have lower CBF 
values. Similar relationships have been reported previously, including negative 
correlations between T2-lesion load and global GM CBF (Amann et al., 2012) and GM 
CVR (Marshall et al., 2014, 2016). Lesion volume was not significantly related to GM 
CMRO2  averages but the trend appeared very similar. In fact, Ge et al (2012) report a 
significant negative correlation between their whole-brain CMRO2  measure and lesion 
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load. These findings are interesting, as the majority of these lesions were not identified 
within GM, meaning the level of WM damage relates to the level of GM CBF impairment. 
It could be assumed that  a higher WM lesion load simply reflects a higher GM lesion 
load; GM lesions that are likely present in this MS group based on previous literature 
(Klaver, De Vries, Schenk, & Geurts, 2013a) but not measured in our study. However, 
it is not clear from the literature whether this assumption can be made: some literature 
reports no correlations between WM and GM damage (Bö, Geurts, van der Valk, 
Polman, & Barkhof, 2007), whereas others show that they are related (Mühlau et al., 
2013). The GM masks for the patients likely included both healthy and damaged GM; 
we cannot separate these with the data collected. For future studies, it would be 
valuable to include other scans more sensitive to GM damage, to report alongside these 
GM physiological measurements, for example double inversion recovery FLAIR 
sequences to characterise GM lesions (Abidi, Faeghi, Mardanshahi, & Mortazavi, 2017) 
and techniques using quantitative mapping of MR parameters to characterise 
myelination within GM (Lutti, Dick, Sereno, & Weiskopf, 2014). 
 
The voxel-wise analysis showed multiple small clusters that had significant decreases 
in the patient group, for CBF and CMRO2 only. Both CBF and CMRO2 were decreased 
in the subcallosal cortex and medial frontal regions, just CBF in the occipital pole and 
the para-hippocampal gyrus, and just CMRO2 in the nucleus accumbens and the 
paracingulate gyrus. Considering the wide-spread nature of the damage reported in MS 
we did not have any clear predictions of certain regions showing vascular or metabolic 
differences at the group level, and it must be noted that these clusters are very small. 
However, it is interesting that some of the regions we report are areas where new 
lesions appear more frequently. For example Calabrese et al (2015) tracked the 
distribution and evolution of GM lesions over 5 years and showed new lesions appeared 
more frequently in the hippocampus, parahippocampal gyri, insula, cingulate cortex, 
superior frontal gyrus and cerebellum. The corpus callosum, subcortical regions and 
visual pathways are also common regions (Ge, 2006), which are close to the regions  
we observe these voxel-wise differences. We can therefore speculate that these 
differences in GM CBF and CMRO2  are driven by existing or developing lesions in these 
areas, however this link has not been directly tested. 
 
Patients reported lower GM volumes on average, lower CMRO2 signals on average, 
and GM volumes positively correlated with CMRO2 signals. Therefore, this is consistent 
with the idea that CMRO2 is modelling tissue oxygen demand and that this demand is 
decreasing as GM volume decreases. It is difficult to say whether this relates simply to 
GM atrophy, or if there is a more generalised metabolic dysfunction in the GM of MS, 
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as has been proposed (Paling et al., 2011). Nevertheless, it adds to the evidence for a 
clear GM dysfunction in MS, mediated by metabolic and vascular impairments.  
 
Model Assumptions  
 
In order to estimate all these physiological parameters, there are many assumptions 
made about the underlying biology. It is important to consider whether the same 
assumptions would hold for a patient group, and also consider assumptions specific to 
this model. Future research should investigate these model assumptions to maximise 
the applicability of this method to an MS population, and disease populations in general. 
 
We did not measure CBV but estimate the CBV changes within our model by assuming 
a power law relationship with CBF changes. This CBF-CBV coupling constant is based 
on animal data which was later confirmed with human data (Chen & Pike, 2010). 
However, this coupling relationship has not been explicitly studied in disease, and it 
may be that the assumptions are not valid for an MS population. The coupling may 
spatially vary with the variation in GM or WM tissue integrity. Indeed, DSC MRI studies 
have typically reported CBV reductions in an MS group (Aviv et al., 2012; Inglese et al., 
2007, 2008; Papadaki et al., 2012; Vitorino et al., 2017), although often in the deep GM. 
In this literature, CBF and CBV reductions, in the same participants, have been reported 
in different regions (Vitorino et al., 2017), and significant regional changes in GM CBV 
have been reported without changes in GM CBF, after controlling for confounds (Aviv 
et al., 2012).  The modelling of the dual-calibrated data (Germuska et al., 2019) included 
priors to stabilise the fitting process, as has been done previously (Germuska et al., 
2016; Wise et al., 2013). This was in the form of a non-linear least squares fit, with 
regularisation. This regularisation procedure gives the model additional information, to 
help prevent overfitting, and therefore minimise the effect of random noise on the model 
fit. Germuska et al (2019) carried out digital phantom simulations to optimise the 
amount of regularisation, which was applied to the OEF and Dc parameters only. For 
OEF, an expected value of 0.4 was set for all voxels, and Dc was assumed to be linearly 
related to the voxel-wise GM PVE. The noise variance was estimated for each voxel 
separately, therefore this regularisation technique was spatially adaptive. Considering 
the use of this OEF prior, it is possible that the lack of difference between patients and 
controls for OEF could be driven by underfitting or overfitting of the data, if this is not 
an appropriate assumption to make about the MS physiology in general. If there was a 
true difference in OEF in the MS group that is not being measured, this would also affect 
the CMRO2  group comparisons.  As mentioned in the introduction, Ge et al (2012) 
report decreased global OEF and decreased global CMRO2 using the T2-relaxation-
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under-spin-tagging (TRUST) sequence. Another study (Fan et al., 2015) showed a 
3.4% difference in OEF between MS patients and controls, using a phase-based MRI 
method at 7T. This is a very different method than our dual-calibrated approach: 
selected veins parallel to the magnetic field were modelled as long cylinders to quantify 
the susceptibility difference between the vessel and the tissue, in order to model OEF. 
However, it gives some evidence there may be OEF difference in MS. In contrast to 
this, MR susceptometry-based oximetry data (Jain, Langham, & Wehrli, 2010)  we 
collected on a subset of the same participants (14 controls and 18 patients), in the same 
session as the dual-calibrated data, showed no differences in OEF between groups 
(Supplementary Table 5-1). These results are whole-brain measurements, with no 
priors informing the estimates of CBF, CMRO2 and OEF. Lastly, parameter maps 
looked physiological plausible, and there were no significant differences in model fit (as 
characterised by the average and SD of residuals over voxels) between patients and 
controls.  
 
Practical considerations and applications  
  
We did not find any relationships between the composite disease impact scores 
(cognitive and physical general disease impact and experience of fatigue) and CBF or 
CMRO2. The four sub-scores from the two questionnaires strongly correlated with each 
other, so it was important not to include them in the model as separate predictor 
variables.  Absence of correlation between perfusion abnormalities in MS and clinical 
measures of disability is a common finding in the literature (Lapointe et al., 2018). The 
dual-calibrated study in Alzheimer’s patient’s (Lajoie et al., 2017) also reported no 
significant correlations between the physiological parameters and cognitive 
assessments. Larger samples and further investigation is needed to understand the 
clinical relevance of vascular and metabolic impairments we report. However, as can 
be seen in Figure 5-1 recruitment for this type of study is challenging considering the 
long list of eligibility criteria, and the commitment required from each participant. 
Furthermore, two researchers are required to be both MRI trained and trained to 
administer gases, and in this study an anaesthetist was also present to ensure 
participant safety, and to respond in the case of an adverse reaction to the gas delivery. 
However, compared to the dual-calibrated Alzheimer’s study by Lajoie et al (2017) we 
did not have as many issues with patient drop-out. Lajoie et al (2017) go from n=64 
patients recruited to n=34 datasets due to: 10 dropping out during the hypercapnia 
testing, 4 due to equipment malfunction, 6 due to the presence of mask leakage and 5 
during the gas inhalation. Although we report some similar issues (Figure 5-1) we had 
a lower drop-out rate. One likely contributing factor to this is the age of our participants: 
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the average age our MS sample was 35 years, and for their Alzheimer’s cohort it was 
77 years. Furthermore, individuals with MS are often familiar with the MRI environment 
considering it is used within the diagnostic and treatment monitoring process. 
Therefore, application of these methods to an MS population is likely to be practical 
feasible.  
 
Finally, these vascular and metabolic impairments may differ at different stages of MS.  
In this sample, the MS patients were of the RRMS type, they had no changes in 
medication for at least 3 months, and no relapse in the last 3 months. In actively 
inflamed WM tissue, there are reports of higher CBF and CBV, not lower (Ge et al., 
2005; Haselhorst et al., 2000; Ingrisch et al., 2012; Wuerfel et al., 2004). These CBF 
and CBV increases presumably reflect a higher metabolic demand, but this had not 
been tested directly. For chronic WM lesions, looking T1-hypointense, there is evidence 
for a reduction in CBF (Haselhorst et al., 2000; L. Li et al., 2014).  One study reports 
lower CBF and CBV in cortical lesions, in RRMS patients, compared to normal 
appearing GM (Peruzzo et al., 2013), however, a small subset show increased CBF 
and CBV, suggestive of acute inflammation.   
 
Conclusions  
 
This chapter displayed the first application of a dual-calibrated fMRI method in an MS 
population, showing evidence for reduced blood flow and oxygen metabolism across 
the GM, in the absence of changes in reactivity of blood vessels, OEF and effective 
oxygen diffusivity. As CMRO2 was positively correlated with total GM volume, and GM 
volume was reduced in these patients, this may suggest there is a reduced demand for 
oxygen in the GM. The development of these methods are ongoing, but these results 
demonstrate the feasibility of measuring and estimating many important physiological 
parameters relevant to MS pathology.   
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5.5 SUPPLEMENTARY 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ELIGIBILITY CRITERIA 
[Patient only] 
 
Inclusion 
• Aged between 18 and 45 years  
• Speak fluent English  
• Diagnosis of MS (no other neurological/psychiatric conditions) 
• Medications and rehab stable for at least 3 months 
 
Exclusion  
• MRI contraindications 
• Current smoker 
• History of diabetes, blood-borne disease, haemophilia, rest angina, 
asthma (in past 2 years), shortness of breath at rest, regular dizziness, 
epilepsy, head trauma  
• Pregnant or have given birth in the last 6 weeks 
• Been involved in any drug trials in the last 4 weeks 
• History of drug dependency or have taken any illicit drugs in the last 4 
weeks 
• Have experienced a relapse in the 3 months prior to taking part  
• Have been prescribed steroid drugs in the 3 months prior to taking 
part 
 
Information on any medications the participant was currently taking 
(prescribed and unprescribed) was asked about to ensure that they did not 
interfere with breathing, and therefore interact with the gas protocol. An 
anaesthetist reviewed all reported  medications before proceeding with the 
practise gas protocol. 
 
Supplementary Figure 5-1. Eligibility criteria for controls and patients, for the 
dual-calibrated fMRI study. 
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Supplementary Figure 5.2. A typical testing session for one participant, showing 
which data contributed to Chapters 5, 6 and 9.  
Data presented in Chapter 5 and 6.
Data presented in Chapter 6.⍟⍟ Presented as Supplementary
(Table 5-1)⍟ Not presented in this thesis
Data presented in Chapter 9. 10
patients and 10 controls carried out
the movie scans within the full
session, shown in orange. 5 patients
and 2 controls did not, but were
invited back on a separate day to
complete the MEG session and a
short MRI session involving the
movie and T1-scan. 3 other control
datasets from Chapter 7 were
included in the Chapter 9 analysis, to
get a matched control sample of 15.
Consent & Screening
(~ 15 mins)
MEG
Set-up & Movie Scan
(~ 1 hour)
Clinical and behavioural 
data
Demographics; Disease 
history; Questionnaires; 
SLOAN letter chart; 25-FW; 
9HPT; SDMT; PASAT; 
Hemoglobin Sample 
(~ 1 hour)
Break (~30 mins)
Prep participant for MRI  
(~15mins)
Gas Familiarisation 
(~30 mins)
MRI (1.5 - 2 hours)
• Phase-Contrast (for location of pCASL tagging) 
• pCASL scan with gases  (M0 preceding)
Replace mask with nasal cannula
• Phase-Contrast (for location of pCASL tagging)
• Time of Flight, and OxFlow⍟⍟
• pCASL scan during visual task (M0 preceding)
• pCASL scan during motor task (M0 preceding)⍟
• pCASL scan during movie (M0 preceding)
• Structural scans:  FLAIR, PD/T2, MPRAGE (T1)
Recruited 26 MS; 25 controls
26 MS; 25 C
26 MS; 25 C
10 MS; 10 C
26 MS; 25 C
26 MS; 25 C
10 MS; 10 C
22 MS; 22 C
22 MS; 22 C
26 MS; 25 C
26 MS; 25 C
26 MS; 25 C
   91 
 
 Supplementary Figure 5-3. Gas delivery circuit set-up for the calibrated fMRI study.  
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Patients  
(n=18) Controls (n=14) 
P-value  
(2-tailed) 
CBF 49.22 ± 8.93 51.95 ± 6.46 0.343 
OEF 0.25 ± 0.08 0.24 ± 0.07 0.591 
CMRO2 107.14 ± 35.12 106.10 ± 20.27 0.922 
Supplementary Figure 5.4. Relationship between GM volume and CBF (top), 
and between GM volume and CMRO2 (bottom), for the control group only. p 
values refer to testing the beta coefficients against zero (uncorrected).  
Supplementary Table 5-1. Results from an OxFlow sequence in a sub-set of 
the same participants presented in this chapter. OxFlow calculates SvO2 in 
the superior sagittal sinus (SSS) through susceptometry-based oximetry. 
Scan duration of 1.17 minutes. A time of flight sequence is also acquired to 
localised the SSS, and a phase-contrast scan to localise the neck vessels.  
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6 Blood flow and oxygen metabolism changes in Multiple 
Sclerosis, during visual stimulation, using calibrated-fMRI  
 
6.1 INTRODUCTION 
 
Chapter 5 provided evidence for reduced CBF and CMRO2 in MS, when the brain is at 
rest. It is also important to understand how blood flow and oxygen usage change when 
there is a change in demand (i.e. in response to a functional task) as this may be more 
directly related to functional impairments and therefore disease impact. By measuring 
CMRO2 signals, we are getting closer to measuring the metabolic demand of neural 
activity (Buxton, 2010; Du et al., 2008; Hyder, 2010). If this metabolic demand is altered 
in MS, it may indicate neural or metabolic dysfunction or atrophy in these areas. 
Furthermore, if we characterise the coupling between CBF and CMRO2 signals to the 
same task or stimulus, this will inform whether the vascular system is responding 
appropriately to the level of demand. If it isn’t, this may be a factor contributing to longer 
term damage in the MS brain.  
 
There is evidence to suggest that investigating the visual system may help probe MS 
pathology both when functional impairments are present and when they are not. A 
common initial presentation of MS is optic neuritis, an acute visual impairment 
characterised by a reduction in visual acuity and connectivity in visual pathways 
(Polman et al., 2011; Toosy et al., 2014). However, abnormalities of visual pathways, 
in the absence of optic neuritis and visual symptoms, have also been reported in MS 
(Alshowaeir et al., 2014; Graham & Klistorner, 2017; Sisto et al., 2005), mostly 
attributed to post-chiasmal damage along the visual WM pathways, but could also be 
related to the more widespread vascular and metabolic alterations (discussed in 
Chapter 3.2). Only one research group have previously investigated task-induced 
CMRO2 in an MS population (Hubbard, Araujo, et al., 2017; Hubbard, Turner, et al., 
2017). They demonstrated significant lower CBF and CMRO2 visual evoked changes in 
MS patients compared to controls, and report that the CMRO2 change was one of the 
top measures to accurately classify MS status (Hubbard, Araujo, et al., 2017).  
 
For these reasons, and due to the visual fMRI recordings being easy to implement in 
patient groups, we investigated BOLD, CBF and CMRO2 changes to a visual-
checkerboard stimulus in MS. Based on the findings by Hubbard et al, on the lower 
baseline CBF and CMRO2 signals we report in Chapter 5, and on the reductions in 
BOLD and CBF to a visual stimulus in Chapter 4, we hypothesised reduced visual 
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BOLD, CBF and CMRO2 responses in the MS group, and correlations with disability. 
Unlike the previous work, this chapter also considers the effect of baseline CBF and 
CMRO2 on the task-induced visual BOLD, CBF and CMRO2 changes.  
 
6.2 METHOD 
 
Participants 
 
The same controls and patients were used in Chapter 5, Chapter 6 (this chapter) and 
Chapter 9; an overview of this data collection is displayed in  Supplementary Figure 5-
2. 26 patients and 23 controls completed the visual checkerboard task after the dual-
calibrated acquisition. Of these, 22 patients and 20 controls had corresponding dual-
calibrated fMRI data, allowing us to model the CMRO2 response.  
 
Data Collection 
 
Data collected from questionnaires and behavioural testing is explained in Chapter 5. 
For the imaging, the same DEXI pCASL acquisition, as explained in Chapter 5, was 
acquired during a visual task. The visual stimulus consisted of a reversing checkerboard 
(total size 8x8 degrees of visual angle, checks 3 cycles per degree, 100% contrast, 
checkerboard polarity reversing every 250ms). The design included a 30 second rest 
block followed by a 30 second stimulus block, repeated 8 times, then ending on rest 
block (total time 8.5 minutes). Participants were asked to focus on a red fixation square 
in the centre of the image, present during rest blocks and stimulus blocks.  
 
Data Analysis 
 
Pre-processing. The first and second echo from the visual DEXI-pCASL data were 
motion corrected (McFLIRT) and brain extracted (BET). Spatial smoothing was carried 
out with a Gaussian kernel of FWHM 4.3mm, with a high-pass temporal filter applied 
with a cut off of 90s. Registration of CBF data (first echo) and BOLD data (surround 
average of second echo) to individual T1-structural data (linear, 6 DOF) and then to 
MNI standard space (linear, 12 DOF) was carried out using FSL FLIRT. Using FSL-
FEAT, perfusion time courses were modelled from the first echo data, and BOLD time 
courses from the second echo data (in a separate FEAT design), with the inclusion of 
regressors explicitly describing the tag-control signal differences. A higher-level 
analysis was performed with FEAT using a mixed effects model (FLAME 1+2) to model 
the effect of the checkerboard stimulus across all participants (regardless of group), 
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and to model any ‘Control-Patient’ or ‘Patient-Control’ significant differences. Z statistic 
images were thresholded using clusters determined by Z>2.3 and a (corrected) cluster 
significance threshold of p = 0.05 (Worsley, 2001). Diagrams of the FEAT models can 
be seen in Supplementary Figure 6.1.  
 
BOLD, CBF, M and CMRO2 over group ROIs. For each subject, BOLD and CBF 
signals (and therefore the modelling of CMRO2) were characterised as change from 
baseline, averaged over two ROIs. The first ROI consisted of common significant voxels 
between the BOLD group contrast and the CBF group contrast (average contrast 
across patients and controls). The second ROI consisted of common significant voxels 
between the BOLD ‘Control-Patient’ contrast and the CBF ‘Control-Patient’ contrast. 
There were no significant voxels in the ‘Patient-Control’ contrast for BOLD or CBF. 
These two ROIs, in MNI space, where transformed to subject space, binarised, and a 
mean BOLD and CBF percentage signal change to the visual stimulus was calculated 
over each ROI. 
 
In order to model CMRO2 we need an estimate of the calibration factor M over the same 
ROI, to input into: 
𝐶𝑀𝑅𝑂2𝐶𝑀𝑅𝑂2$ = 	d𝐶𝐵𝐹𝐶𝐵𝐹$hA0	>c	 . 1 −	 ∆𝐵𝑂𝐿𝐷𝐵𝑂𝐿𝐷$𝑀 
Ac							 
 
This equation, based on (Davis et al., 1998), was introduced and explained as Equation 
2-7 in Chapter 2. In Chapter 5, the baseline data was quantified using a simplified BOLD 
model (Merola et al., 2016), so for consistency the standard calibration model (Davis, 
Kwong, Weisskoff, & Rosen, 1998) was modified to: 
 GefX=GefX=Z = 	_ GWbGWbZaA0		 . \	1 −	 ∆op78op78Z?		∙	∙[]Z	i										(Equation 6-1) 
 
TE is the echo time of the acquisition, κ is a composite calibration parameter that 
represents the combination of the venous weighted blood volume and water diffusion 
effects, [dHb] is the de-oxyhemoglobin concentration and is equal to Hemoglobin x (1-
SvO2) and θ (assigned a value of 0.06, previously represented by both a and b) is an 
empirical parameter combining contributions from venous blood volume changes and 
extra-vascular water diffusion effects. 
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Therefore, maps of M (specifically: 𝑇𝐸		 ∙ 	κ ∙ [dHb]$) where made from the baseline 
(resting) pCASL data in Chapter 5 for each participant. Example M-maps, for 2 patients 
and 2 controls, are showed in  Figure 6-1. The group visual ROIs (in MNI space) were 
transformed to T1-space, then to the subject’s M-map space, to obtain an average M 
over this region, as with BOLD and CBF response to the visual stimulus. Then the 
relative CMRO2 response to the stimulus was modelled as per Equation 6-1. Baseline 
CBF and CMRO2 were also averaged over these ROIs, in order to include in the 
statistical modelling. The coupling between CBF and CMRO2 to the visual response 
was calculated (CBF/ CMRO2) and represented by the parameter n.    
 
 
Figure 6-1. Maps of the M parameter (𝑇𝐸		 ∙ 	𝜅 ∙ [𝑑𝐻𝑏]$) outputted from the dual-calibrated 
fMRI modelling in Chapter 5. Examples are shown for two controls and two patients. 
 
Statistics 
 
To test the difference between groups for the M and n parameters independent sample 
t-tests were carried out.  If assumptions of normality were violated, Mann Whitney U 
tests were carried out to test medians. In the difference ROI (explained below), variance 
in BOLD, CBF and CMRO2 visual responses were predicted with group membership, 
visual acuity and baseline CBF/CMRO2 over the same ROI, using multiple linear 
regressions. In the patient group only, a linear multiple regression was performed to 
predict the patient’s CBF and CMRO2 visual responses in the difference ROI using the 
composite disease impact score and lesion volume.  All assumptions were met unless 
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other otherwise stated Outliers were defined as being 3xSD above or below the mean, 
or 3xIQR above or below the lower or upper quartile, respectively. 
 
6.3 RESULTS 
 
BOLD and CBF responses to the visual stimulus  
 
Figure 6-2 (A-C) display the BOLD and CBF results from the group FEAT analysis. Four 
significant clusters were found for the BOLD response to the visual stimulus:  an 
occipital cluster (Z-MAX = 8.6, [26,-96,4]), a right precentral gyrus/middle frontal gyrus 
cluster (Z-MAX = 4.82, [-46 0 30]), a left precentral gyrus cluster (Z-MAX =4.33, [52,-
6,50]), and a frontal pole cluster (Z-MAX  =4.06, [-20, 62, 24]). Significant voxels, in 
response to the stimulus, common to BOLD and CBF (across both groups) were found 
in the posterior occipital cortex (occipital pole) and lateral occipital cortex, and this is 
referred to as the ‘Group ROI’ from now on. This region was the only significant cluster 
in the CBF group analysis. A small region (localised centrally, overlapping with the 
occipital pole and posterior areas of lingual gyrus, central voxel: [2,-90,-12]) was found 
to have significantly greater activity for controls than patients, in both BOLD and CBF 
contrasts, and this is referred to as the ‘Difference ROI’ from now on. 
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Figure 6-2. A & C: Red displays significant voxels in response to visual stimulus, 
common to BOLD and CBF (based on Z>2.3 thresholded clusters, p=0.05), across 
both groups. The small blue region displays voxels with significantly greater activity 
for controls compared to patients, common to BOLD and CBF. B: Significant 
clusters in the BOLD analysis, across groups. Yellow shows an occipital cluster, 
light orange a right precentral gyrus/middle frontal gyrus cluster, dark orange a left 
precentral gyrus cluster and red a frontal pole cluster. There were no further 
significant voxels in the CBF analyses, than the one common to BOLD shown in 
Figure A.  D and E: Comparing percentage change BOLD and CBF signals 
between patient and controls, averaged over the Joint ROI (red, A & C) and the 
Difference ROI (blue, A & C) to display the magnitude of the signal changes, on 
average. 
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Modelling the CMRO2 response to the visual stimulus  
 
Group averages for the visual BOLD, CBF and CMRO2  responses for both ROIs are 
displayed in Table 6-1. The Difference ROI (Figure 6-2C) was only made up of 39 voxels 
and therefore averaging M over this ROI for each subject separately, in order to model 
CMRO2, was unreliable. Many participants, in both groups, had very physiologically 
unrealistic M value estimates over this ROI. For example,  the minimum M value was 
6%, the maximum was 62% and the mean ± SD was 15% ± 12, presumably because 
there were not enough voxels to average out noise. Therefore, the subsequent CMRO2 
modelling in the Difference ROI was based on M values averaged over the Group ROI 
(Figure 6-2A) for each subject. For M values in the Group ROI, one patient was an 
extreme outlier (with a z-score of 3.87 and an average M value of 20.03%) so was left 
out of the subsequent CMRO2 group comparison. The remaining 20 controls (7.57% ± 
0.31) and 21 patients (8.01% ± 0.30) did not have significantly different M values, (t(39) 
= 1.01, p = 0.315).  The CMRO2 responses from the Group ROI were not significantly 
different between patients and controls, t(38) = 0.125, p = 0.901. Statistical 
comparisons are not reported for the Difference ROI here, as group comparisons are 
carried out within a regression model later in the results, alongside other predictor 
variables.  
 
 
Table 6-1. BOLD, CBF and CMRO2 visual response, expressed as percentage change 
from baseline,  for each ROI. Extreme outliers were removed from these means: one 
patient for Group ROI CMRO2 and one control for Diff ROI BOLD.  
 
 
Group ROI Diff ROI Group ROI Diff ROI Group ROI Diff ROI
Controls Mean 0.46 1.33 15.79 33.76 7.63 5.05
Patients Mean 0.46 0.87 16.39 21.98 7.44 5.66
Controls SD 0.23 0.57 7.93 15.71 4.51 9.97
Patients SD 0.24 0.64 9.71 16.56 4.91 8.72
BOLD (% change) CBF (% change) CMRO2 (% change)
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Is Flow-Metabolism coupling altered in patients? 
 
The coupling between task-induced change in CBF and CMRO2 was compared 
between patients and controls in each ROI, and this is shown in Table 6-2. A coupling 
of around n=2 is consistent with previous work, however there were no significant 
differences between patients and controls. In the Group ROI, there was a trend for 
patients to have lower n values on average (p=0.07).  
 
 
 
Table 6-2. Comparison of the coupling parameter n (CBF/CMRO2) between patients 
and controls, to the visual stimulus. For the group ROI comparison, two patients and 
one control where removed as they were extreme outliers. For the difference ROI, one 
patient was removed as they were an extreme outlier. The n values for the difference 
ROI were not normally distributed for both groups, so a non-parametric test of medians 
was run.  
 
 
What factors can explain the differences between patients and controls? 
 
We investigated factors that may explain the BOLD, CBF and CMRO2 differences 
between patients and controls in the region where there was significantly reduced 
activity (Difference ROI). As this regression analysis is based on average signals in the 
region where the group FEAT analysis showed significant group differences, we expect 
group membership to make a significant contribution to this model. Including this 
variable also allows us to consider interactions between group and other predictor 
variables. Visual acuity in the right eye (shown in Chapter 5) was significantly worse for 
the patient group, therefore visual acuity (averaged across both eyes, as the stimulus 
was shown bilaterally) was included as a predictor. Visual acuity was included, instead 
of history of optic neuritis, as this data existed for both patients and controls and was 
reflective of the patient’s visual function on the same day of scanning. Ten patients had 
no history of optic neuritis, five patients reported one previous episode, four patients 
reported two and one patient reported three episodes. As baseline CBF and CMRO2 
differences were demonstrated in Chapter 5 their effect on the visual stimulus response 
was also modelled. The relationship between baseline signals and group membership 
with visual stimuli responses is displayed in Figure 6-3.  
 
n  (Mean ± SD) p-value n  (Median, IQR) p-value
Controls 2.07 ± 0.38 1.50, 3.73
Patients 1.82 ± 0.49 2.56, 6.480.07 0.35
Group ROI Difference ROI
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For predicting visual CBF responses, the overall model was significant, R2 of 29.3% (F 
(3, 36) = 4.98, p = 0.005. Baseline CBF (β = -0.362, p = 0.021) and group membership 
(β  = 0.552, p = 0.001) significantly contributed to the model predicting visual CBF. 
Visual acuity did not make a significant contribution to the model (β = -0.193, p = 0.186). 
Including an interaction term in the model between baseline CBF and group 
membership did not make a significant contribution to the model (p = 0.902). For 
predicting visual BOLD responses, the overall model was significant R2 of 29.3% (F (3, 
36) = 4.98, p = 0.005). Baseline CMRO2 (β = -0.377, p = 0.012) and group membership 
(β = 0.387, p = 0.011) significantly contributed to the model predicating visual BOLD, 
but visual acuity did not (p = 0.962). Including an interaction term in the model between 
baseline CMRO2 and group membership did not make a significant contribution to the 
model (p = 0.342). For predicting visual CMRO2 responses, the overall model was not 
significant, R2 of 12.0% (F (3, 36) = 1.63, p = 0.199). Baseline CMRO2 (β = 0.146, p = 
0.361), group membership (β = 0.021, p = 0.898), or visual acuity (β = -0.297, p = 
0.074), did not display beta coefficients significantly different to zero.  
 
What factors can explain variability in the patient group? 
 
As Hubbard et al (2017) showed a relationship between visual CMRO2 and disease 
impact scores (fatigue) and WM damage, we examined whether the composite disease 
impact score and lesion volume could predict  BOLD, CBF or CMRO2  visual responses 
in the patient group only, in this Difference ROI. Lesion volume and disease impact did 
not significant predict BOLD (R2 of 8.3% (F (2, 18) = 0.81, p = 0.459), CBF (R2 of 8.1% 
(F (2, 18) = 0.79, p = 0.468), or CMRO2 (R2 of 8.1% (F (2, 18) = 0.79, p = 0.468) visual 
responses in the patient group.  
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Figure 6-3. Top: relationship between baseline CBF (ml/100g/min) and visual 
stimulus CBF (percentage change). Middle: relationship between baseline CMRO2 
(µmol/100g/min) and visual stimulus BOLD (percentage change). Bottom: 
relationship between baseline CMRO2 (µmol/100g/min) and visual stimulus 
CMRO2 (percentage change). Patients are shown in blue and controls in black. 
Signals are modelled in the Difference ROI from the group FEAT analysis 
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6.4 DISCUSSION 
 
As has been done previously in calibrated-fMRI studies, here we characterised the 
relative CMRO2 response to a visual stimulus, based on a simplified BOLD model 
(Merola et al., 2016), combined with the standard calibration model (Davis, Kwong, 
Weisskoff, & Rosen, 1998). We created the calibration factor M using sequence 
parameters and parameter outputs from the dual-calibrated modelling in Chapter 5, in 
order to model the relative CMRO2 response. As we had quantified baseline CBF and 
CMRO2 responses in the same participants, from Chapter 5, we considered the effect 
of these signals in the same brain region when looking at stimulus responses. In 
response to the visual stimulus, a small region in the visual cortex showed significantly 
lower CBF and BOLD stimulus responses in the patient group compared to the controls. 
However, no significant differences were found between patients and controls for visual 
CMRO2 responses, and disease characteristics did not predict BOLD, CBF or CMRO2 
responses in the patient group. There were no significant differences for flow-
metabolism coupling between groups. For both patients and controls, we found that 
baseline CBF and CMRO2 values significantly predicted stimulus CBF and stimulus 
BOLD responses, respectively. 
 
Changes in the BOLD response to visuomotor tasks have been previously 
demonstrated, showing that inflammation and WM structural damage play a role in 
altering haemodynamic responses in MS (Hubbard et al., 2016; Tomassini et al., 2016). 
Consistent with this, we found a significantly reduced BOLD and CBF response in the 
visual cortex of MS patients, although this could not be predicted by their visual acuity 
scores. It was surprising to not find more wide-spread differences in BOLD, CBF or 
CMRO2 signals in the patient group, except for this small ROI in occipital pole/posterior 
lingual gyrus, considering previous literature, and our results presented in Chapter 4. 
In Chapter 4, we do not report CMRO2 responses to a visual stimulus, but do show clear 
BOLD, CBF and gamma power reductions in the MS group. In fact, the biggest 
difference in gamma power change (directly reflecting neural activity) was seen at 100% 
visual contrast. This is not consistent with the lack of differences we report here with 
the visual checkerboard also at 100% contrast. In Chapter 4, the patients and controls 
were older on average (around 43 years), compared to the cohort presented in this 
chapter, and were treatment naive. This may have meant they had higher levels of 
inflammation, which is one explanation for greater impairments reported. In Chapter 4, 
the visual stimulus was shown to each eye separately; considering optic neuritis and 
visual abnormalities are common in MS, this may have given more sensitivity to 
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measure abnormalities. In this study, we chose to display to both eyes together due to 
time constraints but also to better reflect natural visual processing.  
 
Visual CMRO2 responses and the coupling between CMRO2 and CBF (Blockley, 
Griffeth, Simon, & Buxton, 2013) were in expected ranges. Despite the M values being 
calculated from the dual-calibrated fMRI data in Chapter 5, they are in good agreement 
with the values from studies using only hypercapnia to calibrated the BOLD signals, 
which is more typical. We reported an average of 7.57% for controls and 8.01% for 
patients, which is in good agreement with previous single and dual calibrated studies 
(Driver, Wise, & Murphy, 2017; Gauthier & Hoge, 2013; Wise et al., 2013). Ideally, a 
voxel-wise approach to characterising CMRO2 would be taken, allowing for more spatial 
sensitivity to functional changes. However, here we took an ROI approach, considering 
the level of noise in the M maps, which was particularly noticeable when trying to 
average M values over the small Difference ROI. In order to model CMRO2 changes in 
this area, an average M value from the larger Group ROI was used, unfortunately 
reducing the spatial specificity of the M estimate. 
 
Consistent with our results, Hubbard, Araujo, et al (2017) also report no differences 
between patients and controls for coupling between CBF and CMRO2 to a visual 
stimulus.  They also report no changes in visual BOLD responses. Their study had a 
specific focus on the predictive ability of visual evoked CMRO2 responses in classifying 
MS status; alongside this they report large reductions in visual CBF responses (~45% 
reduced CBF response) and CMRO2  response (~8% reduction) in their MS cohort, 
contrary to our results. Differences in characteristics of their MS cohort may be one 
factor to explain this. For example, their sample of 10 patients and 13 controls were 
much older on average (around 50 years) compared to our sample of 22 patients and 
20 controls (around 35 years). Their patient group therefore had a longer average 
disease duration (119 months) compared to ours (95 months), and less time had 
passed since their last relapse, on average. It is therefore possible that these patients 
had more GM dysfunction due to more disease progression (Klaver et al., 2013a). Their 
visual task was different and more complex than the one used here; they controlled the 
participant’s attention by changing the luminance of the fixation and requiring a button 
press response, they altered the orientation to avoid neural adaptation, and they had a 
flicker rate of 8Hz. Although fMRI studies typically report a peak response at 8Hz (Li, 
Chen, & Chen, 2011; Sun et al., 2014) thereby potentially giving the greatest signal-to-
noise estimate, we wanted to keep our reversal rate (4Hz) consistent with what was 
used in Chapter 4, which was chosen in order to compare with MEG responses. 
Furthermore, as this chapter aimed to characterise CMRO2 to a visual stimulus, there 
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is some evidence that the electrophysiological response, and the CMRO2 response in 
accordance, peaks at 4Hz and not at 8Hz (see data in 11. Appendix 1). 
 
In this chapter, we report no significant relationship between visual BOLD, CBF or 
CMRO2 and disease impact scores (fatigue) and WM damage (lesion volume), in the 
patient group. This in contrary to the study by Hubbard, Turner, et al (2017), a different 
study to the one discussed earlier, which reported positive correlations between visual 
CMRO2 responses and neurological disability and fatigue scores, in a study involving 
MS patients only. The direction of this relationship appears contrary to the results of the 
reduced CMRO2 response in patients, compared to controls, reported in their other 
work. Further to this, they report that radial diffusivity of the occipital tract to be 
significantly positively correlated with visual CMRO2 and negatively correlated with 
visual BOLD. The mechanisms for this are not clear, but they discuss neurovascular 
uncoupling in MS as a potential explanation for these different relationships. It is clear 
that more research needs to be done to characterise task-induced CMRO2 changes in 
MS, particularly if they can show such different relationships with structural damage 
compared with BOLD signals.  
 
In this chapter, baseline CBF (ml/100g/min) predicted CBF visual stimulus responses 
(%), and baseline CMRO2 (µmol/100g/min) predicted BOLD visual stimulus responses 
(%), in the same brain region. These relationships were not significantly different for 
patients and controls, although it is interesting to note that one of the regions showing 
significantly lower CBF values in the voxel-wise analysis of Chapter 5 appears to be in 
a very similar location to the Difference ROI  reported here, so it is likely this may have 
had some effect on the functional patient control differences reported here. Here we 
report that the lower the baseline CBF or CMRO2 a participant has the higher their 
relative stimulus response. This has been reported previously in many fMRI studies 
(Hyder, Rothman, & Shulman, 2002; Kannurpatti, Biswal, & Hudetz, 2003; Pasley, 
Inglis, & Freeman, 2007; Shulman, Rothman, & Hyder, 2007). This suggests, if the CBF 
and CMRO2 is lower at baseline, it will need to increase proportionately more to match 
the  CBF and CMRO2  changes due to neural activity. These findings show the 
importance of characterising the baseline state, in patient and healthy populations, for 
proper interpretation of relative stimulus changes.  
 
Conclusions  
 
We report differences in BOLD and CBF responses in MS, in a small region of visual 
cortex, not explained by changes in visual acuity. We do not report visual CMRO2 
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changes, or differences in the coupling between CBF and CMRO2 in the patient group, 
suggesting the vascular system is responding adequately to the level of demand. 
Although visual abnormalities are common in MS, MS is not specifically a disease of 
the visual system and there is great variability across participants in the type of 
symptoms and their severity. The signals and parameters modelled here, specifically 
CBF and CMRO2, are physiologically specific and interpretable, yet they are noisy and 
sometimes spatially insensitive. With continual improvement of these methods, 
baseline and task-induced CMRO2 changes will be able to be characterised more 
robustly on a voxel-wise basis.  
 
6.5 SUPPLEMENTARY 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 6.1. (A) Diagram of the FEAT model used to estimate 
the BOLD and CBF responses to the visual stimulus for echo 1 and echo 2, for 
each participant, using FEAT’s Full Perfusion Modelling. (B) Diagram of the 
higher-level FEAT analysis  to model the effect of the visual stimulus across 
all participants (Group Av) as well as differences between groups (Controls – 
Patients and Patients – Controls).  
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7 Coupling between brain oscillations, CBF, and BOLD signals 
during naturalistic movie viewing  
 
7.1 INTRODUCTION 
 
In Chapter 1.2.3, we covered the importance of understanding NVC in the healthy brain, 
as it is the physiological basis of many commonly used neuroimaging techniques, 
including fMRI. Coupling between neural activity, blood flow, and oxygen usage is also 
thought to be altered in different disease pathologies. Therefore, to accelerate our 
understanding of this in health and disease, we need to develop non-invasive ways of 
investigating these coupling mechanisms, with practically feasible methods applicable 
to patient populations. 
 
In Chapter 4 we measured the electrophysiological response (with MEG) and the 
hemodynamic responses (with fMRI), and the coupling between them, in response to a 
visual checkerboard stimulus. This type of stimuli, artificial and with highly-controlled 
visual features, is what is typically used in E/MEG and fMRI studies. This approach 
often limits the analysis to a few localised regions, and specific oscillatory frequencies, 
and is not particularly representative of normal visual experiences. Furthermore, 
participants can often struggle to attend to the high-contrast full-field stimulus types, 
typically chosen to elicit maximal signal responses. 
 
In this current chapter, we again compare brain oscillations with CBF and BOLD 
responses, but with a naturalistic movie viewing paradigm. Previous literature has 
shown that passive-viewing of movie clips allows activity to be characterised across 
multiple brain areas, and multiple oscillatory frequency bands, giving reliable inter-
subject correlations and intra-subject correlations (between two repetitions of the same 
clip). This has been shown extensively with BOLD-fMRI (e.g. Bartels & Zeki, 2004, 
2005; Hasson, Nir, Levy, Fuhrmann, & Malach, 2004; Jääskeläinen et al., 2008; 
Lahnakoski et al., 2014; Nummenmaa et al., 2012), as well as with EEG and MEG 
(Chang et al., 2015; Dmochowski, Sajda, Dias, Parra, & Rousselet, 2012; Ki, Kelly, & 
Parra, 2016; Lankinen, Saari, Hari, & Koskinen, 2014). Very few papers have 
characterised CBF responses to movie viewing (Griffeth, Simon, & Buxton, 2015; Rao, 
Wang, Tang, Pan, & Detre, 2007). Rao et al (2007) revealed both CBF and BOLD 
increases and decreases to a movie stimulus, with CBF showing activation patterns 
across more areas.  
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Only a few studies have compared both MEG and BOLD-fMRI signals to a movie 
stimulus (Betti et al., 2013; Kaisu Lankinen et al., 2018; Whittingstall, Bartels, Singh, 
Kwon, & Logothetis, 2010). MEG and BOLD signals often show similar spatial 
topographies, yet their relationship becomes more complex when comparing across 
different oscillatory frequency bands. The strongest and most consistent relationships 
between MEG and fMRI are reported in occipital areas, most likely due to the visual 
stimuli used. 
 
In this study, we aimed to characterise inter-subject correlations (ISCs) to a naturalistic 
movie clip for MEG, BOLD and CBF signals, as well as the coupling between them to 
represent an empirical measure of NVC. To the best of our knowledge, this has not 
been done previously in the same study. We re-sampled the MEG and fMRI data to the 
same spatial and temporal scales, to investigate voxel-wise relationships between brain 
oscillatory amplitude envelopes across a wide-range of frequency bands (1 – 145Hz), 
alongside BOLD and CBF weighted signals, using a pseudo continuous ASL (pCASL) 
acquisition. As CBF images typically have poorer signal-to-noise ratios than BOLD, one 
aim was simply to see if the MEG-BOLD coupling relationships that have been reported 
previously, and that we investigated, can also be seen for MEG-CBF relationships, and 
if there are any differences, spatially and temporally.  
 
We predict that this design will give temporal similarity across participants in each 
modality, and across modalities, allowing us to evaluate its utility as a way to investigate 
NVC in a healthy population. We predict we will replicate previous findings of how 
oscillatory frequencies correlate with BOLD signals and extend this by investigating 
coupling with CBF signals. We characterise the ISCs and the cross-modality coupling 
correlations in a voxel-wise analysis, therefore also investigating spatial variation in 
NVC relationships across different brain regions.    
 
7.2 METHODS 
 
Participants  
 
19 healthy volunteers participated in this study, and 17 were used in the final analysis. 
All participants had normal or corrected-to-normal vision and had no history of 
neurological or psychiatric disorder. All participants gave written informed consent prior 
to participation and received £10 per hour for taking part. The study was approved by 
the Cardiff University School of Psychology ethics committee.  
 
   109 
Design and Procedure 
 
All participants had a MRI scan and a MEG scan (see diagram below). Both scanning 
sessions included passive viewing of the same movie clip from the James Bond film 
‘Skyfall’ (approximately the first 19 minutes 38 seconds). A subset of these participants 
also had a BH scan during the MRI session, and this data is analysed in Chapter 8.  
 
 
 
Figure 7-1 gives an overview of the data collection and analysis pipeline, which is then 
explained in detail in the next section.   
Consent forms 
Screening forms
Session Overview
~15 minutes 
MEG session
Subject set-up: ~30 mins
Scanning: ~20 mins
MEG & MRI SAME DAY (5 datasets)
BREAK (+ Hg sample ⍟)
~20 minutes
MRI session
BH practice & subject set-up ~15 mins
Scanning ~45 mins
MEG & MRI DIFFERENT DAYS 
(12 datasets, average days apart: 24)
COUNTERBALANCING 
Of the 17 subjects analysed:
First scan MEG: 8 subjects
First scan MRI: 9 subjects
MRI session
~30 minutes
Consent & screening 
Hg sample⍟
BH Practice
Subject set-up
~45 minutes
Scanning
MEG session
~30 minutes
Consent & screening 
Subject set-up
~20 minutes
Scanning
MEG SCAN
20 min movie clip 
(SkyFall)
MRI SCANS
MPRAGE (T1-anatomical)
Phase-Contrast 
Time of Flight
OxFlow ⍟
M0 PCASL
SkyFall during DEXI-PCASL
Breath-Hold during DEXI-PCASL (n=15)
Fieldmaps
⍟ Data 
not used
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Figure 7-1. Diagram showing the analysis pipeline used to analyse the MEG and fMRI 
data, to produce the within-modality and between-modality results.  
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MRI acquisition and pre-processing  
 
Data were acquired on Siemens Prisma 3T MRI scanner (Siemens  Healthineers, 
Erlangen, Germany), using a 32-channel head coil. A magnetization-prepared rapid 
acquisition with gradient echo (MPRAGE) T1-weighted scan was acquired for co-
registration and source localisation purposes (matrix 165 x 203 x 197, 1mm3 resolution, 
TR/TE = 2100/3.24ms). During the movie, a pCASL acquisition was run, as explained 
in Chapter 5. A DEXI readout gives BOLD and CBF weighted signals. An effective TR 
of 4.4. seconds was used to acquire 16 slices, in-plane resolution 3.4 x 3.4 mm and 
slice thickness 7mm with a 20% slice gap. Before this scan, an M0 image was acquired. 
 
Motion correction was performed with the FSL-McFLIRT function and spatial smoothing 
(FWHM=4.5mm) of the BOLD data (surround average of TE2) was performed with 
SUSAN (Smith & Brady, 1997). CBF data (surround subtraction of TE1) and the M0 
acquisitions were spatially smoothed using a 3D Gaussian kernel (FWHM 4.5mm). The 
first and last volume of the BOLD and CBF time-series were removed. Registrations 
were carried out with FSL-FLIRT. The BOLD and CBF data were both registered to the 
M0 image. The M0 image was registered to the brain extracted T1 image and this T1 
image was registered to MNI-2mm standard space. The data were then down-sampled 
to 6mm, to match the spatial resolution of the MEG beamformers. BOLD and CBF time-
series at each voxel were up-sampled to 0.5 seconds (with MATLAB’s interp1 function), 
in order to compare with MEG time-series. Spikes were removed using a median 
replacement filter, time-series were changed to percentage change from mean in each 
voxel, and a high-pass filter at >0.01Hz was applied to remove drift. At this stage a 
mean time-series was calculated, across participants, at each voxel, termed the Group 
BOLD time-series and the Group CBF time-series.  Each participant’s data was also 
separately computed and saved, to give a Subject BOLD times-series and Subject CBF 
time-series. 
 
MEG acquisition and pre-processing  
 
Whole-head MEG recordings were collected using a 275-channel CTF Omega system, 
sampled at 600Hz and analysed as synthetic third-order gradiometers. The continuous 
MEG recording was synchronised to the start of the movie clip, which ran for 19 minutes 
and 39 seconds. We used continuous head localisation of electromagnetic fiducial coils; 
these were placed at fixed distances from three anatomical landmarks (1cm anterior to 
left and right tragus, 1cm superior to nasion). Fiduciary locations were later manually 
marked on the anatomical MRI for co-registration (with Fieldtrip toolbox in MATLAB), 
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based on this 1cm distance, as well as verified with photographs. Offline, the data were 
divided into 2-second epochs and visually inspected for major artefacts. Head location 
at each time point was changed to the average head location across the recording. Two 
out of the nineteen participants were removed due to excessive eye and motion 
artefacts. 
 
The data were filtered into these frequency bands: delta (1-4Hz), theta (4-8Hz), alpha 
(8-13Hz), beta (13-30Hz), low gamma (40-70Hz) and a range of 50Hz-wide overlapping 
‘high gamma’ bands (70-120Hz, 95-145Hz). We also filtered the data into two frequency 
bands (120-170Hz, 145-195Hz) above the anti-alias filter cut-off (150Hz for this MEG 
acquisition). This filtered data were source-localised using an LCMV beamformer (Van 
Veen et al., 1997) which provides estimates of the virtual-sensor time-series at each 
voxel in the brain. These time-series were re-constructed on a 6mm grid in standard 
MNI-template space (using the 2mm MNI template brain down-sampled to 6mm), within 
cortical areas only. The time-series at each voxel was converted to an amplitude 
envelope using the analytic function, via the Hilbert Transform. The amplitude 
envelopes were down-sampled to 0.5 seconds to match the up-sampled fMRI data. 
Spikes were removed using a median replacement filter, time-series were changed to 
percentage change from mean in each voxel, and a high-pass filter at >0.01Hz was 
applied to remove drift. At this stage a mean time-series was calculated, across 
participants, at each voxel. This mean time-series was convolved with a canonical 
hemodynamic response function (HRF) from SPM to delay and disperse the oscillatory 
power in order to match to the BOLD and CBF responses.  This will be termed the 
Group MEG time-series for each frequency band. Each participant’s data separately, 
after high-pass filtering, was also convolved with the HRF, to give a Subject MEG time-
series for each frequency band. 
 
Within-modality analysis: inter-subject correlations (ISCs) 
 
For each type of analysis (BOLD, CBF, MEG at each frequency band), we correlated 
the time-series between each pair of participants, transformed the r values using 
Fisher’s Z transform and then averaged all pairwise coefficients to give a mean inter-
subject correlation (ISC) for each voxel. This is a model free analysis to indicate where 
there are changes in activity common across the group. To test if these correlation 
coefficients were significantly different from zero, we performed a one sample-test at 
each voxel. This was statistically tested with randomisation testing (10,000 
permutations, alpha = 0.05). The absolute maximum t-statistic at each randomisation 
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stage was used to define the null distribution, and the absolute t-score was tested 
against this null distribution (Nichols & Holmes, 2001). 
 
Between-modality analysis: MEG-fMRI coupling 
 
First, at each voxel, we performed a linear regression analysis with MATLAB’s fitlm 
function, using the Group MEG time-series (for each frequency band) to predict the 
Group BOLD time-series or the Group CBF time-series, separately, and computed 
maps of correlation coefficients and beta values for each fMRI to MEG regression. R 
values and not R2 values were outputted and tested, in order to represent the shared 
variance between the MEG and fMRI signals whilst still preserving the sign of the 
relationship. Beta coefficients represent the relationship in meaningful units. These 
maps were thresholded to p<0.05 (with false discovery rate (FDR) correction to account 
for multiple comparisons), and also masked to areas that had significant ISCs in either 
the BOLD or MEG data, for that specific frequency band. For example, for the BOLD 
and 1-4Hz correlation analysis results, we plot FDR-thresholded voxels only in areas 
that had significant MEG 1-4Hz ISCs or significant BOLD ISCs, for ease of 
interpretation. Voxel-wise correlation coefficients for the Group-BOLD and Group CBF 
time-series where also produced, to aid with interpretation of results.  
 
At each voxel we had 7 correlation coefficients and 7 beta values, for the BOLD and 
CBF regressions. We performed a principle component analysis (MATLAB’s default 
pca function, centered) on the correlation coefficients and beta values, to explore the 
dominant tuning function across the brain. We examine the principal component 
explaining the most variance and display how this function loads spatially across 
different areas of the brain.  
 
This analysis explained above is performed only on mean time-series data, across 
participants. Therefore, to consider between-subject variance in coupling, we also 
performed a linear regression analysis for each subject separately, regressing the 
Subject MEG time-series in each frequency band at each voxel location onto the 
Subject BOLD times-series and the Subject CBF time-series. To test whether the 
correlation coefficients (Fisher transformed) or beta values were significantly different 
from zero for each voxel, we used FSL’s randomise function to perform a nonparametric 
one-sample t-test at each voxel (5000 permutations), FWER-corrected p-values at 
p<0.05 and TFCE (Threshold-Free Cluster Enhancement). Due to our relative small 
sample size, we used variance smoothing of 12mm, to increase power to detect effects 
(Nichols & Holmes, 2001; Singh, Barnes, & Hillebrand, 2003).  
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A different study carried out at CUBRIC also showed the same movie clip in MEG and 
fMRI (BOLD-weighted sequence only), showing very similar results. With the 
researcher’s approval, their data was combined with some of the data from this study, 
where appropriate, in order to investigate whether significant effects would be seen with 
more statistical power. Their data were processed in the same way, and correlation 
maps between MEG (at each frequency band) and BOLD for each participant (n=16) 
was combined with the ones from this study (n=17). For this data, a BOLD-EPI 
sequence was run (TR = 2 seconds, TE = 30ms, voxel resolution = 2mm3). 
 
7.3 RESULTS 
 
There were 17 participants included in the final analysis, as two were removed for poor 
data quality (excessive head motion and motion artefacts throughout the MEG or fMRI 
recording). The 17 participants were aged 28.29 ± 1.64 (Mean ± SEM), and 4 were 
male. There were 14 who had watched the movie before and 5 who had not.  
 
Within-modality analysis: ISCs for MEG, BOLD and CBF signals 
 
To uncover activity related to the movie, consistent across participants, we calculated 
ISCs at each voxel. Figure 7-2 shows significant ISCs for the BOLD and CBF analyses, 
and Figure 7-3 shows significant ISCs for the MEG analyses for each frequency band. 
Using the whole movie clip or using the first half of the movie clip gave extremely similar 
results, both in the spatial coverage of significant ISCs and the magnitude of 
correlations. Supplementary Figure 7-1 shows cross-correlations of two frequency 
bands above the anti-alias filter cut-off for the MEG acquisition (120 – 170Hz, 145 – 
195Hz), which still show feasible ISCs locations and magnitudes. With a sampling 
frequency of 600Hz, the anti-alias filter in the MEG starts at 150Hz but falls off quite 
slowly, so this is why plausible signals may still be seen just above this cut-off. 
 
We examined what anatomical areas the ISCs where located in by looking at their 
overlap with the AAL atlas (Tzourio-Mazoyer et al., 2002). Common areas with 
significant ISCs in BOLD, CBF, and all MEG frequency bands (both left and right unless 
stated) were seen across inferior, superior and middle occipital regions, including 
calcarine sulci, cuneus, lingua gyri, and fusiform gyri, and superior/middle/inferior 
temporal gyri. Except for CBF, significant ISCs were also found in the angular gyrus 
(anterior parietal). Except in the 40-70Hz frequency band, significant ISCs were seen 
for BOLD, CBF and MEG seen in the pre-cuneus (part of the superior parietal lobe). 
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Significant ISCs in frontal regions (superior, middle, medial or inferior frontal) were seen 
for 4-8Hz, 8-13Hz, 13-30Hz and 40 – 70Hz only. 
 
 
Figure 7-2. Significant BOLD and CBF inter-subject correlations (ISCs) showing movie-
activated areas, using all the data (Whole Movie) and just half the data (First Half). 
Correlation values corrected to p<0.05, with randomisation testing. Correlations are 
displayed on an inflated MNI template brain. Mean correlation over voxels (Mean r) and 
maximum correlation over voxels (Max r) are reported. 
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Figure 7-3. Significant MEG inter-subject correlations (ISCs) showing movie-activated 
areas, using all the data (Whole Movie) and just half the data (First Half). Correlation 
values corrected to p<0.05, with randomisation testing. Correlations are displayed on 
an inflated MNI template brain. Mean correlation over voxels (Mean r) and maximum 
correlation over voxels (Max r) are reported. 
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Between-modality analysis: MEG-BOLD and MEG-CBF coupling 
 
Figure 7-4 displays the relationship between the Group MEG time-series and the Group 
BOLD/CBF times-series, for 1-30Hz, and Figure 7-5 displays this for 40-145Hz. For 
both BOLD and CBF, significant positive and negative correlations are seen between 
all frequency bands, except 40-70Hz which only displays positive.  In fact, activity in 40-
70Hz frequency band displays the largest correlation for both BOLD and CBF signals 
and appears to be one of the MEG coupling relationships that is most similar for BOLD 
and CBF.  
 
Many areas where BOLD displays positive correlations CBF displays negative 
correlations, and vice versa, for example this can be seen clearly in the coupling with 
8-13Hz, 13-30Hz and 70 – 120Hz. There appears to be more negative correlations with 
BOLD signals, than CBF. Areas near the cuneus and the pre-cuneus appear to have 
opposing correlation directions i.e. when one has a positive correlation between MEG 
and BOLD, the other has a negative. However, the correlation between BOLD and CBF 
across the brain appears to be predominately positive (Supplementary Figure 7-2). 
 
We explored these relationships further by running a PCA to determine the dominant 
tuning function across the brain, and this can be seen in Figure 7-6. The first PCA 
component explained 45% of the variance in the BOLD-MEG PCA and 32% in the CBF-
MEG PCA. Here we see that some areas of the brain load positively and some 
negatively onto this first component, indicating different NVC characteristics for different 
areas. Very similar trends were found for PCA analysis run on the beta coefficients 
(data not shown).  
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Figure 7-4. Correlation coefficients between Group BOLD time-series and Group CBF 
time-series with Group MEG time-series, for frequencies 1-30Hz, thresholded to p<0.05 
(FDR corrected), as well as masked to voxels that had significant BOLD ISCs or 
significant MEG ISCs, in that frequency band. Black – Red – Yellow display increasing 
positive correlations, and Black – Blue – Pink increasing negative correlations. 
Correlations are displayed on an inflated MNI template brain.
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Figure 7-5. Correlation coefficients between Group BOLD time-series and Group CBF 
time-series with Group MEG time-series, for frequencies 40-145Hz, thresholded to 
p<0.05 (FDR corrected), as well as masked to voxels that had significant BOLD ISCs 
or significant MEG ISCs, in that frequency band. Black – Red – Yellow display 
increasing positive correlations, and Black – Blue – Pink increasing negative 
correlations. Correlations are displayed on an inflated MNI template brain.  
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So far, the MEG-fMRI relationships have been presented based on the group mean 
time-series data. We also characterised the coupling for each individual first, then 
tested whether correlation coefficients or beta coefficients were significantly different to 
zero, across the group of participants, for each voxel. Figure 7-7 (top) displays the 
MEG-BOLD or MEG-CBF pairings that had significant correlations. All correlation 
coefficients are much lower in magnitude, compared to the group time-series analysis 
explained above. Significant correlations were found between BOLD and MEG signals 
in the 4-8Hz, 40-70Hz, and 70-120Hz frequency bands, in visual areas, specifically the 
cuneus.  Only in the 70 – 120Hz band was there significant correlations between CBF, 
and this was in the middle/superior frontal gyrus. There were no significant voxel-wise 
beta coefficients, except for BOLD and 40-70Hz, again located near the cuneus (data 
not shown). Supplementary Figure 7-3  displays the unthresholded t-statistics (testing 
if beta coefficients are different to zero) for each voxel in the MEG-BOLD coupling, and 
Supplementary Figure 7-4  for the MEG-CBF coupling, which suggested similar trends 
to the mean time-series results (Figure 7-4 and Figure 7-5). Suspecting the lack of 
statistically significant voxels to be due to low statistical power, we combined our BOLD-
MEG correlations maps (17 participants) with some from a different cohort (16 
Figure 7-6. Principle Component (PC) Analysis to investigate how MEG-BOLD and 
MEG-CBF relationships change across frequency bands and in different brain areas. 
The plots show the dominant tuning function (the PC explaining the most variance), 
and the inflated MNI template brains show how each voxel loads onto this PC.  
 
   121 
participants) and tested again whether correlation coefficients significantly different to 
zero. These results are shown in Figure 7-7 (bottom). More significant voxels, in the 
directions we would expect, are seen: negative correlations between BOLD and alpha 
(8-13Hz) and beta (13 – 30Hz), and positive correlations between BOLD and theta (3-
8Hz) and BOLD and gamma (40Hz+).  
Same analysis, on extra participants. Just 
looking at BOLD-MEG coupling. 
Figure 7-7. Top: Significant correlation coefficients, for MEG-fMRI coupling. Only 
shown for coupling relationships that had significant voxels. Bottom: Significant 
correlation coefficients, for MEG-BOLD coupling only, for a combined analysis of this 
dataset (n=17) and data from a different cohort (n=16). There was also a small region 
in superior occipital areas that showed significant coupling between 1-4Hz and 
BOLD. This data was calculated by first calculating correlation coefficients at each 
voxel for each subject, then using FSL’s randomise function to perform a 
nonparametric one-sample t-test at each voxel, FWER p<0.05 corrected, TFCE and 
12mm of variance smoothing. 
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7.4 DISCUSSION 
 
 
Passive viewing of a simple movie stimulus, easy to implement with MEG and fMRI 
acquisitions, allowed us to characterise frequency-dependent NVC, across many brain 
areas. Compared to resting-state paradigms, getting each participant to view the same 
movie clip imposed some common temporal structure on the MEG and fMRI responses, 
allowing group average MEG and fMRI time-series to be correlated. Below, a brief 
discussion of the within modality analysis is given, before moving on to a more detailed 
discussion of the between-modality analysis, the main purpose of this chapter.   
 
Within modality analysis: MEG, BOLD and CBF activity 
 
Significant common activity across participants was seen for MEG (across multiple 
frequency bands up to 145Hz), BOLD and CBF, across occipital, parietal, temporal and 
frontal regions, but most consistently in visual areas. These results are similar to the 
single modality movie literature, but looking at MEG, BOLD and CBF movie responses 
in a single combined study has not been previously reported.  When using half the data, 
the ISCs were almost unchanged, suggesting a shorter movie clip is sufficient to 
characterise significant ISCs.  Showing an isolated movie clip, with no sound or sub-
titles, likely gave varied levels of emotional engagement, and narrative recognition, from 
subject to subject, therefore frontal attentional networks are less likely to be consistently 
activated. Indeed, significant frontal activity, common across participants, was not seen 
in BOLD or CBF movie responses, and only seen for some MEG frequencies. 
Responding to shapes, colour, movement, faces and scenes is likely to be more 
consistent across participants, reflected in the more consistent significant activity we 
report in visual and perceptual regions across BOLD, CBF and MEG. This movie clip 
displayed emotional engaging and high arousal content, and there is evidence that 
these factors increase BOLD ISCs to movie stimuli (Ki et al., 2016; Nummenmaa et al., 
2012). Using audio or sub-titles would increase the emotional engagement and 
attention further, and potentially give more significant ISCs in wider brain areas, 
however achieving similar audio delivery in MEG and fMRI environments is very 
challenging.  
 
The magnitude of the significant MEG ISCs were very small (r < 0.1), and smaller than 
BOLD and CBF ISCs. A recent study by Lankinen et al (2018) report very similar ISCs 
for MEG and for BOLD, and suggest some potential reasons for this difference. They 
suggest spatial inaccuracies going from sensor to source space, but also the fact that 
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MEG time-series have richer temporal information so differences between participants 
may have a greater effect. Fewer ISCs, and ISCs with smaller magnitudes, were seen 
for the CBF analysis, compared with the BOLD, most likely due to poorer SNR for CBF 
signals.  
 
Between modality analysis: Coupling between MEG, BOLD and CBF 
 
Consistent with previous non-invasive (e.g. Zumer, Brookes, Stevenson, Francis, & 
Morris, 2010) and invasive (e.g. Mukamel et al., 2005) human literature, our results in 
Figure 7-7 (bottom, larger sample), show a frequency-dependent NVC relationship, with 
negative correlations with BOLD at lower frequencies (alpha, 8-13Hz, beta 13-30Hz) 
and positive correlations with BOLD at higher frequencies. In fact, EEG and MEG 
paradigms using visual stimuli typically report an increase in gamma oscillatory power 
at the same time as a decrease in alpha (e.g. Muthukumaraswamy & Singh, 2013; 
Swettenham, Muthukumaraswamy, & Singh, 2009). Looking at BOLD and CBF 
coupling with MEG, with the smaller sample (Figure 7-7, top), only positive correlations 
showed significant activity, for BOLD (4-8Hz, 40-70Hz, 70-120Hz) in visual areas, and 
for CBF (70-120Hz only) in the middle/superior frontal gyrus. This was presumably due 
to the smaller sample size, as the T-statistic maps (Supplementary Figure 7-3 and 7-4) 
showed similar trends. This frontal activity in CBF stood out, as it was not seen in BOLD 
or the other analysis approaches; although it could be noise or eye artefacts, it could 
also be meaningful activity of the frontal eye fields, which play a key role in saccadic 
eye movements for the purpose of directing attention (Schall, 2009). This would make 
sense in the context of the free-viewing of the movie clip. 
 
For the results in Figure 7-7, each MEG frequency band is dominated by either a 
positive or negative relationship with BOLD or CBF, unlike the mean time-series 
analysis  which showed both positive and negative relationships with BOLD and CBF 
in a single frequency band. This is summarised in the PCA analysis (Figure 7-6); the 
dominant relationship between frequency and BOLD/CBF was very consistent with 
what has been reported previously (Mukamel et al., 2005; Zumer et al., 2010). This 
function loads positively onto some brain areas, and negatively onto others, suggesting 
opposite NVC for different regions. Regional differences in NVC have been reported 
before (Bentley, Li, Snyder, Raichle, & Snyder, 2016; Devonshire et al., 2012; Huo, 
Smith, & Drew, 2014), but we are not aware of any other studies reporting inverted NVC 
relationships in different brain areas, using the relationship between MEG/EEG and 
fMRI. Many of the inverted relationships where seen most clearly in the pre-cuneus, a 
key area in the default mode network (Utevsky, Smith, & Huettel, 2014), a network of 
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regions that decreases in connectivity during tasks and increases during rest. 
Therefore, these findings could have interesting and important implications for the 
interpretation of activity in the default mode network; a decrease in BOLD-connectivity 
may not directly reflect decreased activity in neural activation, as these regions may be 
functionally coupled together in different ways than assumed.  
 
Hermes, Nguyen, & Winawer (2017) make the distinction between synchronization of 
neural responses, compared with changing levels of neural activity due to metabolic 
demand, and propose this as an explanation for discrepancies between measured 
electrophysiological and BOLD responses, and for different positive and negative 
relationships seen for different frequencies. However, a confound in  the interpretation 
of these positive and negative relationships arises from the fact that MEG beamformers 
are sensitive to source leakage. For instance, a strong oscillatory source may have a 
weak tail of activation that ‘leaks’ to an adjacent brain region which, under certain 
conditions, could arise as a spurious correlation with fMRI signals that do not have the 
same spatial errors.   
 
Not only did the relationship between neural oscillatory frequency and fMRI vary across 
brain areas, but these relationships often appeared opposite for BOLD and CBF. This 
opposite relationship can be seen quite clearly in the BOLD and CBF PCA loadings in 
areas near the cuneus and pre-cuneus, and particularly in coupling with 13-30Hz in 
Figure 7-4 and with 70-120Hz in Figure 7-5. However, there were positive correlations 
between BOLD and CBF signals in these areas (Supplementary Figure 7-2), making 
this divergence of BOLD and CBF coupling with neural activity hard to interpret. In some 
areas, it is possible that BOLD and CBF are explaining different parts of the MEG signal; 
considering it is a rich temporal signal with both amplitude and phase changes reflecting 
functional activity, this could be plausible. Another factor to consider, is that BOLD is a 
complex signal with known vascular contamination. For instance, mislocalisation 
between neural activity and BOLD signal changes can occur due to large velocity 
changes in draining veins (Fukuda, Poplawsky, & Kim, 2016). However, performing the 
analysis at 6mm spatial resolution should have mitigated this effect to some degree.  
 
Animal work has shown similar regional discrepancies between neural, BOLD and CBF 
signals, for example one study showed that increases in hemodynamic, neuronal, and 
metabolic activity were associated with positive BOLD signals in the cortex, but with 
negative BOLD signals in hippocampus, during seizure activity in rats (Schridde et al., 
2008). Although we did not characterise our MEG signals in sub-cortical areas (due to 
depth insensitivity)  this is still evidence for regional differences in the coupling between 
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these signals. Another study with anesthetized macaques showed evidence that the 
cortical layers may have different NVC behaviours, and that CBF and CBV relate to 
positive and negative BOLD changes differently in response to a visual stimulus 
(Goense, Merkle, & Logothetis, 2012). However, there is not a lot of research 
charactering these differences in humans due to the invasive nature of measuring these 
signals simultaneously.  
 
The CBF response, despite having lower SNR, is a more meaningful and interpretable 
signal, directly reflecting blood flow to an amount of tissue. However, the CBF signal 
still only tells us about the delivery of blood to the tissue, and not about neural 
metabolism. The BOLD response cannot be taken as a direct reflection of underlying 
metabolic changes, as it relies on CBF, CBV, CMRO2 changes, as well as the baseline 
tissue state. Furthermore, there is evidence that coupling between CBF and CMRO2 
(Ances et al., 2008), and variations in capillary vascularisation (Ekstrom, 2010) vary 
across brain regions. Both factors would affect the resultant BOLD response, causing 
it to not be a true reflection of neural activity.  Therefore, it is important to develop non-
invasive ways of measuring both CBF and CMRO2  signals and investigate how they 
relate to different types of neural activity, in different brain regions. The relationship 
between MEG and CMRO2  signals has not been characterised previously,  and this is 
the focus of Chapter 8, displaying some exploratory relationships between MEG and 
CMRO2  signals to the movie stimulus.  
 
Methodological considerations and limitations  
 
It is a possible that these inverted coupling behaviours, and the differences between 
BOLD and CBF, have not been reported previously due to the stimuli type normally 
used. Using highly controlled visual stimuli (e.g. checkerboards, gratings) typically 
focuses the analysis on the low gamma-band (similar to our 40-70Hz range). The 40-
70Hz band was actually the only frequency band that showed only positive correlations 
with BOLD and was the most similar in the BOLD and CBF coupling. It also showed 
some of highest correlations with BOLD and CBF, in both types of analyses. 
 
Although these inverse NVC patterns, and discrepancies between BOLD and CBF, 
where seen across multiple frequency bands, it is important to note that this was only 
found for the mean time-series analysis. This was not seen when fitting the model for 
each participant first, then testing for statistical differences, the more typical approach 
taken for neuroimaging data. A larger sample would be needed to adequately 
characterise both fixed effects (parameters constant across individuals, our mean time-
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series correlations/regressions) and random effects (parameters can vary across 
individuals, our subject time-series correlations/regressions). Considering random 
effects in the modelling becomes more important if you want to test differences between 
two populations.  
 
An assumption made in this analysis, is that the neural response to the movie stimuli 
was the same in MEG and fMRI. They are unlikely to be identical, considering they are 
measured at different times, but still share a lot of similarity.  Counterbalancing the order 
of MEG and fMRI movie presentation, as done in this study, is therefore an important 
factor considering reports of how ISCs can change on repeated viewing (e.g. Chang et 
al., 2015), but this only controls order differences at the group level.  
 
When characterising the MEG and fMRI coupling relationship on the group mean time-
series data, the data were masked to significant BOLD or MEG ISCs regions, to look at 
coupling only in places where there was a significant response to the movie.  However, 
Lankinen et al (2018) showed that the regions with the most consistent MEG activity 
across participants may not be the same as regions that are most correlated with fMRI. 
Also, they critique the use of the typical univariate voxel-wise correlation approach to 
characterise responses to a continuous naturalistic stimulus and propose instead a 
spatial filtering approach which they use to demonstrate more significant coupling 
relationships.  
  
Conclusions 
Passive viewing of a simple movie stimuli in MEG and fMRI allowed us to measure 
neural oscillations in multiple frequency bands, BOLD signals and CBF signals, non-
invasively in the same participants. This demonstrated complex patterns of coupling 
between neural activity and vascular and metabolic responses. NVC is dependent on 
both oscillatory frequency and brain region and appears different for BOLD and CBF 
signals.   
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7.5 SUPPLEMENTARY  
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 7-1. Significant inter-subject correlations (ISCs) showing 
movie-activated areas, for the two MEG frequency bands above the anti-alias filter 
cut-off of 150Hz. Correlation values corrected to p<0.05, with randomisation 
testing. Correlations are displayed on an inflated MNI template brain. Mean 
correlation over voxels (Mean r) and maximum correlation over voxels (Max r) are 
reported. 
 
 
Supplementary Figure 7-2. Correlation coefficients between Group BOLD time-
series and Group CBF time-series, unthresholded. Black – Red – Yellow 
display increasing positive correlations, and Black – Blue – Pink increasing 
negative correlations. Correlations are displayed on an inflated MNI template 
brain.   
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Supplementary Figure 7-3. Unthresholded T-statistics for each voxel, testing if the 
beta coefficients are different to zero for MEG-BOLD coupling. Light blue to dark 
blue represents increasing negative T-statistics (beta-coefficients less than zero) 
and red to yellow increasing positive T-statistics (beta-coefficients greater than 
zero). The subject average beta coefficients, across voxels, ranged from -0.0012 
to 0.0013 for BOLD 1-4Hz regression, from -0.0011 to 0.0019 for the BOLD 4-8Hz 
regression, from  -0.0016 to 0.0020 for BOLD 8-13Hz,from  -0.0032 to 0.0031 for 
BOLD 13-30Hz, from -0.0032 to 0.0055 for BOLD 40-70Hz and from -0.0027 to 
0.0055 for BOLD 70-120Hz.  
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Supplementary Figure 7-4. Unthresholded T-statistics for each voxel, testing if the 
beta coefficients are different to zero for MEG-CBF coupling. Light blue to dark 
blue represents increasing negative T-statistics (beta-coefficients less than zero) 
and red to yellow increasing positive T-statistics (beta-coefficients greater than 
zero). The subject average beta coefficients, across voxels, ranged from -0.0012 
to 0.0013 for CBF 1-4Hz regression, from -0.0011 to 0.0019 for the CBF 4-8Hz 
regression, from  -0.0016 to 0.0020 for CBF 8-13Hz,from  -0.0032 to 0.0031 for 
CBF 13-30Hz, from -0.0032 to 0.0055 for CBF 40-70Hz and from -0.0027 to 0.0055 
for CBF 70-120Hz.  
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8 Using a breath-hold design to estimate the calibration factor 
M: can we model CMRO2 to a movie-stimulus? 
 
8.1 INTRODUCTION  
 
Following on from Chapter 7, this chapter aimed to characterise relative change in the 
CMRO2 to the movie stimulus. As covered in Chapter 1.2.1, oxidative metabolism of 
glucose is the predominant mechanism through which the energy demands of neural 
activity are met. Compared with CBF and BOLD signals, CMRO2  is thought to be more 
closely coupled to neural activity (Du et al., 2008; Hyder, 2010). As demonstrated in 
Chapter 6, we can ‘calibrate’ our BOLD and CBF signals with hypercapnic stimuli, 
allowing us to estimate the M parameter.  Estimating the M parameter in the same 
scanning session as measuring BOLD and CBF signals to the movie stimulus can allow 
us to model CMRO2 to the movie stimulus. Here we present an alternative way of 
estimating the M parameter by modelling the relationship between BOLD and CBF 
signals to hypercapnia, induced by a breath-hold (BH) design. Although there have 
been many studies using a BH task to characterise Cerebrovascular Reactivity (CVR), 
very few have gone on to estimate M (One example: Kastrup, Krüger, Glover, & 
Moseley, 1999).  The majority of studies use increases in inspired CO2 gas fractions to 
estimate M (Blockley et al., 2013). Using a BH task is easy to implement and needs 
less equipment but requires more subject compliance to achieve good data.  
 
A previous study characterised the CMRO2 responses to a naturalistic movie stimuli 
(Griffeth et al., 2015). Their focus was to compare flow-metabolism coupling between 
different stimulus types, and they report no significance difference in flow-metabolism 
coupling to a movie stimulus and to a flickering checkerboard stimulus. Their movie 
clips were shown for ~6 minutes, and interspersed with rest blocks, therefore quite a 
different design to our continuous 20-minute recording. Here, we also characterise 
CBF- CMRO2 coupling to the movie stimulus.  
 
In this chapter, we report an exploratory, region of interest, analysis where we model 
the relationship between MEG and CMRO2 signals. In Chapter 7,  we reported divergent 
coupling relationships between MEG and BOLD and MEG and CBF, therefore being 
able to characterise MEG-CMRO2 coupling may bring insight into why these differences 
occur. More generally, it is important to understand how CMRO2 signals modelled with 
fMRI paradigms correlate with neural oscillations, considering CMRO2 is thought to 
more closely reflect the ATP consumption needed to restore ionic gradients after neural 
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signalling (Buxton, 2010). If most energy is replenished by the oxidative metabolism of 
glucose (Buxton, 2009; Du et al., 2008), we would expect CMRO2 to be a good index 
of neural activity, and therefore correlate with the neural oscillations measured with 
MEG. To the best of our knowledge, the relationship between MEG signals and CMRO2 
has not been explored previously.  
 
8.2 METHODS 
 
Participants and Design 
 
15 out of the 19 participants described in Chapter 7 performed a BH task in the same 
MRI session as the movie-watching. 14 out of these 15 participants also had movie 
data from MEG.  The BH task took 8 minutes and 44 seconds and is described in Figure 
8-1. 
 
 
Figure 8-1. The timings for the BH task. Participants practiced this task outside of the 
scanner first, until they fully understood the instructions and were comfortable to 
proceed. Before the task started in the scanner an instruction screen appeared saying 
“The breath-hold task is about to start. Follow the instructions on the screen, and please 
remember to breathe through your nose.” The task started with 24 seconds of paced 
breathing, where a screen alternated from ‘Breath In’ to ‘Breath Out’ with 3 second 
count downs in both. This was followed by a ‘Hold’ instruction where participants knew 
to not breathe through their nose or mouth for 20 seconds. After the breath-hold an 
‘Exhale!’ was given to measure the change in end-tidal CO2. Lastly, a ‘Recover’ was 
shown, where participants could breathe how they wished for 5 seconds. This cycle 
repeated 10 times before ending on one last 24 seconds paced breathing section. 
 
Task Compliance  
 
As the main purpose of the BH analysis was to estimate regional M values, the O2 and 
CO2 traces recorded through-out the experiment were not used in the modelling. The 
modelling of the M parameter was simply based on the fact that BOLD and CBF signals 
are changing in the response to the same CO2 increase due to the BH manipulation. 
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However, the physiological traces were inspected to ensure sufficient quality, and 
compliance with the BH task.  Two participants were left out of the analysis due poor 
compliance with the BH task (Figure 8-2). This left 12 participants, all of which had at 
least 8 clear BH segments in their physiological traces. Examples of acceptable and 
good traces from two participants are shown in Figure 8-2. 
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Figure 8-2. Example BH traces from 4 participants. X-axis is time and y-axis are 
CO2 in mmHg. In example 1, it is very hard to notice any breath-holds. In example 
2, the breath-holds are noticeable but still inconsistent, and there are many spikes 
of exhalations. In example 3, there are also spikes of exhalation in the breath-hold 
segments however the end-tidal increases are clearer and there are more prolonged 
breath-hold segments. In example 4, you can see 10 clear breath-holds ending in 
10 clear end-tidal increases. 
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MRI acquisition and Data Analysis 
 
During the BH  task, the sequence used was the same pCASL acquisition that was run 
during the movie stimuli (described in detail in Chapter 5), with a total of 119 volumes. 
 
Data Pre-processing  
 
BH data was pre-processed in the same way as the pCASL movie data, explained in 
Chapter 7. In brief, motion correction with FSL-McFLIRT, spatial smoothing 
(FWHM=4.5mm) for the BH-BOLD data with SUSAN, and for the BH-CBF data with a 
3D Gaussian kernel (FWHM 4.5mm). Surround subtraction and surround averaging 
was performed on the BH-CBF and BH-BOLD data, respectively. The BH-BOLD and 
BH-CBF data were both registered to the M0 image that was acquired before the movie. 
The BH-BOLD and BH-CBF data were transformed to M0 image, then to the T1 image 
and to the MNI-2mm image, using the movie-data transformation matrices made 
already. The BH-BOLD and BH-CBF data were then down-sampled to 6mm, in order 
to estimate M values in same space as the fMRI and MEG movie analysis.  
 
In this MNI-6mm space, M was only estimated in voxels that had significant movie-
BOLD ISCs (Figure 7-2A). We split the significant movie-BOLD ISC image into 
anatomical areas using the AAL atlas (Tzourio-Mazoyer et al., 2002). We chose this 
ROI method instead of doing a voxel-wise analysis (as in Chapter 7) to: (1) constrain 
the M estimates to areas where the movie was activated as these are the areas where 
movie-CMRO2 will go on to be modelled (assuming movie-BOLD activation to be 
spatially similar to movie-CBF activation but with more voxels reaching statistical 
significance), and (2) to average out noise. The AAL atlas regions where in MNI-2mm 
space so these where first down-sampled to 6mm in order to overlay onto the movie-
BOLD ISC image. This gave 28 ROIs (see Table 8-1 for list). For each ROI, a mean 
over voxels was calculated for BH-BOLD and BH-CBF data, resulting in a 
representative time series (119 volumes) for that ROI. 
 
Baselining the BOLD and CBF BH data 
 
The equation used to model M (see page 136) based on the relationship between BOLD 
and CBF to an isometabolic stimulus, requires both BOLD and CBF signals to be 
expressed as change from baseline. As this experimental design did not include a long 
continuous baseline period at the beginning (limitations of which are covered in the 
discussion), we did not take a block-design approach to baselining the data. Instead we 
   135 
defined an empirical baseline. In MATLAB, for BH-BOLD and BH-CBF times-series 
over each ROI, we calculated the 40th percentile of the time series (to approximately 
reflect the proportion of data points in the paced breathing periods) and took a mean 
over any data points less than the 40th percentile to be represent the baseline. We then 
transformed the BH-BOLD and BH-CBF time-series to change from this baseline (for 
every point we divided by this baseline value). Plotting this 40th percentile with the data, 
for each participant, seemed to give a reasonable estimate of where the baseline was 
(via visual inspection) and Figure 8-3 demonstrates this for one participant.  
 
 
 
 
 
 
 
 
Figure 8-3. Average BOLD and CBF time-series for one participant, in response to 
the BH task, shown for two example ROIs (Calcarine Left – top, Superior Parietal 
Left – bottom). Note the 10 BHs that can be seen in these BOLD and CBF time 
series. Plots on the left side show data that is not relative to baseline, with the 40th 
percentile being plotted as the straight blue line. Average of the values below this 
40th percentile where taken as ‘baseline’ and used to change the time-series into 
change from baseline (plots on the right).  
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Fitting for M  
 
Assuming no change in CMRO2  to hypercapnia or very mild hypoxia due to the BH, 
Equation 2-6 introduced in Chapter 2.3.3 (based on Davis, Kwong, Weisskoff, & Rosen 
(1998)) showed that: 
 ∆WXYTWXYTZ = 	𝑀 d1 −	_GWbGWbZa>0ch	    
 
Using MATLAB’s curve fitting function (‘fit’), with non-linear least squares, the below 
curve was fitted to the inputted BH-BOLD (B) and BH-CBF data (C), to estimate the M 
parameter. A start point of 0.05, a lower point of 0 and an upper point of 2 was given to 
guide the fitting. An estimate for M alongside R2 and the Root Mean Square Error 
(RMSE) were extracted for each fit. 
 𝐵 = 𝑴(1 − 𝐶0A.A), as setting 𝛼 = 0.2 and 𝛽 = 1.3, so 𝛼 – 𝛽 = -1.1 
 
CMRO2 movie time-series 
 
Only in ROIs where the M parameter could be reasonably estimated (no complex 
values in the fitting, and R2 > 0.1) was the CMRO2 time-series to the movie estimated 
for each subject. The pre-processed BOLD and CBF movie data, explained in  Chapter 
7 were averaged over each voxel within the anatomical ROI to give a representative 
time-series. Therefore, in each ROI, there was an average M value, a BOLD movie 
time-series (relative to baseline) and CBF movie time-series (relative to baseline). 
Therefore, CMRO2 (relative to baseline) could be estimated using the Equation 2-7 
introduced in Chapter 2.3.3 (based on Davis, Kwong, Weisskoff, & Rosen (1998)):  
 
𝐶𝑀𝑅𝑂2𝐶𝑀𝑅𝑂2$ = 	d𝐶𝐵𝐹𝐶𝐵𝐹$hA0	>c	 . 1 −	 ∆𝐵𝑂𝐿𝐷𝐵𝑂𝐿𝐷$𝑀 
A/c
 
 
CBF-CMRO2 and MEG-CMRO2 coupling in each ROI 
 
The relationship between CBF and CMRO2 responses (n = DCBF/DCMRO2) is an 
important physiological parameter that has been characterised widely in the calibrated-
fMRI literature, so this was characterised over each ROI. In order to look at the 
relationship between MEG and CMRO2 signals, a representative amplitude envelope in 
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each frequency band needed to be obtained over each ROI. Instead of averaging the 
MEG amplitude envelopes over each voxel in the ROI, the coefficient of variance 
(SD/Mean) was calculated for each voxel, to locate the voxel with the biggest variance 
in signal, scaled by the mean. This is important as the SNR of MEG source 
reconstructions are spatially non-uniform (for example, poorer SNR for sources deeper 
in the cortex), (Hillebrand & Barnes, 2002). Therefore, the SD/Mean approach gives 
voxel-wise scaling and is similar to typical BOLD-fMRI analysis where signal changes 
are often expressed in terms of the mean intensity. Therefore, the MEG time-courses 
(pre-processing explained in Chapter 7) that were correlated with CBF/BOLD/CMRO2 
were taken from one voxel within this ROI, that had the largest coefficient of variance.  
 
Statistical Testing  
 
For each participant, over each ROI, a linear model was fit using the MEG data (in each 
frequency band) to predict the CMRO2 signals. For each fit, the beta coefficients were 
extracted for each participant. One sample t-tests tested whether these beta 
coefficients were significantly different to zero across the group.  
 
As was done with MEG-fMRI coupling in Chapter 7, we also tested the coupling 
between MEG and CMRO2 signals on the group mean-time series data. The MEG and 
CMRO2 signals that were averaged over each ROI were then averaged across 
participants, before fitting the linear model to characterise if MEG data (in each 
frequency band) could predict the CMRO2 signals. 
 
8.3 RESULTS 
 
M fitting 
 
Table 8-1 shows the group average estimates of M, including the model fit parameters. 
These group averages are based on variable numbers of participants because of 
variability in the M fitting across ROIs. Figure 8-4 displays examples of the M fitting for 
five ROIs for one participant. 
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Table 8-1. Estimates of M, including fit parameters. Averages for each ROI are 
displayed, only for subjects that did not have complex values in the model fit (often due 
to negative CBF values) and had an R2 of greater than 0.1. RMSE = Root Mean Square 
Error. 
 
ROI 
N 
subjects 
R2 > 0.1 
R2 
Mean 
R2 
SD 
RMSE 
mean 
RMSE 
SD 
M 
mean 
M 
SD 
Angular_R 4 0.324 0.150 0.004 0.001 0.028 0.012 
Occipital_Inf_R 9 0.437 0.161 0.004 0.001 0.030 0.010 
Occipital_Inf_L 9 0.512 0.160 0.003 0.001 0.030 0.008 
Occipital_Mid_R 7 0.443 0.096 0.003 0.001 0.029 0.005 
Occipital_Mid_L 9 0.528 0.152 0.003 0.001 0.027 0.007 
Occipital_Sup_R 8 0.438 0.174 0.004 0.001 0.031 0.007 
Occipital_Sup_L 8 0.416 0.167 0.004 0.001 0.031 0.011 
Calcarine_R 9 0.501 0.147 0.004 0.001 0.034 0.007 
Calcarine_L 11 0.412 0.172 0.006 0.001 0.045 0.014 
Cuneus_R 8 0.377 0.189 0.005 0.001 0.035 0.008 
Cuneus_L 6 0.376 0.144 0.005 0.001 0.038 0.011 
Lingual_R 9 0.438 0.114 0.005 0.001 0.042 0.011 
Lingual_L 11 0.408 0.184 0.005 0.001 0.041 0.015 
Parietal_Inf_R 4 0.276 0.078 0.006 0.003 0.035 0.012 
Parietal_Inf_L 2 0.196 0.027 0.005 0.001 0.026 0.000 
Parietal_Sup_R 3 0.223 0.070 0.008 0.001 0.042 0.009 
Parietal_Sup_L 3 0.257 0.091 0.005 0.000 0.027 0.005 
Precuneus_L 3 0.421 0.128 0.004 0.000 0.022 0.003 
Precuneus_R 4 0.280 0.070 0.007 0.001 0.039 0.009 
Temporal_Inf_R 5 0.515 0.126 0.004 0.001 0.036 0.010 
Temporal_Inf_L 8 0.370 0.188 0.005 0.001 0.033 0.013 
Temporal_Mid_R 5 0.353 0.162 0.004 0.001 0.031 0.004 
Temporal_Mid_L 6 0.394 0.177 0.004 0.001 0.028 0.008 
Temporal_Sup_R 3 0.252 0.197 0.005 0.000 0.032 0.011 
Fusiform_R 9 0.426 0.168 0.004 0.001 0.031 0.009 
Fusiform_L 9 0.425 0.160 0.004 0.001 0.030 0.011 
Postcentral_R 1 0.109 / 0.006 / 0.027 / 
Postcentral_L 2 0.196 0.030 0.004 0.000 0.024 0.001 
 
Grand 
Mean 0.368 0.136 0.005 0.001 0.032 0.008 
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Figure 8-4. Examples of the M fitting for one participant, across 5 different ROIs. 
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CBF-CMRO2 coupling to the movie stimulus 
 
Table 8-2 shows the average n coupling values (n = DCBF/DCMRO2) across 
participants for each ROI, and Figure 8-5 displays shows an example of this coupling 
for a single participant, across three example ROIs.  
 
 
 
 
 
ROI subjects  n Mean n SD 
Angular_R 4 2.78 1.83 
Occipital_Inf_R 9 1.55 2.96 
Occipital_Inf_L 9 2.41 1.33 
Occipital_Mid_R 7 2.67 1.14 
Occipital_Mid_L 9 3.14 2.58 
Occipital_Sup_R 8 2.64 0.93 
Occipital_Sup_L 8 3.40 2.38 
Calcarine_R 9 2.24 0.68 
Calcarine_L 11 1.92 0.43 
Cuneus_R 8 2.23 0.67 
Cuneus_L 6 2.02 0.50 
Lingual_R 9 1.73 0.32 
Lingual_L 11 1.74 0.47 
Parietal_Inf_R 4 1.94 0.76 
Parietal_Inf_L 2 2.97 0.80 
Parietal_Sup_R 3 2.22 1.22 
Parietal_Sup_L 3 2.70 1.20 
Precuneus_L 3 3.34 1.83 
Precuneus_R 4 1.95 0.68 
Temporal_Inf_R 5 2.55 0.57 
Temporal_Inf_L 8 2.13 0.74 
Temporal_Mid_R 5 2.97 1.50 
Temporal_Mid_L 6 2.25 0.69 
Temporal_Sup_R 3 2.05 0.57 
Fusiform_R 9 1.91 0.58 
Fusiform_L 9 1.71 0.39 
Postcentral_R 1 1.77 / 
Postcentral_L 2 5.12 5.14 
Table 8-2. Average n parameter across participants, for each ROI, representing 
CBF-CMRO2 coupling to the movie. The number of participants that CMRO2 was 
estimated for varies across ROI and is shown in the ‘subjects’ column. 
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Coupling between MEG and CMRO2 movie signals  
 
Figure 8-6  shows an example subject time-series for BOLD, CBF, CMRO2 and MEG 
1-4Hz activity extracted over the same ROI, to demonstrate the shape and magnitude 
of each signal change. The relationship between MEG and CMRO2 signals to the movie 
was explored in six ROIs with some of the largest numbers of participants showing 
Figure 8-5. CBF-CMRO2 coupling to the movie stimulus, for one participant, over 
three different ROIs.  
 
   142 
acceptable M fitting in both hemispheres: Calcarine Left (n=10), Calcarine Right (n=8), 
Lingual Left (n=10), Lingual Right (n=8), Fusiform Left (n=8) and Fusiform Right (n=8). 
These values are one less than those displayed in Table 8-1 due to there being only 14 
participants, out of the 15 participants with BH-data, also having MEG data.  
Figure 8-6. An example time-series for BOLD, CBF, CMRO2 and MEG 1-4Hz activity 
extracted over the same ROI. This data is from one participant, just to demonstrate the 
shape and magnitude of each signal change. Per-change refers to signals expressed 
as percentage change from baseline.  
 
MEG, in each frequency band separately, was used to predict CMRO2 for each 
participant, in each ROI. Beta-coefficients were extracted for all participants. There 
were no beta coefficients significantly different to zero for any MEG-CMRO2 
relationships. Two relationships showed p-values less than 0.05 (1-4Hz and CMRO2, 
8-13Hz and CMRO2 in Right Fusiform gyrus) however considering the many statistical 
tests performed this would not reach statistical significance after any multiple 
comparison correction. These beta-coefficients are shown in Table 8-3.  We explored 
the relationships between  CMRO2  and MEG using the group mean-time series data, 
in these ROIs. Three model fits had p-values less than 0.05 (1-4Hz and CMRO2, and 
95-145Hz and CMRO2 in the Right Fusiform gyrus, and 1-4Hz and CMRO2 in the Right 
Calcarine Sulcus). Again, these do not survive corrections for multiple comparison. 
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These relationships are displayed in Supplementary Figures 8.1 - 8.3, alongside the 
MEG-BOLD and MEG-CBF coupling in the same ROI, for comparison. 
 
 
Table 8-3. Averages (AV) and standard deviations (SD), across participants, of beta 
coefficients (unstandardised) from the model fit of MEG activity (in each specific 
frequency band) and CMRO2  activity, over 6 ROIs that showed acceptable M fitting for 
either 10 participants (Calcarine Left, Lingual Left) or 8 participants (Calcarine Right, 
Lingual Right, Fusiform Left, Fusiform Right). The beta coefficients highlighted in grey 
were significant at p<0.05, uncorrected for multiple comparisons.  
 
 
Calcarine Left  (n=10) 
 
1-4Hz 4-8Hz 8-13Hz 13-30Hz 40-70Hz 
70-
120Hz 
95-
145Hz 
CMRO2 AV 0.001 0.005 0.010 0.013 -0.019 -0.008 0.013 
CMRO2 SD 0.010 0.019 0.023 0.026 0.071 0.090 0.103 
 
Calcarine Right  (n=8) 
  1-4Hz 4-8Hz 8-13Hz 13-30Hz 40-70Hz 
70-
120Hz 
95-
145Hz 
CMRO2 AV 0.006 0.007 0.004 0.005 -0.056 -0.033 0.005 
CMRO2 SD 0.014 0.017 0.021 0.037 0.075 0.080 0.062 
 
Fusiform Left (n=8) 
 
1-4Hz 4-8Hz 8-13Hz 13-30Hz 40-70Hz 
70-
120Hz 
95-
145Hz 
CMRO2 AV -0.003 0.007 0.008 0.012 -0.063 -0.020 0.022 
CMRO2 SD 0.019 0.015 0.023 0.033 0.112 0.050 0.087 
 
Fusiform Right (n=8) 
 
1-4Hz 4-8Hz 8-13Hz 13-30Hz 40-70Hz 
70-
120Hz 
95-
145Hz 
CMRO2 AV 0.013 0.008 0.011 0.005 -0.041 -0.025 -0.007 
CMRO2 SD 0.012 0.020 0.011 0.037 0.078 0.099 0.105 
 
Lingual Left (n=10) 
 
1-4Hz 4-8Hz 8-13Hz 13-30Hz 40-70Hz 
70-
120Hz 
95-
145Hz 
CMRO2 AV -0.003 0.009 0.004 0.001 -0.019 0.006 0.008 
CMRO2 SD 0.019 0.022 0.026 0.030 0.080 0.082 0.092 
 
Lingual Right (n=8) 
 
1-4Hz 4-8Hz 8-13Hz 13-30Hz 40-70Hz 
70-
120Hz 
95-
145Hz 
CMRO2 AV 0.001 0.009 0.006 0.010 -0.024 -0.005 0.000 
CMRO2 SD 0.017 0.023 0.016 0.035 0.077 0.083 0.064 
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8.4 DISCUSSION 
 
Breath-Hold Task to estimate M  
 
In order to model CMRO2 to the movie an estimate of M had to be obtained in the same 
brain region. M is a scaling parameter which represents the maximum BOLD signal 
change that would occur if all deoxyhaemoglobin was washed out of the venous blood 
vessels. In practice, smaller physiological changes are induced with hypercapnic 
stimuli, but it is enough to change the BOLD and CBF responses to get some estimate 
of the baseline tissue state, summarised by M. In this chapter, we fit for the M parameter 
using an accepted biophysical model linking BOLD and CBF changes. Although the 
model fit of M varied across participants, an adequate model fit was achieved in multiple 
brain regions, particularly in the visual cortex. It is important to highlight that in this 
study, we fit for the M parameter and only characterise CMRO2 in ROIs where the fit 
was reasonable. Most studies that have estimated M from a hypercapnic stimulus have 
taken baselined BOLD and CBF signals, averaged over time, and inputted these point 
estimates into the equation for M. The average M values we report were around 3%. 
However higher values of at least 6% are more typically reported for these brain regions 
(e.g. Wise, Harris, Stone, & Murphy, 2013). As M does not only depend on physiological 
factors, but also on image acquisition parameters and data analysis choices, it can be 
difficult to make meaningful comparisons across studies. However, there are many 
factors that may have contributed to these lower M values, some of which are discussed 
below. 
 
An assumption in the model fit for M is that the BH-paradigm induces isometabolic 
changes in BOLD and CBF. The assumed mechanism is an increase of PCO2 causing 
blood vessels to dilate, resulting in increased CBF and resultant increased BOLD 
signals (Ainslie & Duffin, 2009), without any change in oxygen metabolism. However, 
this assumption has been challenged and there is evidence for metabolic changes 
induced by hypercapnia (Driver et al., 2017; Yablonskiy, 2011; Zappe, Uludaǧ, 
Oeltermann, Uǧurbil, & Logothetis, 2008). There is recent work demonstrating how to 
measure and correct for the likely reduction of resting CMRO2 during hypercapnia, and 
therefore increase the accuracy of the M value estimates, and therefore the modelled 
task-induced CMRO2  changes (Driver et al., 2017), and this should be considered for 
future work. Unlike with a gas-delivery design, inspired oxygen is not being held 
constant, therefore there will also be small reductions in arterial PO2 (Bulte, Drescher, 
& Jezzard, 2009), which will decrease the BOLD signal and cause an underestimation 
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of M. Although these changes in arterial PO2 are likely to have a small effect over a 
short BH, this is a likely explanation for why we report lower M values with this design.  
 
Another factor contributing to the lower M values we report here could be an 
underestimation of the CBF change in the BH paradigm. This underestimation in CBF 
could be due to the long TR in the ASL sequence used (4.4 seconds) due to a pseudo-
continuous tagging design with dual excitation. The CBF changes are therefore 
effectively smoothed due a low sampling rate. This lower sampling rate is the same for 
the BOLD-weighted signal but for CBF it is worsened by the need to do tag-control 
subtraction in order to obtain the perfusion signal.  The estimate of the baseline BOLD 
and CBF signals was challenging due to this low sampling rate, accompanied with a 
dynamically changing stimulus. For each block of paced-breathing, only 5 brain 
volumes were acquired.  A clear improvement to this BH design would be to include a 
long baseline at the start and/or end, to more accurately estimate the baseline BOLD 
and CBF under normal breathing conditions, in each brain region. This BH task design 
is more appropriate for fMRI sequences with a shorter TR. Nevertheless, the relative 
values we got for BOLD and CBF response to the BH stimulus are in the ranges we 
would expect  (see Figure 8-3), which shows BOLD changes of around 1-2% and CBF 
of around 20-60%). There was a large variability in the fitting of M for each participant, 
presumably due to different task compliance and data quality. There was also a 
difference in the fitting of M across brain regions. There is evidence that coupling 
between CBF and CMRO2 (Ances et al., 2008), and variations in capillary 
vascularisation (Ekstrom, 2010) vary across brain regions. Fitting for M was best in the 
visual cortex; this could be explained by the fact the visual cortex has a higher density 
of capillaries (Buxton, 2009; Zheng, LaMantia, & Purves, 1991) and therefore this will 
result in higher CBV and higher M values. 
 
Modelling CMRO2 to the movie-stimulus  
 
Modelling the CMRO2 response with the standard calibrated-fMRI model (Davis et al., 
1998) gave physiologically reasonable CMRO2 changes (Buxton, 2009), see Figure 8-6 
showing CMRO2 increases and decreases to the movie stimuli of around 0-10%. 
Importantly, the CBF-CMRO2 coupling (n) was close to 2 or 3 in 27 out of the 28 ROIs, 
very consistent with what has been reported previously (Blockley et al., 2013). Griffeth 
et al (2015) characterised n to a movie stimulus and found very similar values: their 
average n over the visual cortex was 2.47, and our grand average n over the 12 visual 
ROIs was 2.31. They did not measure M but assumed different values (as well as 
different values for the parameters a and b) when comparing between their conditions. 
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They assumed a much higher M when modelling CMRO2 (11.6%), and actually show 
that when modelling the data with a lower M of 8.1% the difference between the 
increase in relative CMRO2 from the movie compared to the 10% visual contrast 
condition was no longer statistically different. Our underestimation of M, already 
discussed above, could have led to an underestimation in CMRO2, and contributed to 
the lack of significant correlations seen between MEG and CMRO2 movie signals.  
 
There were no reliable significant relationships between CMRO2 and MEG signals. This 
was most likely due to sample size, and propagated noise. CMRO2, being a derived 
parameter, is highly sensitive to the noise in the CBF timeseries, measured with ASL. 
Only datasets from 12 out of the 14 participants who had completed the BH task were 
good enough quality to analyse, and after this the fitting of M greatly varied over brain 
region, such that 10 was the maximum number of participants left to characterise MEG-
CMRO2 relationships over a specific ROI. Unfortunately, in areas showing different 
BOLD-MEG and BOLD-CBF coupling in Chapter 7 (for example, cuneus and pre-
cuneus) M could not be well estimated, and therefore CMRO2 time-series were not 
characterised over these regions. In the regions that suggested at a relationship 
between MEG and CMRO2, these were mostly in neural oscillations at lower 
frequencies (1-4Hz and 8-13Hz) which is possibly driven by the 1/f power spectrum 
known to exist in the brain i.e. higher amplitudes at lower frequencies (Jia & Kohn, 
2011).  For the relationships shown in Supplementary Figures 8.1 - 8.3, based on the 
mean-time series data, all beta coefficients (relating MEG to BOLD, CBF and CMRO2) 
were negative, which is not expected for delta and gamma frequencies, which we would 
predict positive correlations based on previous literature with BOLD-fMRI (Mukamel et 
al., 2005; Zumer et al., 2010).  
 
Conclusions  
 
This chapter demonstrated it is possible to use simple modelling of BOLD and CBF 
signals, elicited with a BH-design, to give reasonable estimates of M in different brain 
regions, although a slight underestimation compared to other literature. This allowed 
characterisation of CBF-CMRO2 coupling across different brain regions. With an 
improved BH design, including better estimation of the baseline, these M values, and 
therefore the modelled CMRO2 values, are likely to be more accurate. This research 
acts as a proof of principle that MEG and CMRO2 signals can both be modelled in 
response to the same stimulus, however much larger samples and optimised modelling 
of the relationship between these signals, is needed to characterise this relationship 
robustly.  
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8.5 SUPPLEMENTARY  
 
 
 
Supplementary Figure 8.1. The relationship between MEG (1-4Hz) and CMRO2, 
CBF and BOLD signal changes in response to the movie stimuli, based on the 
mean-times data across participants, averaged over the right fusiform gyrus. 
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Supplementary Figure 8.2. The relationship between MEG (95 – 145Hz) and 
CMRO2, CBF and BOLD signals changes in response to the movie stimuli, based 
on the mean-times data across participants, averaged over the right fusiform 
gyrus. 
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Supplementary Figure 8.3. The relationship between MEG (1 – 4Hz) and 
CMRO2, CBF and BOLD signals changes in response to the movie stimuli, 
based on the mean-times data across participants, averaged over the right 
calcarine sulcus. 
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9 Coupling between brain oscillations, CBF, and BOLD signals 
during naturalistic movie viewing in Multiple Sclerosis 
 
9.1 INTRODUCTION 
 
As discussed in Chapter 7, the rationale of using a movie stimulus to investigate NVC 
was partly motivated by the aim to develop engaging and easy designs that can be 
used in patient populations during both MEG and fMRI. Another motivation of using 
such a design is that it is more representative of visual processing in natural real-world 
environments, and therefore may be more disease relevant (compared to highly 
controlled visual stimuli) as it simultaneously recruits more areas of the brain. 
Therefore, in this chapter, we applied the methods presented in Chapter 7 in order to 
investigate differences in NVC between the healthy and MS brain.  
 
Although visual abnormalities are common in MS (Graham & Klistorner, 2017), MS is 
not specifically a disease of the visual system and there is great variability across 
participants in symptom severity. The movie stimulus used in Chapter 7 still 
predominantly recruits visual areas, however it recruits more of the occipital cortex than 
a visual checkerboard stimulus which is often more localised to primary visual areas. 
Furthermore, Chapter 7 also showed common movie activity, across participants, in 
temporal and parietal areas. Therefore, this design allows us to study NVC across more 
areas of the brain, which is important considering the wide spread damage in MS, and 
the fact that NVC is shown to vary across brain region (e.g. (Devonshire et al., 2012) 
and results from Chapter 7).   
 
In Chapter 4, no significant differences in NVC to a visual stimulus were reported in MS, 
although the MS group did show lower amplitude changes for gamma oscillations, 
BOLD and CBF signals. Despite no significant NVC differences, the MS group 
displayed more variability in their coupling relationships. It may be the case that NVC 
is not uniformly altered in MS, despite the inflammatory environment affecting NVC 
signalling mechanisms (D’haeseleer et al., 2015; Lapointe et al., 2018; Paling et al., 
2011; Spencer et al., 2018). Alternatively, the methods used may not have been 
sensitive enough to find differences between groups, considering they focused only on 
oscillations in the gamma frequency range in the early visual cortex. 
 
The design presented in Chapter 7 allowed us to characterise neural oscillations from 
1-145Hz. Different oscillatory frequencies are hypothesised to reflect activity across 
different scales of neural networks (Buzsáki & Draguhn, 2004) and in different cell 
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populations. Therefore, finding abnormalities in MS at specific oscillatory frequencies 
could give insight into possible disease mechanisms. This chapter presents the same 
methods used in Chapter 7, extending them to test differences between MS patients 
and healthy controls. The lack of baseline period in this continuous movie recording 
restricts the analysis approaches. Therefore, a simple aim of this chapter was to test 
the feasibility and utility of this type of design for studying NVC in MS. We also 
characterised the coupling between BOLD and CBF signals to the movie, as this may 
be informative about how blood flow and metabolism are coupled in MS.  Based on 
previous work on neural, vascular and metabolic impairment in MS, we predicted the 
MS group would have more variable responses to the movie stimulus and altered NVC 
in some brain regions.   
 
9.2 METHODS 
 
Participants  
 
15 MS patients with RRMS and 15 healthy controls are presented in this chapter. All of 
these patients and 12 of these controls were presented in Chapter 5, and three of these 
controls were from Chapter 7. Supplementary Figure 5-2 gives an overview of the data 
collection for the wider study. All participants gave written informed consent prior to 
participating in this part of the study and received £10 per hour for taking part. See  
Table 9-1 for participant details.   
 
Design and Procedure 
 
All participants had a MRI scan and a MEG scan.  The order of these scans is given in 
Table 9-1. Both scanning sessions included passive viewing of the same movie clip 
from the James Bond film ‘Skyfall’ (approximately the first 19 minutes 38 seconds). For 
the MRI session, all participants also had a T1 structural scan. 
 
Data Acquisition and Pre-Processing  
 
MEG data and fMRI data were collected and pre-processed with the identical pipeline 
used in Chapter 7, for both patients and controls.  
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Within modality analysis: inter-subject correlations (ISCs)  
 
The same within-modality analysis was run as was presented in Chapter 7, to get ISCs 
for BOLD, CBF and MEG in each frequency band. This was done for the control group 
and the patient group separately, simply to see where there was significant common 
activity to the movie stimulus in each group.  
 
Cross-modality analysis: MEG-fMRI and CBF-BOLD coupling 
 
The focus of this analysis was to understand if there are differences in NVC and CBF-
BOLD relationships between patients and controls. Therefore, to take into account 
individual subject variability, MEG-BOLD, MEG-CBF and CBF-BOLD regressions were 
run for each subject separately, using MATLAB’s fitlm function. For each participant, 
and for each voxel in the 6mm template brain, a beta coefficient and an r value were 
outputted (as explained in Chapter 7). FSL’s randomise function was used to perform 
unpaired nonparametric t-tests at each voxel (5000 permutations) with FWER 
correction at p<0.05, and TFCE. T-statistic contrasts for Patients > Controls and 
Controls > Patient were examined.  
 
9.3 RESULTS 
 
Demographics for patients and controls are presented in Table 9-1, alongside disease 
characteristics for patients only. Patients and controls did not significantly differ in age, 
t(28) = 1.24, p = 0.225.  Each group had the same number of male and female 
participants.  
 
Table 9-1. Demographic and clinical information for patients and controls. First scan = 
which scanner they watched the movie in first. DM = data missing. Onset refers to 
disease onset and relapse refers to patient’s last clinically confirmed relapse.  
 
Patients Controls
Age (Mean ± SEM) 36.93 ± 1.60 34.13 ± 1.58
Gender (M/F) 3/12 3/12
First scan (MEG/fMRI) 15/0 10/5
Watched Movie (Y/N/DM) 10/3/2 11/4
97 ±  15 (28, 213)
36 ±  4.4 (11, 64)
2.2 ±  0.3 (1, 4)
Patients
Months since onset  (Mean ± SEM, min, max) 
EDSS  (Mean ± SEM, min, max) 
Months since relapse (Mean ± SEM, min, max) 
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Within modality results 
 
To uncover activity related to the movie, ISCs were calculated at each voxel, for the 
control group and patient group separately. Figure 9-1 shows significant ISCs for the 
BOLD and CBF analyses,  Figure 9-2 shows significant ISCs for the 1-30Hz MEG 
analyses, and Figure 9-3 shows significant ISCs for the 40Hz+ MEG analyses. The 
location of the significant ISCs are very similar to those reported in Chapter 7: across 
occipital, parietal and temporal cortical areas.  
 
 
Figure 9-1. Significant BOLD and CBF inter-subject correlations (ISCs) showing 
movie-activated areas, for control and patient groups separately. Correlation values 
corrected to p<0.05, with randomisation testing. Correlations are displayed on an 
inflated MNI template brain. Mean correlation over voxels (Mean r) and maximum 
correlation over voxels (Max r) are reported. 
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Figure 9-2. Significant MEG (1-30Hz) inter-subject correlations (ISCs) showing 
movie-activated areas, for control and patient groups separately. Correlation 
values corrected to p<0.05, with randomisation testing. Correlations are displayed 
on an inflated MNI template brain. Mean correlation over voxels (Mean r) and 
maximum correlation over voxels (Max r) are reported. 
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Figure 9-3. Significant MEG (40-145Hz) inter-subject correlations (ISCs) showing 
movie-activated areas, for control and patient groups separately. Correlation values 
corrected to p<0.05, with randomisation testing. Correlations are displayed on an 
inflated MNI template brain. Mean correlation over voxels (Mean r) and maximum 
correlation over voxels (Max r) are reported. 
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MEG-fMRI coupling 
 
Maps of beta coefficients and r values for each MEG-BOLD and MEG-CBF relationship 
were created for each subject, and group differences were tested at each voxel. The 
only relationship showing significant differences between patients and controls was the 
8-13Hz MEG and BOLD relationship. Significantly larger r values and significantly larger 
beta coefficients were reported in the patient group compared to the controls, see 
Figure 9-4. This figure displays the group mean beta or r values in areas where there 
were significant mean differences between the two groups. The sign of the relationship 
is different between groups, and not simply the magnitude of the relationship.  For each 
group separately, a few small significant clusters of r or beta values were found to be 
significantly different to zero (similar to Chapter 7, data not plotted).  
 
For each group, the r and beta maps for each subject were averaged and each 
relationship is displayed in Supplementary Figure 9-1 to demonstrate the unthresholded 
mean coupling relationships. These figures are not statistically thresholded but masked 
to areas that had significant ISCs for BOLD, CBF or that MEG within the frequency 
band of interest.  
 
 
Figure 9-4. MEG-fMRI relationships that showed significantly different beta or r values 
between patients and controls. The values displayed are means across groups. 
Red/Orange/Yellow indicate positive values and Blue indicates negative values.  
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BOLD-CBF coupling 
 
There were no r values or beta coefficients significantly different between patients and 
controls. However, for both groups, BOLD and CBF showed significant voxel-wise 
positive correlations to the movie stimulus in many areas across the brain. These 
significant correlations are displayed in Figure 9-5. 
 
 
Figure 9-5. BOLD-CBF correlations to the movie stimulus, for patient and controls. Data 
displayed is thresholded at p<0.05 with tfce correction. 
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9.4 DISCUSSION 
 
Responses to a continuous movie stimulus were compared between 15 MS patients 
and 15 controls, using MEG and fMRI. Results in a healthy population were explored in 
depth in Chapter 7, and therefore the focus of this chapter was to compare patients and 
controls in the context of NVC. Patients and controls were matched on age and gender, 
but there were differences in the order in which they watched the scan, with all patients 
watching the movie in the MEG first compared to only 10 out of the 15 controls. As 
habituation and memory effects have been demonstrated to affect the ISCs during 
movie watching (Chang et al., 2015; Dmochowski et al., 2012) this may have introduced 
bias in the group comparison.  
 
For the within-modality results, significant ISCs were reported for both patients and 
controls across occipital, parietal and temporal cortical areas, consistent with what was 
found in Chapter 7. For all fMRI and MEG ISCs, the patient group displayed lower 
average and maximum correlations, suggesting the patients have more variable MEG, 
BOLD and CBF responses to the movie. This variability refers to how similar their 
responses are to one another. Some spatial differences in the distribution of the ISCs 
can also be seen. There are noticeably fewer significant ISCs for CBF in the patient 
group, compared to the controls, whereas the BOLD ISCs appear similar between 
groups. Patients display significant ISCs in the temporal cortex for 1-4Hz and in the 
frontal cortex for 40-70Hz, which was also seen in the control group in Chapter 7. As 
with Chapter 7,  these ISCs are small, only explaining a very small fraction of shared 
variance between participants.  A similar movie design has been used previously to 
study ISCs in a patient group; Hasson, Malach, & Heeger (2010) reported more 
variability in BOLD-fMRI activity for individuals with autism (lower ISCs), in response to 
10 minute clip from a feature film. Although their questions were not centered around 
NVC, as they only report fMRI data, it demonstrates the application of this type of 
stimulus to studying disease related impairments. 
 
For the MEG-fMRI coupling, we examined both beta coefficients to represent the 
strength of the relationship between MEG and fMRI signals in meaningful units, as well 
as r values to represent how much shared variance there is in the MEG and fMRI time-
series. Despite some big visual differences in the mean correlation maps (in 
Supplementary Figure 9-1) there were only a few significant voxels found. This was 
between BOLD and 8-13Hz MEG responses showing patients to have significantly 
higher correlations and beta coefficients than controls. The sign of the relationship was 
in fact reversed for patients, showing a positive relationship instead of a negative. 
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Typically, negative correlations are reported between alpha (8-13Hz) frequencies and 
fMRI signals (Logothetis, 2002; Mukamel et al., 2005; Zumer et al., 2010). Therefore, 
this could reflect a reversed NVC pattern in patients, possibly reflecting an adaptation 
to damage.  However, this is a tentative interpretation that needs further investigation. 
The results are hard to interpret with so few voxels making up the significant cluster. 
Also, considering this relationship is with BOLD and not CBF, this could point to a 
difference in CBF, CMRO2, CBV or baseline tissue state and we cannot disentangle 
which with this data. 
 
In Chapter 7, we did not statistically test CBF-BOLD relationships to the movie stimulus 
as done here. Here, we demonstrate that the movie stimulus elicits very strong positive 
correlations between BOLD and CBF signals, widely across the brain. Although no 
significant differences in the relationship between BOLD and CBF were reported in the 
patient group, this strong positive correlation in functionally relevant areas indicates the 
movie must be imposing a strong temporal structure on these two signal contrasts.  
 
Considering Chapter 7 also reported an insensitivity to characterising NVC at the 
individual level, it is not surprising that few group differences were found between 
patients and controls. It is therefore difficult to establish whether this lack of differences 
are due to the limitations of the method, or no true difference in NVC in MS. A larger 
sample size is needed to address these questions, as Chapter 7 did demonstrate more 
significant coupling relationships between MEG and BOLD when expanding the 
dataset. A recent study comparing MEG and fMRI advocates the use of a spatial-
filtering approach on the MEG data . This helped uncover consistent canonical variables 
which increased sensitivity to characterising coupling relationships (Lankinen et al., 
2018), as opposed to this typical univariate voxel-wise approach. Therefore, different 
analysis strategies and larger sample sizes may make this design more applicable to 
investigating NVC in MS. 
 
9.5 SUPPLEMENTARY 
 
 Supplementary Figure 1 (see next page). Correlation values between each 
MEG and fMRI relationship, displayed for  each group. These maps are 
averages of  each participant’s correlation map and are not correlations based 
on the mean-time series. These images are not statistically thresholded but 
masked to areas that had significant ISCs for BOLD, CBF or the MEG frequency 
band of interest. Only views of the left hemisphere are shown; the right 
hemisphere showed similar trends.  
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10 GENERAL DISCUSSION  
 
One aim of this thesis was to develop different methods of investigating NVC in healthy 
and MS populations. A visual checkerboard design, with contrast manipulation, gave 
robust measurements of gamma oscillations, BOLD and CBF signals in the primary 
visual cortex, consistent with previous work. The amplitude of these signals was lower 
in the MS group, but there was no evidence to suggest NVC to this visual stimulus was  
impaired.  As there is evidence showing NVC varies across brain regions, and neural 
oscillatory frequencies, it is important to consider that this visual checkerboard design 
only gives a narrow window into investigating these mechanisms. The movie design 
made some progress at addressing these limitations allowing characterisation of BOLD, 
CBF and neural oscillations from 1-145Hz across more brain regions. However, this 
design was not able to robustly characterise individual subject variability in NVC but 
only group averaged responses. With larger samples, and more refined analysis 
pipelines, the results presented show that this type of design has potential to provide 
useful information about NVC variability. This type of research provides insight into 
important biological processes and also can aid in the interpretation of how fMRI signals 
reflect changes in neural activity. More work is needed to investigate these mechanisms 
in the healthy brain before wider application to disease populations.   
 
Another main aim of this thesis was to develop more quantifiable and interpretable 
measures of vascular and metabolic brain function, and this was demonstrated with the 
use of calibrated and dual-calibrated fMRI. The improvement of these methods and 
modelling strategies is an active area of research, but current application of these 
methods to patient populations still has practical value. Blood flow and oxygen 
metabolism signals were investigated in the brain at rest and in response to a stimulus. 
These signals are more physiologically interpretable than the BOLD-fMRI signal alone. 
At baseline, these blood flow and oxygen metabolism signals can also be estimated 
alongside oxygen extraction fraction, cerebrovascular reactivity and oxygen diffusivity, 
allowing clearer interpretations of patient-control differences. Our results demonstrated 
clear baseline vascular and metabolic impairment in MS, as well as some evidence for 
impaired stimulus responses. These methods are applicable to many patient 
populations that may have vascular and metabolic impairments contributing to the 
cause and/or progression of the disease.  
 
In the next sections (10.1 and 10.2), a summary and interpretation of the main results 
is given (for healthy populations and MS), then a consideration of the strengths and 
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limitations of the methods. The interpretation of the results should be considered within 
the context of the validity of the methods used, which is discussed in Section 10.3. 
 
10.1 Neurovascular coupling and metabolic function in healthy populations 
 
Chapter 4 demonstrated that the change in BOLD and CBF signals were positively 
correlated with gamma oscillations and had good spatial overlap. This is consistent with 
a lot of previous work showing positive correlations between gamma amplitude and 
hemodynamic signals. In Chapter 7, the PCA results from the movie stimulus showed 
the characteristic tuning function that has been reported previously: in general, negative 
correlations between BOLD/CBF signals and low frequency oscillations and positive 
correlations at higher frequencies. Although these frequency-dependent relationships 
have been reported before, what is not clear from the literature is whether the same 
population of neurons is changing its oscillatory frequency patterns under conditions of 
stimulation, or different neural populations contribute to these frequency-dependent 
changes.  A clear finding from Chapter 7, is that these frequency-dependent 
relationships vary across the brain, i.e. in some areas the low frequency-negative 
correlations and the high frequency-positive correlations were reported but in other 
areas this relationship appeared opposite. Furthermore, the direction of the coupling 
relationships appeared opposite for BOLD and CBF in some areas. This reminds us 
that (1) BOLD and CBF reflect different aspects of the NVC response with changes in 
CMRO2 and CBV also contributing to BOLD signal changes and (2) interpretation of 
how BOLD and CBF responses reflect neural activity is complex and brain-region 
dependent.  
 
There are many reasons why differences in BOLD and CBF responses to the same 
stimulus can be found, and many of these were discussed in Chapter 7. One reason 
not discussed in Chapter 7 is the consideration of how oxygen diffusivity can change in 
response to neural activity. There is evidence suggesting that CBF and CMRO2  
responses can be decoupled due to the CMRO2 response reflecting a combination of 
the increased CBF and an increase of oxygen diffusion in the active region, because 
the oxygen diffusivity from the capillaries into the tissue can change locally in response 
to neural activity. These changes in oxygen diffusivity in response to a stimulus would 
therefore affect the CMRO2 and BOLD measurement, but not CBF. Empirical evidence 
for this, and a short discussion, is given in Appendix 1 (Chapter 11). One potential 
mechanism for these changes in diffusivity is via pericyte control of capillary diameter 
(Hamilton et al., 2010), and not just at the level of arterioles and arteries as previously 
assumed. 
   163 
 
In an attempt to investigate some of these mechanisms, the relationship between MEG 
and CMRO2 signals in response to the movie stimulus was investigated in Chapter 8. 
Despite estimating reasonable M values across the brain and showing CBF-CMRO2 
coupling ratios in normal ranges, there no significant relationships between CMRO2 and 
MEG signals. This is unlikely to reflect the underling physiologically but the insensitivity 
of the design and measurements.  
 
10.2 Neurovascular coupling and metabolic function in Multiple Sclerosis 
 
Chapter Key Findings relating to MS 
4 • No difference in baseline CBF, GM volumes, visual acuity and VEFs 
in MS 
In response to a visual checkerboard stimulus (5 contrasts):  
• Decreased amplitude of gamma oscillations, BOLD and CBF signals 
in MS over a visual ROI common to both groups 
• A small visual area showed increased BOLD and CBF responses in 
MS 
• No significant differences in NVC in the MS group but more variability  
5 • Reduced baseline CBF and CMRO2 in MS (quantified GM averages)  
• Reduced GM volumes in MS 
• No differences in baseline CVR, OEF or Dc in MS 
• Reductions in CBF and CMRO2 in 2 small clusters: subcallosal cortex, 
medial/orbital frontal regions. Further CBF reductions in occipital pole, 
parahippocampal gyrus. Further CMRO2 reductions in nucleus 
accumbens and paracingulate gyrus. 
• Self-report disease impact scores did not predict these reductions  
• Lesion volume predicted variability in CBF (negative relationship) 
• GM volume predicted variability in CMRO2 (positive relationship) 
6 In response to a visual checkerboard stimulus (100% contrast): 
• BOLD and CBF reductions were found in a small occipital cluster, in 
the MS group, not explained by visual acuity. 
• No differences in visual CMRO2 responses in MS, and no differences 
in the coupling between CBF and CMRO2.  
• In both controls and MS, baseline CBF and CMRO2 values 
significantly predicted stimulus CBF and stimulus BOLD responses, 
respectively. 
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9 In response to the movie stimulus: 
• Reduced inter-subject correlations in the MS group for BOLD, CBF 
and all MEG frequency bands 
• MS group had significant differences in the 8-13Hz MEG to BOLD 
relationship only, showing a positive coupling relationship in the 
parietal lobe and middle frontal gyrus (whereas the controls displayed 
a negative).  
• No significant differences in the correlations between BOLD and CBF 
in the MS group 
 
In general, the work presented in this thesis demonstrates clear vascular and metabolic 
impairment in MS. In terms of the brain at rest, CBF and CMRO2 were significantly 
reduced, and so was total GM volume.  Considering no differences were found in CVR, 
OEF or Dc, this suggests that the CBF is lower due to a lower metabolic demand. 
Furthermore, these CBF and CMRO2 reductions were based on averages across each 
voxel in GM i.e. the CBF and CMRO2  were lower per unit volume of the remaining GM. 
Therefore, the total brain oxygen consumption is likely to be even further reduced once 
the GM loss is also factored in.  Consistent with this, in Chapter 4 a large decrease in 
gamma power amplitude was seen in MS, for example this decrease was close to 20%, 
for the visual checkerboard contrast of 100%.  These gamma power reductions could 
be indicator of GM dysfunction in MS, mediated by GABAergic changes in interneuron 
populations (discussed in Chapter 4). The BOLD and CBF reductions seen in Chapter 
4 are likely to be reflective of this decrease in neural activity. However, the baseline 
CBF and CMRO2  signals from Chapter 5 correlated with different metrics of disease 
burden; they both appeared to have a similar negative relationship with lesion volume 
(although CMRO2 not significantly), but only CMRO2 positively correlated with GM 
volume. This suggests that explaining the CBF reduction simply as a reflection of a 
CMRO2 reduction may not be sufficient (this is discussed in more detail in Chapter 5), 
and more research is needed to understand these relationships. 
  
Unlike in Chapter 4, differences in BOLD, CBF or CMRO2  to a visual checkerboard 
stimulus was not as pronounced in Chapter 6. There was a small visual area showing 
decreased BOLD and CBF responses in the MS group, but no changes in relative 
CMRO2 and no changes in CBF-CMRO2 coupling. This difference in findings was 
unexpected; one contributing factor could be that the patients in Chapter 4 were 
treatment naive, as opposed to the patients in Chapter 6 who were on DMTs. In the 
untreated group in Chapter 4, there was actually a small cluster in the visual cortex that 
showed increased BOLD and CBF responses compared to controls. This could be 
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interpreted as a compensatory mechanism, or it could be related to levels of 
inflammation being higher in this group. This relates to a broader point about testing 
these metabolic and vascular signals in MS: characterising the levels of inflammation 
and structural damage is very important for the interpretation of these results. Evidence 
reviewed in Chapter 3.2.1 showed that atrophy is likely to lead to a decreased CBF due 
to a lower metabolic demand, whereas increased CBF may be found due to active 
inflammation leading to higher metabolic demands. If both processes happen in 
parallel, averaging signals over course spatial scales could result in no differences. 
Therefore, developing non-invasive markers of levels of inflammation is crucial, ideally 
with regional information. Quantifying the level of GM atrophy is also important for the 
interpretation of these results, which is an ongoing challenge in the MS literature, 
particularly non-invasively (Amiri et al., 2018).  
 
In Chapter 4 there were no significant differences in NVC, despite more variability in 
the patient group and a trend towards increased NVC in the visual cortex. In Chapter 9 
there was also evidence showing the patient’s MEG and fMRI responses were more 
variable. Differences in NVC relationships were found in two small clusters, only in one 
frequency band. Therefore, this data does not provide much evidence for alterations in 
NVC in MS. This may be due to the relatively small sample sizes, or it may be due 
limitations in the way NVC was studied (see Section 10.3.1 below). However, it could 
of course be due to no impairment of NVC in MS, at least within the range of damage 
and disability studied in this thesis. At the group level, this suggests that blood flow is 
generally responding appropriately to the level of neural activity in MS.  
 
To understand the role of these metabolic and vascular impairments in disease 
progression, longitudinal studies are needed to track changes over time. Unfortunately, 
very few significant correlations between clinical disease measures  were reported in 
this thesis, which is a pattern that has been noted on in previous studies (Lapointe et 
al., 2018). Therefore, there is still a lot of progress to be made in linking together 
changes between clinical and imaging metrics.  
 
10.3 Strengths and limitations of methods 
 
10.3.1 MEG-fMRI relationship as an empirical measure of NVC 
 
An empirical measure of NVC was characterised, defined as the relationship between 
neural oscillations and BOLD/CBF signals. It is important to note that this is 
representative of the consequences of NVC, and not an investigation of the signalling 
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mechanisms themselves. The process of NVC is very complex; how the vascular cells, 
glial cells and neural cells all interact to produce a blood flow response in the right 
location at the right time is still not fully known (Cauli & Hamel, 2010; Chen, Kozberg, 
Bouchard, Shaik, & Hillman, 2014; Petzold & Murthy, 2011). From a modelling 
perspective, there is some evidence to suggest that NVC may be non-linear in some 
circumstances (Hoffmeyer, Enager, Thomsen, & Lauritzen, 2007; Sheth et al., 2004), 
and this should be considered for future studies. The majority of the research informing 
the work on NVC in humans comes from examining the relationship between neural 
activity and BOLD signals. As covered previously, there are many factors that can affect 
the variability in the BOLD signal, some of which are not related to neural activity. The 
CBF response is therefore more relevant, however, fewer studies have looked at the 
relationship between MEG or EEG signals and CBF, in the context of NVC. 
 
NVC was investigated using two very different stimuli: a visual checkerboard within a 
block design and a clip from a movie within one continuous recording. Despite no 
significant differences between patients and controls, the gamma oscillations and fMRI 
signals displayed strong positive correlations in response to the checkerboard. 
Correlations of this magnitude were not seen with the movie paradigm, possibly due to 
it being a continuous recording. For the movie data, MEG and fMRI signals were 
correlated across time, whereas for the visual checkerboard the contrast manipulation 
was used to tune the amplitude of the MEG and fMRI responses in a similar way, and 
this manipulation was the basis of the NVC measure. For this low-level stimulus, the 
brain is likely to respond more similarly during MEG and fMRI, and more similarly across 
participants. For the more complex movie stimuli, there is likely to be more variation 
across people, and the neural responses may be slightly different on second viewing 
(Chang et al., 2015). Furthermore, it was challenging to characterise individual 
variability in NVC with this movie design; most of the significant results discussed are 
based on averaged time-series across individuals.  However, despite these limitations 
with the movie paradigm, it has the advantage of inducing activity over multiple brain 
areas, in multiple oscillatory frequency bands, and is more reflective of naturalistic 
stimuli. Some potential strategies to improve the usefulness of this type of design for 
investigating NVC could be: (1) to use a resting state paradigm to help characterise the 
baseline noise profile of the MEG and fMRI signals (2) to implement a potentially more 
sensitive independent component analysis to characterise the responses to the movie 
and (3) look at the amplitude and phase coupling between the frequency bands and 
how this relates to the fMRI signals (explained below).  
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The assumption made in using the MEG-fMRI relationship as an empirical measure of 
NVC is that both the signals are sensitive to changes in the same type of neural activity. 
The empirical evidence that was summarised in the introductory chapters has led to the 
common view that both neural oscillations and BOLD/CBF signals closely reflect LFPs 
(of which PSPs mostly contribute) as opposed to multi-unit spiking activity (MUA).  
However, this has also been acknowledged to be an oversimplification, and it is likely 
that the BOLD, CBF and neural oscillatory signals reflect both LFPs and MUA (Ekstrom, 
2010; Mukamel et al., 2005; Whittingstall & Logothetis, 2009). It is important to note 
that in some cases there is a strong correlation between spike rate, LFPs and BOLD, 
and in other cases they are decoupled (Ekstrom, 2010). More research is needed to 
understand the conditions that lead to this coupling or decoupling. A fairly recent idea 
proposed in the literature, with accompanying empirical evidence, is that high-frequency 
oscillatory activity (>100Hz) in LFPs reflect spiking activity (Scheffer-Teixeira, Belchior, 
Leão, Ribeiro, & Tort, 2013). With the movie paradigm, we characterised significant 
MEG correlations between subjects in frequencies up to 195Hz. It is intriguing that only 
in the highest frequency band (145-195Hz) we saw significant common activity in the 
thalamus  (Supplementary Figure 1.1). Although this cannot be fully disentangled with 
this study, and was not the main aim, this provides promising new research avenues to 
explore if such a simple non-invasive design is sensitive to spiking activity.  
 
Spatial sensitivity to neural activity is also an important factor to consider when 
comparing MEG and fMRI; activity of neurons in gyri that are perpendicular (radial 
orientation) to the cortical surface do not project outside the head and cannot be 
measured with MEG (Ahlfors et al., 2010), whereas fMRI signals would be sensitive to 
this activity. The main challenge with comparing MEG and fMRI signals to the same 
stimuli comes from their very different spatial and temporal resolutions. In order to carry 
out voxel-wise comparisons across the whole brain, we spatially down-sampled the 
fMRI to match the resolution of the MEG beamformers. Similarly, the fMRI time-series 
was temporally up-sampled and the MEG time-series was down-sampled. This results 
in pre-processing steps that are not optimum for each modality and may introduce bias 
in statistical testing as the DOF are altered. The need to perform the MEG and fMRI 
scans separately is a clear limitation in using their relationship to study NVC. 
Simultaneous EEG-fMRI is an alternative non-invasive methodology that can be applied 
to studying NVC. The decreased signal quality for both modalities makes the data 
acquisition and analysis challenging, however progress is being made to improve this 
(Huster, Debener, Eichele, & Herrmann, 2012).  
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Only the amplitude and frequency of neural oscillations were considered in this thesis.  
However, evidence suggests that the phase of the wave is also important for neural 
communication. A large area of research into neural oscillations is focused on 
characterising functional connectivity between brain regions, by looking at the how 
amplitude, frequency and phase correlate across regions (Bastos & Schoffelen, 2016). 
Coupling between phase and amplitude (Phase-Amplitude Coupling, PAC) also 
changes in response to a stimulus and is theorised to play a key role in neural 
communication. It is normally demonstrated by the phase of a low frequency oscillation 
modulating power of a higher frequency oscillation, i.e. when the slow wave is in one 
phase of its cycle the power in the fast wave increases, and when it’s in the other phase 
the power decreases  (Canolty & Knight, 2010). There is very little research studying 
how the PAC of neural oscillations is related to fMRI signals in humans, however one 
recent study did investigate this by simultaneously recording electrocorticography 
(ECoG) and fMRI data in the same participants whilst they performed a finger-tapping 
task (Murta et al., 2017). They reported the typical positive correlations between higher-
frequency (>70Hz) oscillations and BOLD, and negative correlations between lower 
frequencies (4-30Hz) and BOLD. More importantly, they showed the PAC strength for 
alpha/gamma and for beta/gamma was negatively correlated with the BOLD amplitude 
in the contralateral hemisphere. Furthermore, they report that the PAC for beta/gamma 
explained variance in the BOLD amplitude that was not explained by amplitude changes 
in alpha, beta or gamma. The complexities of modelling the amplitude, frequency, 
phase and the couplings between them brings new challenges to relating fMRI signals 
to neural oscillations measured with EEG or MEG. However, it is clearly an important 
metric to consider in future studies investigating NVC and may partly explain why the 
amplitude of MEG signals in one frequency band are not strongly correlated with fMRI 
signals (as seen in Chapter 7).  
 
10.3.2 Calibrated-fMRI to estimate oxygen metabolism 
 
In Chapters 5, 6 and 8 we used calibrated-fMRI to model CMRO2 at rest, and during 
stimulation. Chapter 5 was the first application of a dual-calibrated methodology in MS. 
Characterising multiple physiological parameters relating to cerebrovascular health 
(CBF, CBV, OEF, CMRO2, Dc) brings a clearer picture of the vascular and metabolic 
impairments in MS, as interpretation of the changes in one parameter can be taken in 
the context of changes in others. The validity of the modelling assumptions in healthy 
populations are still being investigated and regularly updated, and caution must be 
taken when implementing these methods in patients groups, considering the biological 
assumptions may be less valid (Germuska & Wise, 2018). The most significant 
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assumption, common across all calibrated-fMRI implementations, is that the increasing 
inspired O2 and CO2 does not alter CMRO2. Empirical data has shown that this is 
unlikely to be completely true (Yablonskiy, 2011; Zappe et al., 2008) and simulation 
data shows that if CMRO2 changes during hypercapnia and hyperoxia this would 
strongly affect the estimates of baseline OEF (Merola et al., 2016). Much more research 
is needed to understand the magnitude of this effect, and how best to correct for it 
(Driver et al., 2017).  
 
There are two main approaches to modulating end-tidal gases: fixed inspired fractions 
or targeted end-tidal changes. The methods presented in Chapter 5 used the former 
(fixed inspirations). In principle, targeting exact end-tidal changes in PCO2 and PO2 is 
better, as this allows for more controlled and repeatable modulation of Cv02 (in the case 
of PETO2) and of CBF (in the case of PETCO2), (Germuska & Wise, 2018). In practice, 
fixed inspirations are used more commonly due being less expensive and having a 
simpler equipment set-up. 
 
A robust measurement of CBF is one of the main technical challenges in calibrated 
fMRI methodologies. All these models rely on an accurate quantified estimate of CBF, 
in order to model many other parameters.  A limitation of all the ASL sequences used 
in this thesis (with the exception of the multi-TI ASL used in Chapter 4) is in assuming 
one value for how long the labelled blood takes to travel from the labelling site to the 
slice being imaged (TI for PASL sequences, and PLD for pCASL sequences). However, 
mean transit times have been shown to be altered in MS (see evidence in Chapter 
3.2.1). One study showed that prolonged arrival times in MS, in both GM and WM, were 
associated with higher disability scores (Paling et al., 2013). If patients have altered 
arrival times, this could lead to a bias in CBF quantification.  
 
Although fMRI gas studies are non-invasive, they can be complex from a data collection 
and analysis perspective. Furthermore, application of these methods in some 
populations (children, people with anxiety) may be challenging due the experience of 
breathing in raised CO2. This is why other alternatives have been investigated to 
calibrate the fMRI signals. As discussed in Chapter 8, one of these is a BH design. This 
allows the participant to have more control and often a nasal cannula instead of a face-
mask can be worn, making it a more comfortable procedure. This design requires a 
certain level of task compliance which can be variable across participants, although 
practising outside of the scanner can help improve this. However, unlike dual-calibrated 
fMRI, this BH modulation can still only give relative changes in CMRO2, and not 
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baseline estimates. It also involves more physiological confounds due inspired O2 
decreasing during the BH (discussed in Chapter 8). 
 
10.3.3 Statistical Power  
 
Improvements in experimental design 
 
Before considering the effect of sample size on statistical power, first let us consider 
improvements in the validity of the experimental designs. In relation to MEG-fMRI 
studies to investigate NVC, future studies should give more attention to controlling order 
effects (counterbalancing MEG/MRI session order), time-of-day effects (having each 
scan on a different day but at the same time) and measuring attentional levels to the 
stimulus. Considering the challenges that come with comparing MEG and fMRI signals 
at the same temporal and spatial scales, the experimental design needs to ensure that 
the subject’s experience of the stimuli shown during MEG and fMRI is as similar as 
possible.  
 
Some studies attempt to measure and/or control for lifestyle factors known to effect 
CBF (e.g. exercise, caffeine, nicotine), which have relevance for the validity of our 
methods characterising both resting and stimulus-induced CBF. Recruiting based on 
these factors must be done with caution because (1) a very long list of exclusion criteria 
may lead to recruiting a sample that is not representative of the population, and (2) 
instructing people to refrain from consuming their normal levels of caffeine on the day 
of the scan, for example, will lead to withdrawal effects which may also affect these 
measurements (Addicott et al., 2009). Nevertheless, these are important confounds to 
consider as these methods start to be applied to more questions and patient groups. 
Therefore, this type of data should be collected alongside the imaging data. 
Familiarisation sessions with hypercapnic gases, and practises with BH tasks, before 
the main MRI session is a valuable inclusion into a study design. This helps improve 
the quality of the data collected during the scan as well as ensuring safety.  
 
All of these experimental controls should reduce subject variability due to confounding 
factors, making it more likely to detect an experimental effect if one is present.   
 
Estimation of adequate sample size 
 
In some of these chapters, particular Chapters 4 and 9 for patient-control comparisons, 
the sample sizes were particularly small. It is of course possible that the lack of 
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significant differences we report in NVC is partly or completely due to low statistical 
power. Improving the SNR of imaging techniques and minimising the confounding 
variables may help to reduce this variability, as well as increasing sample sizes. It is 
important to note that post-hoc power analyses, as a way to add some interpretation to 
a null result, are often criticised in the literature as not being meaningful or informative 
(Mumford, 2012), so they will not be covered here. Also, estimating sample sizes based 
on pilot data has been criticised in a recent paper due to inaccuracies in estimating the 
effect size, amongst other factors (Albers & Lakens, 2018). Pilot data are thought to be 
more useful in assessing feasibility of recruitment, methods and analysis than 
estimation of future effect sizes (Leon, Davis, & Kraemer, 2011). Power analyses for 
neuroimaging studies are even more challenging considering the multiple statistical 
comparisons performed for each voxel of the brain, or within ROIs (Mumford, 2012). 
Furthermore, the variability of the MEG and fMRI data will not be spatially uniform 
across the brain and statistical comparisons at each voxel are not truly independent of 
one another. It was often difficult to estimate appropriate sample sizes needed for the 
research studies in this thesis due to the fact that many of these methods are novel and 
in active development. However, the next paragraph describes some approaches that 
were used to assess this as well as some sample size recommendations for future 
studies.  
 
For the data presented in Chapters 5 and 6, 26 MS patients and 25 controls were 
recruited.  These numbers were broadly based on numbers in previous studies that 
showed CBF/CVR differences in MS using a pCASL sequence, for example: Marshall 
et al (2014) with 19 controls and patients, Marshall et al (2016) with 28 controls and 
patients, and Ota et al (2013) with 27 patients and 24 controls. In future, it would be 
advisable to collect 3-5 extra controls and MS patients than is needed based on sample 
size estimates (so ~30 in each group). This is because these (dual) calibrated-fMRI 
methods can often lead to data drop-out due to a participant not being eligible for the 
study, or the data quality being poor due to the gas challenge being novel and 
uncomfortable for some. When using the movie design to investigate NVC, data in 
Figure 7-7 attempted to address the question of sufficient sample size by combining 
data collection from the study with other researchers’ data (common data only existed 
for MEG-BOLD coupling, not MEG-CBF). With a sample size of 33, significant positive 
or negative coupling relationships were seen across all frequency bands and in wider 
brain regions compared with the analysis including only 17 participants. Importantly, 
these coupling relationships were characterised at the individual level first, then 
statistically tested, taking into account individual variability. Therefore, similar studies in 
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the future should aim for at least a sample size of ~33 to characterise these NVC 
relationships, and even more if patient differences are to be compared. 
 
10.4 Conclusions  
 
Multi-modal neuroimaging studies, as presented in this thesis, can contribute to the 
knowledge of how neural, metabolic, and vascular responses interact. The non-invasive 
nature of MEG and MRI means they have wide applicability to studying young, old and 
disease populations, across multiple time points. In the context of studying MS, these 
methods have a lot of potential utility at investigating mechanisms that  may contribute 
to disease progression. For future studies investigating vascular and metabolic changes 
in MS, longitudinal designs and more characterisation of GM damage would allow 
clearer interpretation of results. With any neuroimaging method, a good generative 
model is crucial; one that explains the biological underpinnings of the measured signals. 
More research is needed in this area, to help us model the signals we measure, and 
this will lead to greater applications in understanding the brain, in health and disease.  
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11 APPENDIX 1: Gamma Oscillations, BOLD, CBF and CMRO2 
signals in response to a moving annular grating stimulus  
 
 
Study rationale: To investigate the relationship between different MEG and fMRI 
derived signals, including how they change with visual stimuli manipulation, in order to 
inform about NVC mechanisms.  
 
Study design: 12 healthy volunteers (10F, 3M,18-28 years, right handed, normal or 
corrected to normal vision) performed a visual task during a MEG scan and during a 
pCASL fMRI scan. A T1-weighted structural scan was also obtained. Approved by the 
School of Psychology Ethics Committee. 
 
 
• Annular grating stimuli, full-field, 100% contrast, 3 cycles per degree 
• Projector dimensions, screen refresh rate and degree of visual angle kept 
consistent between MEG and fMRI  
• Stimuli drifted inwards towards the centre at 0,4,8 or 12Hz 
• Participants told to fixate on red circle in centre and count colour changes from 
red -> green to maintain attention  
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Trial
30secs 30secs
1 Block
0Hz 
(static)
4Hz 8Hz 12Hz
1 task
(16 mins)
4 Block 
repetitions
Order pseudo
-randomised 
• Annular grating stimuli, full-field, 100% contrast, 3 cycles per degree
• Projector dimensions, screen refresh rate, degree of visual angle consistent between MEG and fMRI.
• Stimuli drifted inwards towards the center at 0, 4, 8 or 12Hz
• Participants told to fixate on red circle in center and count colour changes from red à green to maintain attention
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MEG data collection and analysis: 275-channel CTF axial gradiometer system was 
used to obtain whole-head MEG recordings. To obtain the peak gamma response to 
the stimulus, the data was collected and analysed using very similar methods and 
pipelines as in Chapter 4.  In brief, data was band-pass filtered between 40 and 90Hz. 
Source reconstruction with LCMV beamformer, contrasting active and stimuli periods. 
Across the four conditions, the location of the peak gamma amplitude was found.  At 
this peak location, the source-level time-series were constructed by multiplying the 
sensor level data with the beamformer weights and constructing time-frequency 
information by calculating the amplitude envelope using the Hilbert transform. For each 
of the four conditions, the Peak Gamma Amplitude is the peak amplitude change, 
across the 30 seconds block, in this location. The Frequency of Gamma Peak was the 
specific frequency (constrained to 40-90Hz) of this peak amplitude. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peak Amplitude change 
XX
X
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MEG Source Localisation. Gamma amplitude (40-90Hz) percentage change 
from baseline, shown as averages across the group in MNI space (left plot) and 
shown for one individual (right plot). The blue cross-hairs represent the peak 
gamma response for that individual. All participants had a peak gamma response 
in the primary visual cortex.   
 
%change 
from baselineGROUP
INDIVIDUAL
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fMRI data collection and analysis: 3T GE MRI system, 8-channel receiver head coil, 
ran a PASL sequence, acquiring CBF and BOLD weighted images (TI1/TI2  = 
700/1500ms, 20cm tag), with a dual GRE spiral readout (TR/TE1/TE2 = 2400/2.7/29ms, 
64 x 64 x 14 (3x3x7mm,1.5mm gap). To obtain the BOLD and CBF responses to the 
stimulus, the data was collected and analysed using very similar methods and pipelines 
as explained in Chapter 4. In brief, BOLD time courses (surround average of the second 
echo) and ASL time courses (first echo) were modelled with FEAT’s Full Perfusion 
Signal modelling, for each of the 4 conditions. A group ROI representing the significant 
activity to stimulus (across the four conditions, and common to both BOLD and CBF) 
was transformed from MNI to subject space and percentage change from baseline 
BOLD and CBF signals were extracted from this ROI. As explained in Chapters 8, the 
CMRO2 response to the stimulus was modelled, based on the standard calibration 
model (Davis et al., 1998), assuming a value for M of 0.075, an alpha of 0.2 and a beta 
of 1.3, based on previous literature (Wise et al., 2013).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BOLD
(Z>2.3)
CBF
(Z>2)
fMRI group Z-stat images
Corrected cluster significance threshold of p =0.05. 
Example of a subject ROI containing voxels that were significant in the CBF and
BOLD analyses, where the BOLD and CBF signals were extracted.
BOLD
(Z>2.3)
CBF
(Z>2)
fMRI group Z-stat images
Corrected cluster significance threshold of p =0.05. 
Example of a subject ROI containing voxels that were significant in the CBF and
BOLD analyses, where the BOLD and CBF signals were extracted.
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TEMPORAL FREQUENCY TUNING OF MEG AND FMRI SIGNALS 
 
Two participants had MEG source localisation errors (due to eye artefacts and co-
registration errors) leaving n=10 common MEG and fMRI datasets to compare (8F, 2M). 
For each parameter plotted below, the maximum percentage change from baseline was 
obtained, across the four stimuli conditions, for each participant. Each stimuli condition 
response was converted into a percentage of this maximum value, in order to compare 
the stimuli manipulation between all parameters, which have different magnitudes. The 
table shows unnormalised values for each parameter, averaged across the stimuli 
conditions (‘Grand Mean’) to give an indication of scale. Group means ± SEM are 
displayed. 
 
 
 
 
 
 
What do these results show?  
 
• Peak amplitude of neural oscillations in the gamma band (40-90Hz), and the 
frequency of this peak, are tuned differently by this visual stimulus manipulation  
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Temporal Frequency of Stimuli Movement
MEG:Peak Gamma Amplitude MEG: Frequency of Gamma Peak
fMRI: BOLD fMRI: CBF
fMRI:CMRO2
PeakAmplitude (%) FrequencyOfPeak (Hz) CBF (%) BOLD (%) CMRO2 (%)
Grand Mean 69.68 53.03 30.70 1.06 11.33
SE 15.13 5.63 2.66 0.09 1.05
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• BOLD, CBF, and the frequency of the gamma peak all display peak responses at 
8Hz of stimuli movement, whereas peak gamma amplitude and the modelled 
CMRO2 response both peak at 4Hz  
 
Why is this important? 
 
• The biological mechanism that drives gamma oscillations is still not fully known, but 
there is evidence to suggest they are driven by a network of interconnected 
excitatory pyramidal cells and GABAergic inhibitory interneurons (Bartos et al., 
2007). The balance of this excitation and inhibition is thought to play a role in setting 
the peak gamma oscillation frequency (Brunel & Wang, 2003). Increases in gamma 
amplitude may simply reflect a larger population of neurons firing in synchrony.  
 
• These results very closely mirror those of a study using PET imaging (Vafaee & 
Gjedde, 2000b) that looked at CBF and CMRO2 responses to similar visual grating, 
showing that CBF peaked at 8Hz and CMRO2 peak at 4Hz of stimuli movement, as 
we have shown here. They modelled the oxygen diffusivity from capillaries into the 
active tissue and found that this followed the same pattern as CMRO2, peaking at 
4Hz. They explained this increase of oxygen consumption at 4Hz to be a 
combination of increased CBF and increased oxygen diffusion in the active region, 
and that oxygen diffusion can therefore change locally in response to neural activity. 
Another study testing visual responses at  0, 1, 4, 8, 16, 32, and 50Hz showed that 
CMRO2 response peaked at 4Hz (Vafaee et al., 1999).  
 
• This provides support that the CMRO2 response may better reflect the energy 
demands of neural activity compared to both the BOLD and CBF response, and 
therefore developing methods of measuring CMRO2  is important. There is other 
evidence to suggest that the CBF response is mediated by factors other than the 
demand of oxygen (Lin, Fox, Hardies, Duong, & Gao, 2010).However, the CBF 
response very closely follows the tuning pattern of the frequency of the gamma 
peak, suggesting instead that CBF and CMRO2  may represent different information 
about neural activity. More generally, the fact that CBF and CMRO2  responses to 
the same stimulus are different suggest that CMRO2  responses may also be 
reflecting a more local regulation of blood flow, at the level of capillaries (Hamilton 
et al., 2010).  
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